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Abstract 
Obesity is associated with an increased risk of developing type 2 diabetes and 
women with diabetes have a higher relative-risk of cardiovascular mortality than 
men. Polycystic ovary syndrome (PCOS) is a common condition that is associated 
with obesity and confers a particularly high risk of diabetes.  
There is a need to identify cardiovascular dysfunction in the pre-diabetic stage 
because, once diabetes is evident, it is difficult to improve the prognosis. Left 
ventricular hypertrophy (LVH) and diastolic dysfunction are well-established 
consequences of obesity, but the mechanisms which underpin these findings are not 
well-defined.  
Measurements of ventricular-arterial coupling characterise the load which the 
ventricle must overcome to eject blood. This thesis investigated whether quantitative 
measures of ventricular-arterial coupling could explain the development of LVH and 
diastolic dysfunction in young women at risk of diabetes. Two methods of 
quantifying ventricular-arterial coupling were used (i) a comparison of arterial and 
ventricular end-systolic elastance, and (ii) the amplitude and timing of wave 
reflections in the carotid artery using wave intensity. 
Increases in elastance were associated with general and central obesity. In 
contrast, increased wave reflections were predominantly associated with fat around 
the organs and with worse metabolic health. Arterial elastance and wave reflections 
were independent contributors of left ventricular mass but did not independently 
contribute to diastolic function. 
Women with PCOS had similar cardiovascular risk, elastance and diastolic 
function to matched controls. However, they had a lower odds-ratio of LVH which 
appeared to be explained by lower amplitude wave reflections. There may be an 
aspect of PCOS which mitigates the effects of obesity and pre-diabetic states on the 
pulsatile loading of the left ventricle.  
The quantification of ventricular-arterial coupling provides new insights to the 
effects of obesity and pre-diabetic states on sub-clinical cardiovascular disease. 
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Explanation of Study Acronyms 
DECODE Diabetes Epidemiology: Collaborative Analysis of Diagnostic 
Criteria in Europe 
DECODA Diabetes Epidemiology: Collaborative Analysis of Diagnostic 
Criteria in Asia 
ACCORD  Action to Control Cardiovascular Risk in Diabetes  
ADVANCE Action in Diabetes and Vascular Disease: Preterax and 
Diamicron MR Controlled Evaluation Trial 
VADT   Veterans Affairs Diabetes Trial 
ORIGIN  Outcome Reduction with Initial Glargine Intervention 
ARIC   Atherosclerosis Risk in Communities 
MESA   Multi-Ethnic Study of Atherosclerosis 
CARDIA  Coronary Artery Risk Development in Young Adults
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1. General Introduction 
Obesity is driving an increase in the prevalence of diabetes 
The modern lifestyle of nutritional excess and reduced physical activity is leading to 
epidemic levels of obesity with up to two thirds of the population being overweight 
or obese.
1
 Obesity is driving an increase in the prevalence of type 2 diabetes,
2
 a 
large-scale problem with significant healthcare costs. In 2013, the prevalence of 
diabetes in European adults was 8.5% (~ 56 million people) and 95% of these had 
type 2 diabetes. The prevalence is projected to rise to 10.3% by 2035.
3
  
Type 2 diabetes lies at the end of a continuum of disorders of glucose 
metabolism that also includes insulin resistance, impaired glucose tolerance (IGT) 
and impaired fasting glucose (IFG). With the exception of insulin resistance, all 
stages are defined by diagnostic thresholds in European guidelines (Table 1-1). It is 
noteworthy that the diagnostic threshold for type 2 diabetes is based on the level of 
glucose at which microvascular disease occurs, but there is evidence that the larger 
blood vessels may be affected in the pre-diabetic stage.
4
 
 
Table 1-1. Diagnostic criteria for pre-diabetic and diabetic conditions.
4 
Diagnosis Criteria 
Impaired fasting glucose  Fasting plasma glucose 6.1- 6.9mmol/L 
AND 2-hr post-load plasma glucose <7.8mmol/L 
Impaired glucose tolerance Fasting plasma glucose <7.0mmol/L 
AND 2-hr post-load plasma glucose ≥7.8<11.1mmol/L 
Diabetes Fasting plasma glucose ≥7.0mmol/L  
OR 2-hr post-load glucose ≥11.1mmol/L 
 
 
 
3 
 
In the earliest stages of abnormal glucose metabolism there is insulin resistance. 
Cells become less sensitive to circulating insulin and higher levels are required for 
glucose uptake so pancreatic beta cells produce more insulin to maintain normal 
blood glucose (euglycaemia). Over time, the higher levels of insulin 
(hyperinsulinaemia) may not be sufficient to regulate fluctuations in blood glucose 
after eating and there is IGT. Finally, beta cells will fail, resulting in IFG or type 2 
diabetes.   
Many individuals with type 2 diabetes remain asymptomatic until complications 
occur several years after the development of high blood glucose. A lack of symptoms 
in early stages of the disease results in around half of all cases being undiagnosed at 
any one time 
5
 and this precludes early intervention which may delay the onset of 
complications. Screening for diabetes at a population level is not currently indicated 
because there is insufficient evidence that early diagnosis and intervention can affect 
the prognosis of cardiovascular disease. In addition, there is no simple biomarker 
that can identify the pre-cursors to diabetes. Accurate diagnosis is based on fasting 
plasma glucose and an oral glucose tolerance test; these are relatively costly and 
time-consuming at a population level. 
An increase in the prevalence of diabetes is also partly driven by a rising 
proportion of elderly individuals. The DECODE  and DECODA studies  
demonstrated that the prevalence of diagnosed type 2 diabetes increased with age in 
European and Asian cohorts. 
5,6
 The combined prevalence in European cohorts was 
less than 10% in those under 60 years, rising to 10-20% in those between 60 and 80 
years.  
The prevalence of undiagnosed diabetes and pre-diabetic conditions may depend 
on the diagnostic criteria used in screening. One study found that when the diagnosis 
was defined by the presence of hyperglycaemia at two hours after an oral glucose 
load, the prevalence of undiagnosed diabetes and IGT was higher in women. In 
contrast, a diagnosis based on an isolated fasting glucose revealed higher prevalences 
of diabetes and IFG in men.
5
 Furthermore, European women were more likely to 
have IGT than men in all age groups up to 70 years. These data support the use of a 
diagnostic strategy that includes both fasting plasma glucose and oral glucose 
4 
 
tolerance testing in order to avoid under-diagnosis of abnormalities in glucose 
metabolism.  
An increase in the prevalence of diabetes does not necessarily reflect an 
accumulation of new cases since prevalence is also affected by differences in 
survival. Data on the incidence of diabetes provide a better insight to how the 
patterns of the condition have changed over time. Results for the Framingham 
Offspring Study confirmed that the age-adjusted 8-year incidence rate of diabetes 
increased between 1970 and 1990. Most of the increase occurred in obese 
individuals and the increase in incidence of diabetes was lower in women than in 
men.
2
 These data confirm that obesity is contributing to higher levels of type 2 
diabetes in modern society.  
The proportion of cardiovascular disease cases attributable to 
diabetes is increasing  
The cardiovascular mortality rate in the European general population has fallen by 
more than 30% in recent years.
7
 This improvement may be attributed, at least in part, 
to better control of cardiovascular risk factors by medications such as aspirin, anti-
hypertensive drugs and statins. The absolute risk of cardiovascular disease in those 
with diabetes has fallen in a similar manner, with large longitudinal studies such as 
the Framingham Heart Study reporting a 49% reduction between the 1950s and 
1990s.
8
 However, in the same study, the relative risk of developing cardiovascular 
disease in those with diabetes did not fall, remaining at double the risk of those 
without diabetes. As a result, the proportion of all cardiovascular disease cases 
attributable to diabetes has increased.
9
  
The risk of cardiovascular mortality increases with the duration of diabetes and 
those who develop diabetes under 55 years have a greater risk than those who are 
older.
10
 The Hoorn study compared all-cause mortality in subjects with diabetes 
identified by (i) screening, (ii) known diabetes of short duration and (iii) known 
diabetes of long duration.
11
 The age- and sex-adjusted relative risks of mortality 
increased from 2.06 in the screening group to 3.19 in the known diabetes groups.  In 
those with short duration diabetes, the elevated mortality risk was predominantly 
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explained by risk factors other than diabetes, while in those with long-duration 
diabetes, the elevated mortality risk was independent of such risk factors.  
The actual duration of diabetes in these subjects is likely to be underestimated 
because individuals are frequently asymptomatic at the true onset of hyperglycaemia. 
In addition, those with known diabetes may have presented with symptoms because 
of a more ‘aggressive’ form of diabetes that could affect the mortality risk beyond 
the duration of the condition. However, if long-duration diabetes is an independent 
risk factor for mortality, this might suggest that chronic hyperglycaemia is associated 
with irreversible alteration to cardiovascular structure and function. This is further 
supported by a review of the largest randomised controlled trials on tight glycaemic 
control in diabetes (ACCORD, ADVANCE, VADT, ORIGIN) which failed to 
demonstrate clear evidence of reduced medium-term adverse outcomes.
12
 
Furthermore, there is some evidence that sub-clinical cardiovascular dysfunction 
progresses despite good glycaemic control.
13
 The reasons for this are unclear. It may 
be that macrovascular and cardiac changes occur at a pre-clinical stage in the 
development of type 2 diabetes and are irreversible by the time of diagnosis. In 
addition, the macrovascular complications may be more strongly related to other co-
morbidities such as dyslipidaemia, pro-thrombotic state and vascular dysfunction 
than to glucose levels.  
Women with diabetes have a higher relative risk of cardiovascular 
mortality than men 
Men have a higher absolute risk of cardiovascular mortality but the relative risk 
associated with diabetes is higher in women.
10
 The reasons for this are unclear. 
However, compared with men, it appears that women have to gain more weight to 
develop diabetes.
14
 The greater storage capacity of subcutaneous fat in women 
means that greater adiposity is needed to result in ectopic fat deposits that contribute 
to insulin resistance. In addition, data from the British Regional Heart Study/ British 
Women’s Heart and Health Study suggested that diabetes may have a more adverse 
influence on adiposity, inflammation and vascular function in women.
15
 It appears 
that compared with men, women with diabetes have undergone more significant 
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alterations in a cluster of risk factors, and this might have a greater impact on their 
cardiovascular morbidity and mortality.  
Fat is an endocrine organ 
Adipose tissue comprises adipocytes, connective tissue matrix, nerve tissue, 
stromovascular cells, and immune cells. The primary role of adipocytes is to store 
energy. In situations of calorie excess, free fatty acids (FFAs) in the form of 
triglycerides are stored in adipose tissue which increases in mass. This fuel can be 
released back into the circulation at times of calorie deficit and contributes to 
survival. Obesity is therefore characterised by increased storage of FFAs in a 
significantly expanded tissue mass.  
In 1953, Kennedy suggested that a circulating metabolite may be acting upon the 
hypothalamus to reduce food intake in the event of reduced energy expenditure and 
increased fat mass.
16
 His hypothesis of ‘lipostasis’ in the rat centred around adipose 
tissue producing a metabolite that initiated a negative feedback loop to prevent the 
rat from becoming obese. This is believed to be the first description of adipose tissue 
as an endocrine organ. The circulating metabolite was not identified until 1994 when 
Zhang identified and sequenced the mouse obese (ob) gene and its product, leptin.
17
  
In animal models leptin causes decreased food intake, reduced body fat and 
restores euglycaemia.
18
 However, obese humans appear to develop leptin resistance 
which limits its role in regulating metabolism. One study in obese men demonstrated 
that while recombinant leptin injection decreased appetite, it did not affect basal 
metabolic rate, body mass or composition.
19
 This suggests that while the central 
effects of leptin may be preserved in obesity, there is likely to be peripheral leptin 
resistance in metabolically active peripheral tissues such as skeletal muscle.  
Following the discovery of leptin a series of other secretory proteins were 
identified in fat, including adiponectin, tumor necrosis factor-α (TNF-α), and 
interleukin-6 (IL-6). The modern understanding of adipose tissue is that together, its  
components work as an integrated unit to express, secrete and react to a range of 
proteins that have autocrine, paracrine (local) and endocrine (systemic) effects.
20
 
  
 
7
 
 
Figure 1-1. Fat as an endocrine organ. Adapted from Galic, Oakhill and Steinberg. 
18
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Several detailed reviews of adipose tissue as an endocrine organ can be found in 
the published literature.
18, 20
 Figure 1-1 summarises the key concepts. Greater detail 
about the effects of adiponectin is given below since this is relevant to subsequent 
discussion chapters.  
Adiponectin 
Adiponectin is a protein secreted by fat cells which increases hepatic insulin 
sensitivity and decreases hepatic glucose production, as well as being involved in the 
metabolism of lipids. Therefore, this may be one of the mechanisms linking obesity 
with atherosclerosis and with insulin resistance. A detailed review of the basic and 
clinical studies of the anti-atherosclerotic and insulin-sensitizing effects of 
adiponectin was published by Han et al. in 2009.
21
 
The protein was first described in mice by Scherer in 1995 
22
 who found that it 
was exclusively secreted by adipose tissue and noted to circulate at high 
concentrations in plasma. Several single nucleotide polymorphisms in the 
adiponectin gene have been identified and these have been associated with obesity, 
type 2 diabetes and coronary artery disease.
23
 Adiponectin can assemble into a form 
with three macromolecules (trimeric complex), and can further combine into 
hexameric or high-molecular weight forms; the latter having 18-36 molecules. The 
most metabolically-active form of adiponectin is believed to be the high-molecular 
weight (HMW) form.
24
  
Unlike leptin, adiponectin is decreased in obesity and increases with weight loss. 
Levels are maintained in a narrow physiological range and it has a long half-life so it 
does not alter significantly with dietary challenges. Changes in concentration occur 
over a prolonged period of time as a result in changes to body weight, hormone 
levels and insulin sensitivity.
24
  
Females tend to have higher levels of HMW adiponectin than males 
24
 and this is 
thought to be because of higher levels of subcutaneous fat 
25
 and because in men, the 
hormone testosterone inhibits secretion of adiponectin from adipocytes.
26, 27
 Thus 
adiponectin may contribute to the finding that males have a higher degree of insulin 
resistance than females.  
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There is evidence that adiponectin has a protective effect against the 
development of type 2 diabetes regardless of ethnicity and gender.
28-32
 The largest of 
these studies was conducted in the ARIC population (Atherosclerosis Risk in 
Communities) comprising 1153 white and African-American subjects (581 incident 
diabetes cases).
29
 Those with the highest quartile of adiponectin had 40% lower risk 
of developing diabetes compared with those in the lowest quartile. However, this 
difference was absent in smokers and in those with high markers of inflammation, 
suggesting that there are conditions within which adiponectin is less effective at 
counteracting metabolic abnormalities. 
In addition to its insulin sensitizing effects, adiponectin has anti-inflammatory 
and anti-atherogenic properties 
21
 which should mean that it protects against 
cardiovascular events and mortality. However, a recent review reports a paradoxical 
positive association between adiponectin and cardiovascular mortality.
33
 Most of this 
evidence is drawn from studies of older people often with established cardiovascular 
disease but data from the Dallas Heart study extends these findings to a younger 
population (43±10 years) who were free from overt cardiovascular disease.
34
 These 
authors found that increasing adiponectin quartiles were associated with a better 
cardiovascular risk profile but in multivariate models adjusted for other 
cardiovascular risk factors, increasing total adiponectin quartiles were associated 
with higher rates of all-cause mortality, cardiovascular mortality and cardiovascular 
events.  
The mechanisms underpinning this apparent paradoxical positive association are 
yet to be defined and it may be that there is a subset of the population with 
pathologically elevated adiponectin which is a biomarker of an as yet unappreciated 
risk factor. However, Moreno et al. 
35
 have suggested a cause-effect relationship 
between adiponectin and cardiovascular mortality in subjects with type 2 diabetes 
and coronary artery disease enrolled in the Gargano Heart Study (n=356). Their 
findings are based on the A allele of single nucleotide polymorphism rs822354 
(located in the ADIPOQ locus, the gene that encodes for adiponectin) which was 
associated with total and HMW adiponectin levels as well as a high cardiovascular 
mortality rate.  Further studies with larger sample sizes are needed to confirm this 
hypothesis.  
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Not all fat depots are equal 
Several large-scale studies have demonstrated that central obesity is more strongly 
associated with diabetes and cardiovascular disease than is body mass index (BMI).
1, 
36, 37
 Waist circumference is a simple and inexpensive measure of central obesity 
which makes it suitable for epidemiological studies across wide geographic areas. 
The IDEA study 
1
 investigated the relationship of waist circumference with diabetes 
and cardiovascular disease in 168,000 people across 63 countries. Waist 
circumference was consistently associated with higher odds-ratios for diabetes and 
cardiovascular disease than was BMI. Women with waist circumference greater than 
88cm had an odds ratio of 1.97 for cardiovascular disease and 3.94 for diabetes.  The 
relationship between waist circumference and diabetes or cardiovascular disease 
extended to those who were classified as ‘lean’ by BMI. These data add to earlier 
questionnaire-based studies showing the relative risk of diabetes associated with 
waist circumference in US males 
38
 and females.
39
  
The endocrine function of adipose tissue varies according to the location of the 
fat. Hormones derived from fat around the organs (visceral fat) are secreted into the 
portal vein which supplies ~80% of blood flow to the liver. Therefore, visceral fat 
may have a greater effect on hepatic metabolism than subcutaneous fat which 
releases hormones into the systemic circulation. In addition, visceral fat expresses 
and secretes proportionally greater levels of cytokines such as interleukin-6 (IL-6) 
which correlates with arterial C-reactive protein (CRP), a measure of systemic 
inflammation.
40
 Systemic inflammation is known to induce insulin resistance. 
Finally, each depot may have specific receptor patterns that determine their ability to 
respond to other circulating factors such as androgens and angiotensinogen.
41
  
It is possible to differentiate visceral from subcutaneous fat using non-invasive 
imaging techniques such as computed tomography (CT), magnetic resonance 
imaging (MRI) and dual-energy x-ray absorptiometry (DEXA). Many research 
studies have used these techniques to ascertain whether visceral fat is more strongly 
associated with cardiovascular risk factors and dysfunction than general obesity.   
In the population-based Framingham Heart Study 
42
  both visceral and 
subcutaneous fat were associated with the cardio-metabolic risk factors of blood 
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pressure, fasting glucose and triglycerides. However, the associations were stronger 
with visceral fat, and in a multivariate analysis visceral fat contributed to risk factor 
variation beyond the proportion explained by BMI and waist circumference. Similar 
results were found in African-American subjects in The Jackson Heart Study.
43
 In 
both studies there was a gender difference in relationships; visceral fat was 
associated with higher odds-ratios of cardiovascular risk and diabetes in women than 
in men. 
Lower levels of insulin resistance and higher subcutaneous fat levels in women 
25
 
have led to speculation that subcutaneous fat may be protective. The theory centres 
on an ‘overspill’ hypothesis that ectopic fat stores develop when subcutaneous fat 
becomes saturated with FFAs because of chronic energy excess. Therefore, those 
with greater capacity for subcutaneous fat are less likely to develop significant levels 
of visceral fat. One study has demonstrated that for each standard deviation increase 
in visceral fat, the odds of insulin resistance increased by 80%, while for each 
standard deviation increase in subcutaneous fat the odds decreased by 48%.
44
 
Furthermore, when grouped by visceral fat tertile, those who were insulin sensitive 
had significantly more subcutaneous fat.  
Obesity and insulin resistance affect left ventricular mass 
Left ventricular (LV) remodelling or hypertrophy 
45-47
 and diastolic dysfunction 
48
 
are well-established consequences of obesity. 
Data from the Framingham study has shown that left ventricular hypertrophy is 
an important marker of cardiovascular risk.
49
 Historically, uncomplicated obesity 
was thought to result in an eccentric pattern of hypertrophy while the addition of 
hypertension would result in a more concentric pattern. More recent evidence has 
shown that this is not necessarily accurate and that even those who are obese without 
hypertension may have a concentric pattern. Indeed, a recent systematic review 
concluded that both eccentric and concentric patterns of hypertrophy were evident in 
those who are obese 
45
 and this mixed pattern appears to be more evident in women 
than in men. The precise mechanisms underlying the pattern of remodelling are yet 
to be clearly defined and this may have therapeutic implications. Whatever the 
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mechanisms involved, both patterns are associated with adverse cardiovascular 
outcomes in those with heart failure and preserved ejection fraction (HFpEF).
50
  
A detailed description of all potential mechanisms linking obesity and ventricular 
hypertrophy is beyond the scope of this thesis. A review of such mechanisms was 
published by de Simone et al. in 2013 
51
 and the key components identified in that 
review are highlighted in Figure 1-2.  
In general, mechanisms may be considered as having a haemodynamic or non-
haemodynamic effect but some mechanisms appear to affect haemodynamic load 
and have a direct effect on the structure and composition of the myocardium. 
Particular attention is given below to the major haemodynamic effects of general 
obesity, central obesity and insulin resistance, since these have direct relevance to 
the results chapters which follow. 
 
 
Figure 1-2. Haemodynamic and non-haemodynamic factors influencing the development of 
increased ventricular mass in obesity. Adapted from de Simone et al. 
51
 SNS: sympathetic 
nervous system, RAAS: renin-angiotensin-aldosterone system, FFA: free fatty acids. 
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General obesity is associated with an increased fat and lean mass (predominantly 
comprising skeletal muscle) and both are positively associated with increased LV 
mass.
52
 It is well established that general obesity is associated with a greater 
circulating blood volume and that the additional tissues require an increased cardiac 
output to meet the demands of metabolic function. This increased volume-loading of 
the LV results in increased wall stress and hypertrophy develops as a compensatory 
mechanism. The increased cross-sectional area of the vascular bed in obesity might 
be expected to result in a decreased systemic vascular resistance so that blood 
pressure remains normal even in the presence of increased cardiac output. In fact, 
systemic vascular resistance is variable in obese subjects and has been found to be 
low, pseudo-normal or elevated, depending on the population studied.
53
 A pseudo-
normal systemic vascular resistance coupled with increased circulating volume 
would contribute to a higher mean arterial pressure, even in the absence of overt 
hypertension.     
There is also more recent evidence that obesity is associated with a relative 
deficiency of lean mass likely due to lower muscle mass than is expected for body 
size. The term sarcopenia is sometimes applied to this finding although it is more 
traditionally used to describe a loss of muscle mass associated with ageing and 
chronic disease. In the Strong Heart Study, obese subjects who had a relative 
reduction in lean mass also had increased left ventricular mass,
46
 an effect that was 
particularly evident in women. This may be explained by the fact that individuals 
with reduced lean mass tend to have even higher levels of adipose tissue with 
reduced perfusion,
54
 demanding greater cardiac output for metabolism. 
Central obesity appears to contribute independently to the development of 
abnormal ventricular geometry, across a wide range of BMI and obese subjects. In 
the Multi-Ethnic Study of Atherosclerosis (MESA), central obesity and insulin 
resistance were independently associated with concentric left ventricular remodelling 
after adjustment for BMI and other risk factors such as hypertension.
47
 Central 
obesity suggests increased visceral fat, which secretes a range of pro-inflammatory 
molecules that contribute to insulin resistance, cardiac remodelling and heart failure. 
In addition, visceral fat is particularly metabolically active and requires a more 
substantial blood supply to support its metabolic activity than subcutaneous fat.
51
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Arterial stiffness is a predictor of mortality 
55
 and it is likely that the 
haemodynamic effects of increased stiffness explain some of the increased mortality 
through the development of ventricular hypertrophy. Studies have reported that 
obesity is associated with increased arterial stiffness even in children 
56
 and before 
the development of hypertension 
57
. In addition, this is reversible with weight loss in 
a young population 
58
 which suggests that uncomplicated obesity may be associated 
with increased arterial stiffness before there are any irreversible structural changes.  
The most commonly used method to assess arterial stiffness is carotid-femoral 
pulse wave velocity (PWV) which gives a measure of regional aortic stiffness. This 
is considered a gold-standard technique which is reproducible, inexpensive 
59
 and  
predicts cardiovascular events as well as all-cause mortality.
55
 However, PWV is an 
integrated measure affected by functional haemodynamic factors such as heart rate 
and blood pressure (which is influenced by cardiac output), as well as by structural 
stiffness.
60
 This probably contributes to its usefulness as a powerful predictor of 
mortality but also means that, in isolation, it does not help unpick the effects of 
obesity on these component parts. In addition, accurate measurement of PWV 
depends on assessing the central aortic path length from measurements made on the 
body surface which can be significantly overestimated in those who are centrally 
obese. 
Obesity and insulin resistance affect diastolic function 
Impaired diastolic function is evident in the earliest stages of uncomplicated obesity 
in children and young adults.
48, 61
 The typical finding is a pattern of reduced early 
diastolic function and filling with an increased active atrial component. This pattern 
is not simply a consequence of increased circulating volume since increased venous 
return would typically cause an increase in early diastolic filling. Obese individuals 
also tend to have increased left atrial volume, although in the earliest stages of 
disease this may be related to haemodynamic load and increased filling rather than as 
a consequence of increased left ventricular end-diastolic pressure. Later in life and 
with increasing co-morbidities such as hypertension and diabetes, there may be overt 
diastolic dysfunction which is the underlying pathophysiology in patients with 
symptoms of HFpEF.
62
 Despite this evidence, the precise mechanisms underpinning 
diastolic dysfunction in obesity are not clearly defined.  
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Diastolic function appears to be more strongly associated with central obesity 
and insulin resistance than with general obesity. A study of cardiovascular function 
in overweight Australian youths (10-19 years) reported that those who were 
overweight and insulin resistant had worse diastolic function than those who were 
overweight and metabolically healthy, but only the difference between the insulin 
resistant group and controls was statistically significant.
48
 In multiple regression 
analysis insulin resistance (HOMA-IR), inflammation (CRP) and adiponectin were 
significant independent predictors of the early diastolic tissue velocity after adjusting 
for BMI. 
A detailed review of the potential mechanisms linking obesity and myocardial 
dysfunction was published by Wong and Marwick in 2007.
63
 There is considerable 
overlap in the mechanisms linking obesity with hypertrophy and with diastolic 
dysfunction. Briefly, the key mechanisms are thought to include insulin resistance, 
increased free fatty acids (FFA), altered adipokines, activation of the renin-
angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS), and 
small vessel disease (as well as myocardial remodelling). 
Few studies consider the effect of epicardial fat on diastolic function. Epicardial 
fat is the visceral fat around the heart. Obese subjects with high levels of abdominal 
visceral fat also tend to have increased epicardial fat which may affect cardiac 
function through non-haemodynamic pathways such as by paracrine secretion of 
inflammatory cytokines. A detailed description of the effects of epicardial fat on 
myocardial metabolism has been published by Iacobellis, Malavazos and Corsi.
64
 
Epicardial fat volume measured by CT scanning appears to independently explain 
some of the variation in diastolic function in a healthy population of older subjects 
(55±13 years) after accounting for comorbid factors such as hypertension and 
metabolic syndrome. In addition, it was a stronger correlate of the early diastolic 
tissue velocity than BMI.
65
 Similar results have been found using the 
echocardiographic method validated by Iacobellis 
66
 in older subjects with metabolic 
syndrome.
67
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Obesity and interventional studies 
While many of the studies demonstrating diastolic dysfunction and increased left 
ventricular mass in obesity are cross-sectional in nature, there is evidence from 
interventional studies that weight loss improves ventricular geometry and diastolic 
function. A review of these studies  showed that dietary interventions resulting in 
successful weight loss were associated with improved diastolic function with and 
without accompanying changes in left ventricular mass.
68
 Similar findings are 
described in patients who achieved weight loss following bariatric surgery. There is 
also some evidence that the combination of exercise and dietary weight loss appears 
to have a greater impact on the improvement in diastolic function than weight loss 
alone.  
Together, these studies imply that alterations in cardiac structure and function are 
affected by haemodynamic factors (loading) related to increased body size and non-
haemodynamic factors such as visceral fat and insulin resistance. While many of the 
key epidemiological studies include obese subjects with confounding factors such as 
hypertension or diabetes, there is emerging evidence that similar results are found in 
obese children who have yet to develop co-existing pathologies. Kozakova et al.  
recently reported that obese children (age ~13years) had ventricular remodelling that 
was most strongly associated with body size implying that loading was a significant 
factor, while diastolic function was most strongly associated with abdominal obesity 
and fasting insulin.
61
  
Therefore, it appears that general obesity, central obesity and insulin resistance 
impact different aspects of cardiovascular structure and function. It is unclear 
whether quantification of the ventricular arterial interaction, particularly pulsatile 
loading, might help to explain the mechanisms linking obesity and increased LV 
mass or diastolic dysfunction.  
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Polycystic ovary syndrome and insulin resistance  
It is difficult to assess the independent and additive effects of obesity and insulin 
resistance in the general population since they tend to exist together in many 
individuals. However, exploration of their individual effects on cardiovascular 
function may provide insights that are relevant to therapeutic interventions. 
Polycystic ovary syndrome (PCOS) is a common condition in women. Although 
diagnosis is based upon hyperandrogenism and dysfunctional or polycystic ovaries, 
insulin resistance is present in the majority of women with the disorder, including 
those who are lean. Therefore, PCOS may provide a model through which to study 
the individual and combined effects of insulin resistance and obesity on the 
cardiovasculature. In addition, PCOS is considered to be a risk factor for diabetes by 
the American Diabetes Association.
69
 For these reasons women with PCOS were 
included as a comparative group in this thesis.  
Interdisciplinary interest, uncertainty about the aetiology and significant 
variation in presentation has led to three different diagnostic definitions for PCOS 
which identify several different reproductive phenotypes (Table 1-2). 
  
Table 1-2 Diagnostic criteria for PCOS (adapted from Dunaif and Fauser).
70
 
 Criteria 
National Institute of Health  BOTH hyperandrogenism and chronic anovulation 
Rotterdam 
71
 Two of the following: hyperandrogenism, chronic 
anovulation, polycystic ovaries 
Androgen Excess Society 
72
 Hyperandrogenism plus ovarian dysfunction 
(oligo/amenorrhea) and/or polycystic ovaries 
 
The National Institute of Health (NIH) definition focuses on the endocrine 
abnormalities of chronic anovulation and hyperandrogenism; this is considered the 
‘classic’ PCOS phenotype. The Rotterdam criteria do not require both these to be 
present but permit ovarian morphology to be considered, leading to a greater number 
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of potentially mild phenotypes.
71
 The Androgen Excess Society has attempted to 
bring these definitions together but their diagnostic criteria are used infrequently.
70
 
The current position of the European Society of Endocrinology is to support the use 
of the more inclusive Rotterdam criteria in diagnosis, but clinicians and researchers 
are urged to consider how the specific phenotype will affect risk factors and 
treatment.
73
  
Many studies have examined insulin sensitivity in women with PCOS but there 
has been debate about whether insulin resistance is extrinsic i.e. solely attributable to 
visceral adiposity, or intrinsic to the condition. Reports of the prevalence of insulin 
resistance have been heterogeneous due to differing methods of measuring insulin 
resistance, thresholds for diagnosing resistance and PCOS diagnostic criteria. 
Stepto et al. recently reported their results of euglycaemic-hyperinsulinaemic 
clamp (considered to be a gold-standard technique) in women with PCOS according 
to the Rotterdam criteria.
74
 Insulin resistance was defined by clamp-derived glucose 
infusion rate (GIR) below the 25
th
 centile of lean, matched controls. This 
comprehensive study found that insulin resistance was present in 75% of lean 
women with PCOS and 95% of overweight women with PCOS compared with 62% 
of overweight controls. Furthermore, the negative relationship between GIR and 
BMI was more marked in women with PCOS than in controls (p<.01). These data 
support a theory of intrinsic insulin resistance in PCOS, even in those who are lean 
or from milder phenotypical categories. There appears to be an additional extrinsic 
level of insulin resistance in the presence of obesity with a greater impact of BMI in 
PCOS than in controls. 
There is little doubt that women with PCOS are at increased risk of developing 
impaired glucose tolerance (IGT) and type 2 diabetes compared with BMI-matched 
healthy women. A recent systematic review and meta-analysis calculated an odds-
ratio of 2.54 (95% CI 1.44-4.47) for IGT and 4.00 (95% CI 1.97-8.10) for type 2 
diabetes in studies where BMI was matched.
75
 The magnitude of risk differs 
significantly between studies and this might be related to different phenotypes, race 
or ethnicity and levels of obesity.
76
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Impaired glucose tolerance and type 2 diabetes are associated with increased risk 
of cardiovascular disease in the general population 
8
 but it is unclear whether the 
insulin resistance related to PCOS necessarily progresses to dysglycaemia. Few 
longitudinal studies have examined the rates of progression from normal glucose 
tolerance to IGT and to type 2 diabetes.
76
 In small studies the annual rate of 
conversion for women with PCOS is 2-3.6% 
77, 78
 but this is lower than the 7% 
annual conversion rate in the general population.
79
 It may be that the rates in PCOS 
are an underestimate because of small sample sizes but it is also possible that the 
degree of dysglycaemia is particular to a PCOS phenotype with limited potential for 
conversion. 
Polycystic ovary syndrome and obesity 
Women with PCOS are frequently overweight or obese and this is known to have an 
adverse effect on the metabolic and reproductive features of the condition.
80
  
It may be difficult to establish the precise prevalence of overweight status and of 
obesity in women with PCOS since this varies according to ethnicity, geographical 
location and recruitment source. Many studies recruit patients from clinics rather 
than from the general community and this may introduce selection bias with results 
tending towards exaggerated levels of adiposity.
81
 Clinicians typically expect 
subjects with PCOS to be overweight or obese which may result in under-diagnosis 
of the condition in lean women who carry cardio-metabolic risk factors.  
One recent systematic review and meta-analysis reported an increased prevalence 
of overweight status and obesity in women with PCOS [pooled risk ratio (95% CI) 
of 1.95 (1.52, 2.50) and 2.77 (1.88, 4.10) respectively].
82
 In addition, Caucasian 
women with PCOS had a greater prevalence of obesity than Asian women with the 
condition [10.79 (5.36, 21.70) versus 2.31 (1.33, 4.00) p<.001 between-groups]. 
There were similar risks of obesity in patients with PCOS diagnosed by NIH and 
Rotterdam criteria but the studies included in the meta-analysis did not specifically 
compare mild and more severe phenotypes. A more recent study by Stepto et al. 
found greater adiposity in those with more severe phenotypes.
74
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There seems little doubt that women with ‘classic phenotype’ PCOS have 
increased cardiovascular risk factors (beyond insulin resistance) with reviews and 
meta-analyses confirming dyslipidaemia 
83
 and elevated CRP 
84
 amongst many other 
markers. However, there is debate about whether these risk factors are attributable to 
increased visceral adiposity in this group 
81
 and there are limited data on the cardio-
metabolic risk in milder phenotypes defined by the Rotterdam criteria.  
It is unclear whether any increased cardio-metabolic risk in PCOS translates to 
adverse cardiovascular outcomes. One systematic review and meta-analysis in 2011  
concluded that women with PCOS had a two-fold risk of coronary heart disease or 
stroke compared with ovulatory controls.
85
 The relative risk remained high when 
data were adjusted for BMI (1.55 95% CI 1.27, 1.89) suggesting that the risk is not 
entirely attributable to the effects of adiposity. However, the review was based on a 
very small number of eligible studies (five) and the authors noted significant 
heterogeneity related to PCOS definition, outcome data and study design. In 
contrast, a subsequent study in general practice comprising more than 21,000 women 
with PCOS compared with two groups matched for (1) geographic location and age, 
and (2) BMI, found an increased risk of diabetes but no increased risk for cancer, 
large vessel disease or all-cause mortality after adjustment for BMI.
86
 This 
observational study included milder phenotypes of PCOS but the women may have 
been too young to have developed adverse cardiovascular outcomes. Large 
prospective longitudinal studies of women with clear definitions of PCOS 
phenotypes are needed to address this topic.  
Even if the effect of PCOS on outcomes is unclear, there is emerging evidence 
from small studies that women with PCOS have subclinical arterial dysfunction with 
considerable debate about which aspects are important in the pathogenesis. Some 
authors suggest that arterial stiffness and/or endothelial dysfunction in those with 
PCOS are independent of obesity,
87-90
 while others maintain that it is obesity and the 
accompanying insulin resistance which are important.
91, 92
  
For example, Meyer et al. demonstrated that overweight women (BMI >27kg/m
2
) 
with the classic PCOS phenotype had increased arterial stiffness (pulse wave 
velocity [PWV] 7.5±0.1 vs. 6.6±0.2m/s) and decreased brachial endothelial function 
(flow-mediated dilatation [FMD] 9.8±0.4 vs. 13.3±0.9%) compared with age- and 
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BMI-matched healthy controls.
87
 The authors suggest that increased arterial stiffness 
is independent of obesity but lean women were not included in the study.  One small 
case-control study (n=38) demonstrated that lean women with PCOS 
(BMI<30kg/m
2
) had significantly worse endothelial function than controls but 
similar arterial stiffness (FMD 6.5±2.9% vs. 10.5±4.0% [p<.01], PWV 5.8±1.1 vs. 
6.0±1.0 [p=.58]).
90
 The authors conclude that a diagnosis of PCOS per se is 
associated with endothelial dysfunction (rather than the confounding factor of 
obesity). The women in this study were not necessarily typical of the PCOS 
population since they did not have the intrinsic insulin resistance or elevated 
testosterone confirmed in larger studies. This suggests that a significant proportion 
of the lean PCOS group were drawn from a ‘mild’ reproductive phenotype 
comprising anovulatory cycles and polycystic ovaries without hyperandrogenemia. It 
is possible that the finding of arterial stiffness differs according to reproductive 
phenotype.  
A more recent, small, but comprehensive study found that artery stiffness in 
PCOS is solely attributable to the central obesity associated with the syndrome.
91
  
The authors used multiple methods of assessing arterial stiffness, considered 
different locations in the arterial tree, and included lean as well as obese women with 
PCOS. After careful adjustment for blood pressure and BMI a diagnosis of PCOS 
did not result in different carotid distensibility, compliance, elastic modulus or aortic 
augmentation index. Obesity itself, regardless of PCOS status, was associated with 
stiffer arteries when measures of distensibility, elastic modulus and compliance were 
considered. There were no differences in pulse wave velocity or aortic augmentation 
index. Regression analyses confirmed that obesity but not PCOS was associated with 
measures of arterial stiffness. Any associations between insulin resistance and 
measures of stiffness disappeared after adjustment for obesity.         
Therefore, while obesity may have a more profound effect on arterial stiffness in 
women with PCOS than in controls, it is unclear whether lean women with insulin 
resistance and hyperandrogenemia have increased arterial stiffness. 
Common carotid intima-media thickness (ccIMT) has been used as a marker of 
subclinical atherosclerosis in the general population with increased thickness 
associated with a higher number of cardiovascular events. There have been several 
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small studies of ccIMT in women with PCOS with disparate results. A systematic 
review and meta-analysis of these studies in 2012  pooled the results of 19 studies 
eligible for meta-analysis and found that women with PCOS had a ccIMT that was 
0.072 – 0.084mm higher than controls.93 The authors considered that this is clinically 
significant because a previous study has estimated that a thickening of just 0.10mm 
increases the risk of myocardial infarction by 15% and stroke by 18%. However, 
there was significant heterogeneity across studies both in terms of PCOS phenotypes 
and quality of ccIMT measurement methods. The review did not seek to establish 
which cardiovascular risk factors were associated with ccIMT. 
Although increased ccIMT is used as a marker of subclinical atherosclerosis in 
the general population it does not necessarily follow that increased thickness equals 
atherosclerosis. In obesity, intima-media thickness may increase to compensate for 
increased circumferential wall stress because of a higher circulating volume which 
enlarges the lumen, and because of higher blood pressure. Therefore, in obese 
subjects an increased ccIMT might represent an adaptive vascular hypertrophy.
94
 It is 
also unclear whether the altered ccIMT is present regardless of the metabolic 
phenotype and whether, given the lack of proven altered outcomes in PCOS, there is 
an aspect of the syndrome which mitigates this risk factor.   
Given the proven trophic effects of insulin it seems logical to assume that the 
insulin resistance and obesity associated with PCOS may lead to left ventricular 
hypertrophy and diastolic dysfunction, but there are surprisingly few papers 
examining cardiac structure and function in this population. The studies tend to be 
small, using different PCOS diagnostic criteria, different echocardiographic 
methods, and have disparate results.  
While some have found no differences in echocardiographic variables between 
those with PCOS and controls,
95-98
 others have found a 10-40% increase in LV mass 
and an associated increase in left atrial diameter,
99, 100
 either with 
100
 or without 
poorer diastolic function.
99
 
One of the more frequently cited studies of left ventricular (LV) function is that 
of Orio et al. who studied women with the more severe NIH classification of 
PCOS.
100
 This small prospective study examined LV mass (indexed by height
2.7
), 
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systolic function (by ejection fraction) and diastolic function (by E/A) in 30 young 
women with PCOS compared with age- and BMI-matched controls. The women 
with PCOS had 40% increased LV mass index, poorer systolic function and poorer 
diastolic function. When subjects were grouped by BMI categories, even those 
PCOS subjects who were lean had higher LV mass index and worse diastolic 
function but the difference in systolic function was only evident in the obese 
category.   In the final regression model only the HOMA index was related to LV 
mass index but it is unclear which other variables were used in the model as these are 
not reported. However, the authors do state that echocardiographic variables were 
not related to androgen levels. Since diastolic blood pressure was higher in those 
with PCOS the conclusion drawn was that insulin resistance in PCOS is associated 
with increased LV mass independent of obesity and that increased diastolic blood 
pressure may be the variable that connects these findings.  
These data are supported by the results of a subset of the CARDIA women’s 
study who reported that women with PCOS had an increase in LV mass/height
2.7 
(10%) and left atrial diameter, after adjusting for age and race.
99
  The magnitude of 
difference between-groups was significantly smaller than that reported by Orio and 
this may be the result of the different study designs (population-based vs. academic 
centre respectively).  
In both these studies it appears that it is the insulin resistance which is important 
in the development of altered LV structure rather than obesity or other derangements 
associated with PCOS. It is unclear whether obese women with insulin resistance but 
without PCOS have comparable increases in LV mass index and reduced diastolic 
function.  
The only study which appears to address this issue is that of Kosmala et al. 
examining 150 obese young women categorised by the presence or absence of PCOS 
(by Rotterdam criteria) and insulin resistance (defined by HOMA-IR threshold 
>2.5).
98
 There were no differences in standard echo measures of LV mass/height
2.7
, 
LA diameter, ejection fraction or E/A between groups, but obese subjects with 
insulin resistance had subclinical dysfunction by reduced systolic and diastolic strain 
whether they had PCOS or not. In multivariate analysis, fasting insulin and BMI 
emerged as independent predictors of both systolic and diastolic strain parameters. 
 24 
 
 
Although women who were obese but ‘metabolically healthy’ had better strain and 
strain rate than those who were obese and had insulin resistance, it is not possible to 
ascertain whether strain and strain rate were comparable with lean subjects since 
these were not included in the study.  
There are no studies demonstrating whether these potential subclinical alterations 
in LV structure and function progress to clinically relevant heart failure or worse 
outcomes in women with PCOS.  An increase in LV mass may not be pathological 
and may be related to an increase in lean muscle mass in subjects with PCOS.
101
 
There are no studies which comprehensively examine cardiac and arterial 
function in a cohort of well characterised women with PCOS across a wide range of 
metabolic phenotypes and in comparison with age- and BMI-matched controls. This 
is necessary to understand the confounding effects of obesity and insulin resistance 
and to explore the pathophysiology. For example, it is unclear whether any increase 
in LV mass is due to a direct trophic effect of insulin on the myocardium or 
secondary to increased arterial stiffness and altered wave reflections.   
To better determine the most effective management strategy in PCOS a greater 
number of studies are needed to confirm (1) the causal links between PCOS and 
altered cardiovascular structure/function (2) the natural history of subclinical 
cardiovascular dysfunction (3) whether subclinical cardiovascular dysfunction 
results in altered morbidity and mortality. In the interim, it appears that a strategy of 
reducing obesity (particularly central obesity) in women with PCOS may at least 
ameliorate some of the cardiovascular effects of the syndrome. 
The potential value of assessing the ventricular-arterial interaction 
Cardiac structure and function are affected by arterial structure and function which 
determine the load that the LV has to pump against to eject blood. In addition, 
arterial structure and function are affected by systolic cardiac function since the 
arteries demonstrate increased stiffness at higher pressures and with more rapid 
ejection of blood by the LV.
102
  
Despite this physiological systolic-coupling, many research studies typically 
assess LV function or arterial stiffness in isolation, providing a limited appraisal of 
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pathophysiology. In the case of uncomplicated obesity and pre-diabetic states, few 
studies have established whether any increase in arterial stiffness or pulsatile loading 
contributes to the development of left ventricular hypertrophy or diastolic 
dysfunction. This might have direct relevance to potential therapeutic treatments. To 
the best of my knowledge there are no case-control studies which comprehensively 
characterize body composition, metabolic health, cardiovascular structure and the 
ventricular-arterial interaction in obesity. 
This thesis focuses on two non-invasive methods of quantifying the ventricular-
arterial interaction. The first involves the calculation of arterial and ventricular end-
systolic elastance from echocardiography and permits visualisation of the effects of a 
disease using simplified pressure-volume loops. The second involves deriving wave 
intensity (WI) signals from changes in pressure and velocity in the carotid artery. 
Method 1: Ventricular-arterial coupling and the pressure-volume 
loop 
The pressure-volume (PV) loop provides a detailed visual description of ventricular-
arterial interaction across the cardiac cycle. Since its first description by Otto Frank 
in 1895, the PV loop has been used to understand the effects of pathology on the 
external stroke work that the ventricle does given a set of loading conditions. A 
review of the  use of PV loops in clinical research was published by Burkhoff in 
2013.
103
 
Historically, PV loops have been derived from invasive studies that directly 
measure real-time changes in ventricular pressure while loading or contractility is 
altered in a step-wise and controlled manner. Ventricular end-diastolic volume 
(preload) is frequently reduced by transient balloon occlusion of the inferior vena 
cava (IVC), while the resistance that the ventricle is ejecting against (afterload) may 
be increased by aortic occlusion or decreased by administration of a vasodilator, and 
contractility may be altered by administration of a positive or negative inotrope.   
Although PV loops provided an excellent assessment of the effects of arterial 
load on ventricular function, quantification of the ventricular-arterial interaction 
remained difficult because assessments of LV function were made in the time-
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domain while those of arterial function were made in frequency-domain.  This 
changed with the development of elastance theory which allowed both arterial and 
ventricular function to be assessed in the time-domain. 
The concept of ventricular elastance  
In the late 1960s and early 1970s, a series of papers from Hiroyuki Suga investigated 
the pumping properties of the LV using the time-course of the relationship between 
instantaneous pressure and volume. Using an experimental canine model, Suga 
described a new variable which characterised ventricular pumping properties using 
the equation 
𝑒(𝑡)  =  
𝑝(𝑡) 
𝑣(𝑡)
 
where, e was a new concept of the reciprocal of compliance (elastance), p was LV 
systolic pressure, v was LV systolic volume and (t) was the time from the beginning 
of systole in a given cardiac cycle.
104
  
Figure 1-3 demonstrates the typical time course of ventricular elastance in a 
cardiac cycle. The rising portion (during systole) tended to have two distinct slopes, 
a steeper early component and a more gradual component towards the peak 
elastance. The initial fall of elastance was very steep and then the slope became more 
gradual.  
Suga established that the time-course of elastance retained this pattern regardless 
of alterations in preload 
104
 and afterload 
105
 within their physiologic ranges. 
However, during inotropic stimulation the maximum elastance increased 
significantly, and occurred sooner in the cardiac cycle.
106
 This provided experimental 
evidence that the time-course of elastance was a robust and relatively load-
independent measure of ventricular contractility.  Suga also noted the relatively 
linear time-course of elastance during isovolumetric contraction, a feature that would 
be used to develop non-invasive methods many years later.  
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Figure 1-3. Drawing showing the typical time-course of LV elastance through a cardiac 
cycle. The red curve demonstrates the effects of inotropic stimulation; the maximum 
elastance increases and occurs sooner in the cardiac cycle. Adapted from Suga.
104
 
 
These early experiments included indicator dilution techniques to estimate 
ventricular volume and electromagnetic measurement of aortic flow. Suga 
considered that these methods may have limited the accuracy of volume 
measurements and in a subsequent paper he, Kiichi Sagawa and Artin Shoukas,  re-
investigated the pressure-volume ratio with an improved method.
107
 The 
‘cardiometer’ involved closing the excised ventricle in an airtight chamber and using 
air pressure changes to measure changes in ventricular volume (plethysmography). 
The model was tested using a variety of loading conditions, heart rates and inotropic 
interventions, and confirmed that the pressure-volume relation was not significantly 
affected by preload or afterload. Despite an increase in elastance slope during 
inotropic stimulation, the extrapolated line intercepted the volume axis at a single 
point greater than zero. This was defined Vd, a correction for the ‘dead volume’. The 
authors therefore assumed that changes in inotropic state would not alter the volume 
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intercept but would cause the elastance curve to pivot from this point. Therefore, the 
elastance at any point in time (t) could be calculated by 
𝐸(𝑡)  =  
𝑃(𝑡)
𝑉(𝑡) –  𝑉𝑑
 
While the elastance curves had similar shape during inotropic stimulation, they 
had greater amplitude and shorter duration. The authors found that all curves could 
be ‘normalised’ using the maximum elastance (Emax) and the time to this peak (Tmax) 
so concluded that these variables should be considered the characteristic parameters 
of the elastance curve. Emax was defined by the upper leftmost corner of the pressure 
volume loop and Tmax was the time taken from end-diastole to Emax. Neither variable 
was affected by changes in loading but both were specifically and sensitively 
affected by a change in contractile state (during epinephrine infusion). When heart 
rate was changed by pacing and contractile state was fixed, Emax did not alter 
significantly while Tmax shortened. These results were confirmed by a subsequent 
similar study.
108
 
In summary, ventricular elastance is a measurement of the stiffness of the LV. 
An increased elastance will result in a higher change in pressure for any given 
change in volume. The major determinant of ventricular end-systolic elastance is 
contractility.  The maximum ventricular end-systolic elastance was initially called 
Emax but other terms have been used in the decades that followed the early 
experimental work. The most recent convention is to use the term Ees and this will be 
adopted in this thesis. The volume intercept will be called V0 and not Vd as used in 
the original work.  
The concept of arterial elastance 
In 1983, Sunagawa, Maughan, Burkhoff and Sagawa presented a conceptual 
framework to determine whether the stroke volume ejected from the LV into the 
arterial system could be predicted by quantification of the ventricular-arterial 
interaction.
109
 To achieve this they examined whether the arterial load could be 
characterised by the pressure-stroke volume relationship. They assumed that the 
arterial system could be treated as though it was an elastic chamber with a volume 
elastance (Ea) in the same way that Suga had treated the LV as an elastic chamber 
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with end-systolic volume elastance (Ees). Experimental results from a canine model 
revealed that the equation below was a very good approximation of the arterial 
loading system. 
𝐸𝑎  =  
𝑃𝑒𝑠 
𝑆𝑉
  
where Pes was the end systolic pressure and SV was stroke volume. 
Furthermore, the slope of the pressure-volume relation was highly dependent on 
arterial resistance (increased slope associated with increased resistance), and less 
influenced by arterial compliance. Thus, they concluded that it was a measure of 
‘effective’ arterial resistance that included pulsatile load. Having established that the 
arterial system could be characterised in this way they assessed whether stroke 
volume could be predicted in any coupled system by simultaneously solving the 
equations for Ees and Ea so that, 
𝑆𝑉 =  
𝑉𝑒𝑑 – 𝑉0 
1 + 𝐸𝑎 𝐸𝑒𝑠⁄
 
Predicted stroke volume was closely correlated with measured stroke volume 
(r=.985). This demonstrated that the stroke volume ejected into the arterial 
circulation was dependent on the ratio of elastances, and that the intersection of the 
slopes Ea and Ees could provide a visual means of understanding the effects of altered 
loading and contractility on stroke volume. The authors used diagrams as a means of 
communicating the effects of altered loading or contractility on stroke volume 
(drawings to show examples of these are shown in Figure 1-4). They suggested that 
in a normal heart an increase in preload would not affect the slope of the ventricular 
pressure-volume relation (Ees) but would cause it to shift to the right so that stroke 
volume is at a higher new equilibrium. If ventricular contractility was increased, then 
the slope Ees would increase causing an increase in stroke volume (assuming there 
were no changes in loading). If arterial resistance was increased the slope Ea would 
increase causing a decrease in stroke volume.  
While this visual representation of the ventricular-arterial interaction is useful it 
does not fully represent intact physiology since a change in the condition of one 
factor will result in a change in another. For example, a decrease in stroke volume 
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would result in decrease in mean central blood pressure which, through the 
baroreflex, would trigger increased sympathetic drive to increase contractility and 
heart rate.   
Using echocardiography, the same authors tested whether ultrasound could be 
used to quantify ventricular elastance since non-invasive methods would be 
preferable.
110
 They found that left ventricular end-systolic diameter had a good linear 
relationship with end-systolic volume in a conscious canine model (V = 32.D – 65). 
Results demonstrated that the diameter-derived values of ventricular elastance were 
close approximations of invasive values in control states and in increased inotropy. 
However, only normal canine hearts were used and there was concern that the linear 
relationship may not hold true in dilated, failing ventricles. This work was extended 
to human testing in 11 subjects undergoing cardiac catheterisation at the Johns 
Hopkins Hospital.
110
 These preliminary results showed a good correlation between 
diameter-derived Ees values and subjective grading of LV systolic function.  
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Figure 1-4. Diagrams showing how the intersection between arterial elastance (red) 
and ventricular elastance (blue) affect stroke volume. The equilibrium stroke volume 
is shown by the closed circle (A). The effect of an isolated increase in preload is 
shown in (B) – the ventricular elastance line moves to the right but retains the same 
slope resulting in an increase in stroke volume (open circle) at a higher end-systolic 
pressure. The effect of an isolated increase in contractility is shown in (C) – the 
ventricular elastance line has an increased slope resulting in an increased stroke 
volume at a higher end-systolic pressure. The effect of an isolated increase in arterial 
resistance is shown in (D) – the arterial elastance line has an increased slope 
resulting in a decreased stroke volume but a higher end-systolic pressure. Note that 
matched increases in arterial and ventricular elastance will result in a higher end-
systolic pressure but no change in stroke volume. Adapted from Sunagawa et al.
109
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Validation of a non-invasive method of calculating arterial elastance 
The same team of researchers led by David Kass at the Johns Hopkins Hospital in 
the U.S. validated the simplified equation for arterial elastance (Ea = Pes/SV) in 10 
subjects (9 men) across a wide age range (19-60 years).
111
 Six of the older subjects 
had hypertension and their monotherapy was withheld for 10 days before the study. 
Pressure-volume loops were derived from invasive measures at baseline, during 
stages of preload reduction with transient IVC balloon obstruction and during 
pharmacological afterload changes. The simplified elastance calculation (Ea(PV)) 
was almost identical to that calculated using traditional impedance (Ea(Z)) 
measurements (Ea(PV)= 0.98 x Ea(Z) +0.17, r
2 
0.98, p<.0001).   
In order to facilitate non-invasive estimation of arterial elastance, the authors also 
tested the use of two equations which could estimate central aortic end-systolic 
pressure from brachial cuff pressure. These were 
𝑃𝑒𝑠  ≈  
(2 ×  𝑠𝑦𝑠𝑡𝑜𝑙𝑖𝑐 𝐵𝑃 +  𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐 𝐵𝑃) 
3
 
𝑃𝑒𝑠  ≈  0.9 ×  𝑠𝑦𝑠𝑡𝑜𝑙𝑖𝑐 𝐵𝑃 
Regardless of which equation was used in the calculation of Ea(PV), it remained 
closely correlated with Ea(Z); the latter equation yielded an r
2
 of 0.97, p<.0001. The 
results of this study demonstrated that the simplified calculation of Ea(PV) could be 
used to index pulsatile load and that non-invasive means of estimating central end-
systolic pressure were acceptable. In addition, the similarity of the equation to that 
for ventricular elastance (Ees) made assessment of ventricular-arterial coupling more 
attractive and feasible in a non-invasive environment.  
While generalisation of these results is hampered by the small study size and lack 
of diverse pathology, these methods have been used in other studies.
112-117
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Validation of a non-invasive single-beat calculation of LV elastance 
The slope of ventricular elastance is more challenging to assess by non-invasive 
means since it requires knowledge of the volume intercept (V0) which cannot be 
measured in an intact circulation. The alternative is to undertake interventions that 
alter loading (without affecting inotropy) and to plot the change in end-systolic 
pressure. In experimental studies this has frequently been achieved by transient 
occlusion of the IVC using a balloon. The invasive and time-consuming nature of the 
intervention makes it unsuitable for use in large-scale clinical studies.  
The first study to validate echocardiographic elastance calculations in humans is 
believed to have been undertaken by Asanoi et al. in 1989.
118
 This Japanese study 
comprised 28 subjects categorised by ejection fraction (EF) into three groups: 
(i) Normal LV function, EF ≥60%; (ii) Mild LV impairment, EF 40-59%; and (iii) 
Significant LV impairment, EF <40%. Loading interventions included 
administration of phenylephrine (a vasoconstrictor) and nitroprusside (a vasodilator). 
In an effort to discover a non-invasive means of estimating ventricular elastance, 
echocardiographic measures of left ventricular volume were calculated using the 
Teicholz method and indexed for body surface area; these data were gathered 
simultaneously with arterial pressure waveforms and compared with contrast 
ventriculography. Echo derived volumes correlated strongly with ventriculography 
(r=0.92, p<.01) but echo consistently underestimated the volumes (echo volume = 
0.77*Angio +13.70). The authors postulated that this may be because of an 
underestimated long axis dimension. As expected, ventricular elastance, a measure 
of contractility, declined with ejection fraction (those with normal EF had Ees of 
4.5±2.0mmHg/ml/m
2
, those with mild impairment had Ees of 2.5±1.1mmHg/ml/m
2
, 
and those with significant impairment had Ees of 1.5±0.7 mmHg/ml/m
2
). Heart rate 
and end-systolic pressure were similar between groups. In contrast, Ea was noted to 
increase as EF decreased, largely because of the decrease in stroke volume without 
an accompanying change in end-systolic pressure. Ventricular-arterial coupling was 
expressed by the ratio of arterial to ventricular elastance and the ratio was found to 
progressively increase as ejection fraction decreased. However, only the difference 
between the normal and significantly impaired group was statistically significant. In 
the normal group (i), Ea was always less than Ees and resulted in a smaller stroke 
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work for a given contractility and preload. In group (ii) the ratio was near unity and 
ventricles were performing at almost maximal stroke work for any given preload. 
The ratio in group (iii) was substantially higher indicating decreased mechanical 
efficiency. Their aim was to alter loading without changing contractility in order to 
derive ventricular elastance, but the drugs used in this study could have altered 
contractility through the baroreflex.  
It is difficult to perform loading interventions in large-scale studies and, since the 
volume at a pressure of zero is small in comparison with left ventricular end-systolic 
volume, some authors have simplified the calculation of ventricular elastance by 
assuming that V0 is effectively zero i.e. that it passes through the origin.
112
 This is 
appealing because it means that the slope of ventricular elastance can be calculated 
from a single blood pressure and LV volume measurement. However, this 
assumption can lead to overestimation of ventricular elastance with negative values 
of V0 and underestimation with positive values of V0.
119
   
In addition, there is an assumption that the line can only pivot from a fixed 
volume intercept, whereas it has been shown to shift along the volume axis in 
disease conditions such as in regional ischaemia 
120
 and in patients with severely 
impaired left ventricular function.
118
  
To overcome this problem the group of researchers led by Kass developed a 
more comprehensive method of assessing elastance which sought to calculate the 
volume intercept.
121
 The hypothesis is based on the earlier finding that ventricular 
stiffening and relaxation through a single cardiac cycle cause predictable changes in 
the time-course of elastance.  The method (Chen et al.) establishes two single-point 
elastance calculations within a single cardiac cycle and assumes that the volume 
intercept will be the same for both.  
The calculation of the first elastance point at end-systole was described above. 
The authors selected the second elastance measurement to be at the end of the 
isovolumic contraction period. At this point the pressure in the LV would be similar 
to the aortic diastolic pressure (since this is necessary for the aortic valve to open) 
and the volume would be the same as the end-diastolic LV volume since the blood 
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has yet to be ejected from the ventricle. From these it was possible to calculate an 
end-diastolic elastance.   
 The ratio of diastolic to end-systolic elastance was described as amplitude and 
time-normalised elastance (ENd) for a single cardiac cycle. Therefore, 
𝐸𝑁𝑑  =  
𝐸𝑑  
𝐸𝑒𝑠
 
or,       
𝐸𝑑 =  𝐸𝑁𝑑  ×  𝐸𝑒𝑠           (1) 
          
The normalised elastance could then be used to calculate Ees without making 
assumptions about the volume intercept. Full details of the mathematical derivation 
from the original paper by Chen at al.
121
 are included below in order to facilitate 
understanding of the methods used in this thesis. The method has been adapted by 
the inclusion of additional explanatory mathematical steps. 
If,    
𝐸𝑒𝑠  =  
𝑃𝑒𝑠
𝑉𝑒𝑠 –  𝑉0
             (2) 
and   
𝐸𝑑  =  
𝑃𝑑
𝑉𝑑 – 𝑉0
          (3) 
          
Equations (1) and (3) can be combined to give   
𝐸𝑁𝑑 𝑥 𝐸𝑒𝑠  =  
𝑃𝑑
 𝑉𝑑 − 𝑉0
 
 or  
𝑉𝑑  =  
(𝑃𝑑/𝐸𝑁𝑑) 
𝐸𝑒𝑠
 +  𝑉0          (4) 
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and equation (2) can be rearranged to a similar format   
𝑉𝑒𝑠  =  
𝑃𝑒𝑠 
𝐸𝑒𝑠
 + 𝑉0 
The influence that a change in volume will have on pressure is therefore given by 
   
𝑉𝑑 – 𝑉𝑒𝑠  =  (
(𝑃𝑑/𝐸𝑁𝑑)
𝐸𝑒𝑠
 +  𝑉0) – (
𝑃𝑒𝑠
𝐸𝑒𝑠
+  𝑉0) 
In this way, V0 is removed from the equation and Ees becomes the common 
denominator   
𝑉𝑑 – 𝑉𝑒𝑠  =  
(𝑃𝑑  / 𝐸𝑁𝑑)– 𝑃𝑒𝑠 
𝐸𝑒𝑠
 
Multiplying all terms on the right of the equation by ENd removes the double division 
   
𝑉𝑑 –  𝑉𝑒𝑠  =  
𝑃𝑑  – (𝑃𝑒𝑠  ×   𝐸𝑁𝑑)
𝐸𝑒𝑠  ×  𝐸𝑁𝑑
 
Finally, re-arranging for Ees gives 
   
𝐸𝑒𝑠  =  
𝑃𝑑  – (𝑃𝑒𝑠  ×  𝐸𝑁𝑑) 
𝐸𝑁𝑑  ×  (𝑉𝑑 − 𝑉𝑒𝑠)
 
where Pd was the diastolic blood pressure, Pes was calculated by 0.9 x brachial 
systolic blood pressure and Vd-Ves was the stroke volume by the Doppler method.  
This theory allowed the slope of ventricular elastance to be calculated without 
assuming a volume intercept at the origin. The original work by Suga documented a 
stable elastance during the isovolumic contraction period with limited variations 
caused by contractility and afterload.
104, 105
 However, in the non-invasive method 
measurement needs to be taken at the onset of ejection so that the diastolic blood 
pressure can be used in the calculation of elastance (since an invasive measure of 
pressure is not available). As a result there was more variation in individual elastance 
using this method. The authors sought to overcome this by using data from their 
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invasive experimental work to derive a regression formula based on individual 
ejection fraction (contractility) and the ratio of systolic to diastolic pressure 
(afterload). Thus, the estimated normalised elastance became  
𝐸𝑁𝑑(𝑒𝑠𝑡)  =  0.0275 – (0.165 × 𝐸𝐹 ) +  (0.3656 ×
𝑃𝑑
𝑃𝑒𝑠
)  +  (0.515 × 𝐸𝑁𝑑(𝑎𝑣𝑔)) 
where the group ENd average was given by a polynomial function 
𝐸𝑁𝑑(𝑎𝑣𝑔)  =  ∑ 𝑎𝑖  ×   𝑇𝑁𝐷𝑖
𝑖=0
 
 
and  𝑇𝑁𝐷  =
 𝑇𝑖𝑚𝑒 𝑓𝑟𝑜𝑚 𝑅 𝑤𝑎𝑣𝑒 𝑡𝑜 𝐴𝑉 𝑜𝑝𝑒𝑛𝑖𝑛𝑔
 𝑇𝑖𝑚𝑒 𝑓𝑟𝑜𝑚 𝑅 𝑤𝑎𝑣𝑒 𝑡𝑜 𝐴𝑉 𝑐𝑙𝑜𝑠𝑢𝑟𝑒
 
and values of ai were 0.35695, -7.2266, 74.249, -307.39, 684.54, -856.92, 571.95 
and -159.1 for i=0 to 7, respectively.  
The authors showed that average normalised elastance from the polynomial 
equation had a strong correlation with the normalised elastance measured from the 
invasive data (r=0.88 and p<.0001, SEE 10% about the mean). Results showed that 
the estimated slope Ees tended to overestimate the invasively measured value in 43 
comparisons with regression equation Ees = 0.78 x Ees(est) + 0.55 (r=0.81, p<.0001, 
SEE 0.50). There was no systematic bias and 80% of the errors were <0.6mmHg/ml.  
This way of calculating ventricular elastance was termed a single-beat method 
and was compared with the simple measurement which assumes a volume intercept 
with the origin (Pes/Ves). The simple measurement correlated less well with the 
invasive values (r=0.56) than did the single-beat method and consistently over-
estimated the slope of ventricular elastance, with the error becoming worse at higher 
values.  
Reproducibility of the single-beat method was assessed by repeating non-
invasive measurements over 3 months in 7 subjects. The coefficient of variation was 
20 ± 6% with variability related predominantly to changes in stroke volume (14 ± 
6.6%).  
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Elastance measurements and obesity 
There are many studies of the effects of obesity on ventricular or arterial function but 
few have an integrated approach and fewer still include non-invasive measurements 
of elastance. 
Arterial and ventricular end-systolic elastance are positively related to body size 
in a healthy population. Therefore, it may be necessary to scale these measures 
before interpreting between-group differences associated with obesity. These and 
other echocardiographic variables are frequently scaled by dividing by a measure of 
body size which assumes a linear relationship between the two; this is called 
ratiometric scaling. Ratiometric scaling is inappropriate if the relationship with body 
size is non-linear and can result in both over- and under-estimation of results, 
depending on the true relationship. In such cases allometric scaling may be more 
appropriate; the physiological variable should be scaled by a measure of body size 
raised to some power of a scalar exponent. 
One comprehensive study by the Asklepios investigators has confirmed a 
positive association of arterial (Ea) and ventricular end-systolic elastance (Ees) with 
height, weight and body surface area in a large reference population (n=612) of 
healthy, lean volunteers aged 35-55yrs.
122
 The relationships with height and weight 
were non-linear suggesting that allometric scaling by these variables is necessary. 
The relationship between arterial and ventricular elastance and body-surface area 
was approximately linear so ratiometric scaling might be suitable for this measure of 
body size.   
In the same study these scaling methods were used to assess whether obesity 
affected arterial and ventricular elastance beyond the normal relationship with body 
size. The authors chose to use allometric rather than ratiometric scaling by body 
surface area (the reason for this is unclear). The unscaled arterial elastance decreased 
with overweight (n=901) and obesity (n=316), while the unscaled ventricular 
elastance appeared unaffected. These findings are counterintuitive given the 
established links between obesity, hypertension and increased left ventricular mass. 
In contrast, scaled values of arterial and ventricular elastance significantly increased 
with each category of obesity [mean Ea (mmHg/mL/m
2.4
) was 2.89 in lean subjects 
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(n=1151), 3.1 in overweight subjects (n=901) and 3.89 in obese subjects (n=316); 
mean Ees (mmHg/mL/m
2.1
) was 3.28 for lean subjects, 3.55 for overweight subjects 
and 3.89 for obese subjects; all differences were statistically significant (p<.0001)]. 
The ratio of elastances was unchanged in obesity but this should not be mistaken for 
a ‘normal’ finding. In this case it occurred because the increase in arterial elastance 
was matched by an increase in ventricular end-systolic elastance. This may have the 
effect of preserving ejection fraction but at the expense of elevated systolic pressure, 
reduced ventricular contractile reserve and more labile blood pressure.  
Since the study above was cross-sectional in nature it was not possible to say 
with certainty that obesity was the cause of the increased elastance. Therefore, the 
same authors sought to establish this in a longitudinal study.
116
 Subjects were drawn 
from a randomly selected, community-based population of 1,402 U.S. subjects who 
underwent comprehensive echocardiography on two occasions separated by 4 years. 
Only 56% of subjects had adequate paired data for determining arterial and 
ventricular end-systolic elastance, and while this suggests that the feasibility of the 
technique may be low in a general population, the results are likely affected by the 
absence of elastance measurements among the primary outcome measures in the 
initial study design.  In the four years between study visits, arterial elastance 
decreased by 3% because of improved blood pressure control in the sample 
population which negated the effect of ageing. In contrast, ventricular end-systolic 
elastance increased by 14%. Weight loss between examinations was associated with 
a greater decrease in arterial elastance than was explained by blood pressure control. 
However, central obesity was not an independent predictor of the change in arterial 
elastance.  In women, central obesity resulted in greater age-related changes in 
ventricular end-systolic elastance (after adjustment for arterial elastance) but this 
finding was not evident in men. From this the authors speculate that measures to 
control central obesity are particularly important in preventing heart failure in 
women.  
While these data provide an insight to the relationship between obesity and 
ventricular-arterial coupling, interpretation of the findings is complicated by the 
inclusion of a significant number of subjects with hypertension as well as those 
taking cardiovascular medication. For example, the improved blood pressure control 
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between visits may have masked any age related increase in arterial elastance and the 
anti-hypertensive medication may well have affected several key contributors to 
arterial and ventricular elastance.   
Therefore, there is some uncertainty about the effects of uncomplicated obesity 
on unscaled and scaled measures of arterial and ventricular end-systolic elastance. It 
is also unclear whether central obesity and insulin resistance explain more of the 
variation in elastance than general obesity. In addition, the mechanisms linking 
increased elastance with obesity are unclear; relative contributions of altered 
geometry, structure, heart rate, resistive and pulsatile load to elastance are not well 
defined in an uncomplicated obese population. More detailed physiological 
information is needed to better understand the complexities of these simplified 
measures of stiffness and to inform potential therapeutic targets.   
Elastance and pre-diabetic states 
I have been unable to find conclusive data relating to the independent effects of pre-
diabetic states on elastances and ventricular-arterial coupling. There are also limited 
studies of ventricular-arterial coupling in patients with diabetes. 
Data from the Asklepios study suggest that impaired fasting glucose is associated 
with higher mean arterial blood pressure without a change in aortic stiffness or 
pulsatile indices, whereas diabetes was associated with increased aortic stiffness 
reflected by increased characteristic impedance, and increased pulse wave 
velocity.
123
  These data suggest that arterial elastance may be increased in the later 
stages of abnormal glucose handling but it is unclear whether ventricular elastance 
will be affected. 
One small but comprehensive cross-sectional study has compared elastances and 
their ratio in a group of middle-aged subjects with metabolic syndrome.
115
 All 
subjects were free from hypertension, diabetes and overt cardiovascular disease so 
the authors were better able to examine the effects of metabolic syndrome on 
cardiovascular function. Resting measures of arterial and ventricular end-systolic 
elastance were not different between those with metabolic syndrome and controls.  
The authors found no relation between body surface area and elastances in their very 
small sample population so compared unscaled values despite a significant between-
 41 
 
 
group difference in body size (BMI 36 ± 1 vs. 25 ± 0.8 Kg/m
2
, p <.0001).  Given the 
findings of Chirinos et al.,
122
 this might have masked any difference related to the 
obesity. In addition, the study was powered to look for differences in elastance on 
exercise and the sample size may be too small to detect resting changes in the 
absence of significant LV dysfunction (n= 47 including 20 controls). 
There is currently insufficient evidence to ascertain whether the pre-clinical 
levels of abnormal glucose handling associated with obesity directly affect arterial 
and ventricular end-systolic elastance and cardiac energetics.  
Elastance and polycystic ovary syndrome 
To the best of my knowledge there are no studies of arterial and ventricular elastance 
in women with PCOS. There is evidence that PCOS may be associated with altered 
arterial structure,
93
 increased arterial stiffness,
87, 90
 altered ventricular geometry and 
function 
99, 100
  but this frequently comes from older subjects, those with the most 
severe reproductive phenotype, or from studies where there are confounding factors.   
There is evidence for sex-differences in elastance values in a healthy 
population,
124
 so it is tempting to speculate that the altered hormonal profile in 
PCOS may affect elastance measures. It is unclear whether elastance data will 
enhance our understanding of the effects of the syndrome on cardiovascular risk.  
Reproducibility and sensitivity of non-invasive measures of elastance 
The reproducibility of non-invasive measures of elastance are infrequently reported 
but appear to be ~8-23% (coefficient of variation) for arterial elastance and 8-29% 
for ventricular elastance depending on the methods used to calculate elastance as 
well as whether inter-observer, inter-session data were collected.
115, 121, 125-127
   
For example, Gayat et al. established intra-observer coefficients of variability of 
16 (±17) % for arterial elastance, 22 (±17) % for ventricular end-systolic elastance 
and 13 (±10) % for the ventricular-arterial coupling ratio.
127
 Inter-observer 
coefficients of variability were 23 (±24) % for arterial elastance, 29 (±22) % for 
ventricular end-systolic elastance and 15 (±12) % for ventricular arterial coupling. 
This variability is higher than for many standard echocardiographic measures and 
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may reduce the ability of the method to identify between-group differences precisely 
in a sub-clinical setting.  
In the same study the authors demonstrated that the methods used to derive 
ventricular end-systolic elastance and the coupling ratio were sufficiently sensitive to 
detect small positive changes in inotropy associated with dobutamine stress and 
negative changes associated with left ventricular systolic dysfunction.
127
 It is worth 
noting that the study included modifications to the original validated method.
121
 LV 
volumes were calculated using 3D echocardiography, and end-systolic pressure was 
estimated from 0.9 x central systolic BP by tonometry (rather than brachial arm cuff 
pressure). While these modifications should result in more precise measures they 
were not used in the original validation study of the single-beat ventricular elastance 
method.
121
  
It is unclear whether the unmodified non-invasive methods described in the 
methods of this thesis will be feasible in a predominantly obese female population 
and whether they are sufficiently sensitive to detect what may be subtle differences 
in sub-clinical cardiovascular function in relatively young subjects.  
Limitations of the current evidence-base 
It is difficult to interpret the combined published data on elastance confidently, 
because of significant between-study differences in methods. These differences 
relate to surrogate measures of end-systolic pressure, whether methods assumed a 
volume intercept of the end-systolic pressure-volume relation (ESPVR) at the origin, 
method of measuring of ventricular volumes, and methods of scaling for body size or 
use of unscaled data. In the majority of non-invasive studies of elastance, the 
variables were not scaled for body size even though obesity was sometimes a feature 
of the sample population or there were between-group differences in sex (and 
therefore size).  
Several studies include older subjects with positive family history or comorbid 
conditions which confounds the results and their interpretation. In addition, there are 
very few studies where patients and matched controls are comprehensively 
characterised in terms of metabolic, anthropometric and cardiovascular function. 
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Method 2: Arterial wave physiology 
The Windkessel effect is the term used to describe how large elastic arteries store a 
proportion of the stroke volume in systole and discharge that volume in diastole.
128
 
This ensures that ventricular ejection into the systemic circulation does not generate 
an excessively high pressure (which opposes emptying), as well as smoothing the 
pulsatile blood flow to ensure more even distal flow in arterioles.  
Blood ejected from the LV has kinetic energy and causes the muscular aorta to 
stretch, converting kinetic into potential energy in the wall of the aorta. Elastic recoil 
of the artery causes transfer of potential energy back to kinetic energy in the blood, 
displacing the blood particles. This cyclical energy transfer results in a wave which 
moves through blood more quickly than the blood flows.
129
  
Waves in arteries tend to be longitudinal in nature so that blood particles are 
displaced in a direction that is parallel to wave propagation. Longitudinal waves are 
characterised as compression or expansion depending on their effect on the sign of 
pressure change. A wave that causes an increase in pressure is described as a 
‘compression’ wave while that causing a decrease in pressure is an ‘expansion’ 
wave. Since blood is considered a relatively incompressible liquid, an arterial 
compression wave that is generated by LV contraction will cause expansion of the 
arterial diameter. A reduction in the rate of LV contraction at end-systole causes an 
expansion wave to be generated which has the effect of decelerating aortic flow and 
assisting aortic closure.
129
   
Waves propagated from the LV travel forward through the arterial circulation 
and a fraction of their power may be reflected backward from sites of impedance 
mismatch, such as at bifurcations or at sites of high resistance vessels. The 
magnitude of the reflection (reflection co-efficient) appears to be determined by the 
properties of the artery either side of the junction.
130
 In addition, a backward wave 
may not be transmitted through the circulation in the same way as a forward wave. 
There is experimental evidence that bifurcations may be poorly matched for 
backward waves resulting in significant re-reflections and ‘wave trapping’ in the 
distal circulation so that the magnitude of backward wave is significantly reduced at 
the heart.
130
 The systemic circulation is considered to be a ‘closed-end’ circuit and 
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this has the effect of the reflected wave being of the same type as the forward wave 
e.g. a forward compression wave will be reflected as a backward compression wave 
having the effect of increasing pressure but decelerating flow velocity.  
The kinetic energy in ejected blood depends on LV function, while the 
mechanical properties of the arterial wall are determined by the collagen and elastin 
deposited by smooth muscle cells in the medial layer. Thin, fenestrated sheets of 
elastin are connected by elastic fibres and transfer stress throughout the wall of the 
vessel. The artery wall acts as a ‘two-phase’ material because bundles of collagen 
between these layers do not have a particular arrangement at low pressures, resulting 
in compliance that is predominantly determined by the properties of elastin. At high 
pressure, the collagen fibres become circumferentially aligned so that the vessel 
becomes much less compliant, restricting aortic distension. These properties account 
for the non-linear nature of vascular elasticity.
131
 As a result, the speed of the arterial 
wave has a non-linear relationship with blood pressure and the artery is less 
compliant at high pressures as a result of a greater number of collagen fibres being 
recruited. The aorta also demonstrates dynamic compliance which depends on the 
rate of volume change during ejection. A more rapid change in volume, as occurs at 
higher heart rates with increased ejection velocity, is associated with lower 
compliance (a stiffer artery).
132
 
Therefore, the arterial wave contains information about both ventricular and 
arterial function which may provide valuable insights to the effects of 
pathophysiology on haemodynamics and to assess cardiovascular risk.  
There are two main methods of studying arterial waves. The first is an impedance 
method that presumes a linear relationship between pressure and flow. The 
relationship is described by an equation that is analogous to Ohm’s Law (V = I.R): 
𝑃 =  𝑍. 𝑄 
where P is pressure (analogous to voltage), Q is flow rate (analogous to current) and 
Z is impedance. 
This method is used to derive complex electrical networks designed to represent 
the resistance, capacitance and inertance of different parts of the vasculature.
133
 Each 
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pulse is considered to be one of a number in a series generated repetitively from the 
heart. The characteristics of this series of pulses can be described by Fourier analysis 
in an approach that centres on the frequency-domain.
134
 The method assumes that the 
circulation is in a steady state of oscillation and that waves have an additive effect. 
Some researchers have questioned the assumption of steady state oscillation because 
of the effect of a ventricular ectopic (VE) on arterial pressure. A very early VE does 
not result in an arterial pressure wave and there is usually a smooth exponential 
decline of pressure until the next sinus beat. The pulse pressure immediately 
following the VE may be increased due to the Frank-Starling mechanism but the 
mean pressure is often decreased for ~4-5 beats before the oscillation returns to the 
same state as before the VE. This behaviour suggests that the cardiovascular system 
is over-damped and not in steady-state oscillation.
135
  
These assumptions, coupled with the fact that results presented in the frequency-
domain may be more difficult to interpret by clinical researchers, have led to the 
development of time-domain techniques.
129
   
The time-domain approach applies the method of characteristics based on the 
work of Riemann to solve the nonlinear form of conservation of mass equations 
derived by Euler. These inspired the development of wave intensity (WI) analysis by 
Parker and Jones.
136
 This method considers each arterial pulse to be an individual 
event and does not make assumptions about linearity or periodicity. Since results are 
presented in the time-domain they have the potential of being more readily 
understood by clinical researchers. Further detail regarding the method can be found 
in the following section.  
Whilst there has been debate about which method is best, there are similarities in 
that both are used to separate measured pressure and flow into forward and backward 
components of waves. Both methods are dependent on the determination of wave 
speed and, while wave speed is calculated differently in each method, the magnitude 
of difference between calculations does not appear to affect the results of wave 
separation.
137
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Wave intensity 
Wave intensity is the flux of energy per unit area carried by the wave as it moves 
past a point in the circulation; it has the units of power (W/m
2
). Wave intensity 
analysis was introduced in the late 1980s and early 1990s to overcome the 
limitations of frequency-domain measurements which had dominated studies of 
arterial haemodynamics since the 1960s.  WI has its origins in gas dynamics and is 
based on the solution of equations describing the conservation of mass and 
momentum in an elastic tube. Detailed explanations of the mathematics are described 
in an article by Kim Parker.
135
  
While the mathematical solution of equations is difficult, the process of obtaining 
WI signals is relatively simple and requires simultaneous measurements of arterial 
blood pressure and velocity from the same site in the circulation. Wave intensity at 
any given point in time, dI(t), is the product of the change in pressure (dP(t)) and 
change in velocity (dU(t)) at the same point in time. 
𝑑𝐼(𝑡)  =  𝑑𝑃(𝑡). 𝑑𝑈(𝑡) 
Since WI is a time-domain measurement it can be used to determine the timing 
of wave arrival as well as their magnitude and direction. This is not easily achieved 
with Fourier methods because the wave-train is always present.  
The net WI (dI) indicates whether forward or backward waves are dominant and 
how big they are at a point in the cardiac cycle. Table 1-3 demonstrates the 
relationship between different waves and dI. The main purpose of WI analysis is to 
provide information about the net direction of wave travel at a point in time. 
However, in an arterial wave any change in pressure will necessarily result in a 
change in velocity because wave propagation relies on the transfer of energy 
between kinetic and potential forms. The relationship between pressure and velocity 
in a wave is given by the water hammer equations and these can be used to separate 
the signal into forward and backward components, if the wave speed can be 
calculated. 
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𝑑𝑃+ =  𝜌. 𝑐. 𝑑𝑈 +  for forward waves arising from the heart 
𝑑𝑃− =  𝜌. 𝑐. 𝑑𝑈 −  for backward waves reflected from the arteries  
where ρ is the density of blood and c is the wave speed. When these equations are 
used to separate waves the results are very similar to those derived from impedance 
methods.
137
 
  
Table 1-3. The relationship between wave types and wave intensity. Forward waves will 
always result in a positive wave intensity signal and backward waves will result in a 
negative wave intensity. Adapted from Parker. 
135 
 dP dU dI 
Forward >0 compression >0 acceleration positive 
 <0 expansion <0 deceleration positive 
Backward >0 compression <0 deceleration negative 
 <0 expansion >0 acceleration negative 
 
 
While net WI signals are useful, the separation of waves provides more detailed 
information about the contributions of forward and backward waves to the signal. 
For example, a small positive WI signal may be due to a forward wave of low 
amplitude or the simultaneous arrival of a forward and backward wave of similar 
magnitude.  
Calculation of local wave speed is necessary for separation of waves and this 
also gives independent information about local distensibility of the artery. The 
standard measurement of wave speed is PWV and this relies on measurement of a 
transit time between two sites to give an average wave speed over this section of 
artery. It is typically performed between carotid and femoral artery sites. Local wave 
speed is more difficult to measure clinically because it requires invasive assessment 
of elastic properties of the arterial wall. However, WI analysis can be used to derive 
local wave speed using the water hammer equation.  In the event of a situation when 
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there are only forward waves present, the relationship between pressure (P) and 
velocity (U) should be linear with a slope that is equal to the product of the density 
of blood (ρ) and wave speed (c). Since the density of blood is known, the value of 
wave speed can be calculated. Pressure-velocity loops from experimental and 
clinical data have shown that there is a short time period in early systole when the 
relationship is linear and this period is selected to calculated local wave speed. 
Key invasive studies of wave intensity 
In 1998, Kim Parker’s group were the first to demonstrate the use of WI analysis to 
examine arterial wave reflections in man.
138
  The study population comprised 14 
middle-aged or older subjects who were undergoing coronary artery bypass surgery. 
The aim of the study was not to evaluate the effects of disease, but to study the 
relationship between features of the invasively recorded aortic pressure and flow 
with the amplitude and timing of wavefronts obtained through WI analysis. The 
results confirmed that the first positive peak in WI was the largest and coincided 
with acceleration of blood in the aorta and an increase in aortic pressure (FCW). The 
second positive peak in late systole was smaller and associated with deceleration of 
blood and a decrease in aortic pressure (FEW). A backward mid-systolic wave 
consistently occurred at the time of the inflection point of the aortic pressure tracing 
and was therefore associated with an increase in aortic pressure. This BCW was the 
smallest wave and its amplitude strongly correlated with augmentation index (r=.63, 
p<.001). 
In a later study, data from a canine model confirmed that the compression and 
expansion waves generated by the LV had a significant impact on the acceleration 
and deceleration of blood in the ascending aorta. Furthermore, the intensity of the 
FCW was related to LV inotropy and chronotropy (increased by dobutamine and 
decreased by propranalol) and was decreased by vasoconstriction (methoxamine). In 
contrast, the FEW was not affected by pharmacological changes in inotropy or 
vasoconstriction, but was reduced during vasodilation by nitroglycerin.
139
 This 
confirmed that WI signals could be altered by manipulations of cardiovascular 
performance. 
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Non-invasive studies of wave intensity 
Two main methods of non-invasive measurement are evident in the literature. The 
first involves sequential measurement of carotid pressure using applanation 
tonometry and measurement of carotid flow using Doppler.
140-144
 The second method 
was developed by a group in Japan and allows simultaneous measurement of 
changes in carotid artery diameter (as a surrogate measure of pressure) using echo-
tracking software, and flow using Doppler.
145-153
  
Regardless of the method used, the pattern of WI peaks appears to be consistent 
among non-invasive studies and is comparable with that found in invasive studies. 
The first positive peak in net WI (sometimes called W1) tends to be the largest and 
coincides with acceleration of blood in the aorta and an increase in aortic pressure 
(dominant forward compression wave, FCW). This is followed by a smaller negative 
peak reflected from the circulation which has the effect of increasing pressure and 
decelerating velocity (dominant backward compression wave, BCW).  A second 
positive peak (W2) occurs in late systole associated with deceleration of blood and a 
decrease in aortic pressure (dominant forward expansion wave, FEW).  
Sequential measurement of pressure and flow 
The sequential method was first described in 2002 by Kim Parker’s group.141 The 
purpose of the study was to establish the reproducibility of the method in deriving 
WI measures in the right common carotid, brachial and radial arteries.  Twelve 
subjects with hypertension who were enrolled in the Anglo-Scandinavian Cardiac 
Outcomes Trial (ASCOT) underwent applanation tonometry and pulsed Doppler 
measurements of the three arteries on two occasions. Applanation tonometry was 
applied to the artery so that the force acting on the transducer represented the intra-
arterial pressure. Once pressure waves had been recorded, ultrasound was applied to 
the same site to obtain Doppler measurements of velocity. Acquisition data were 
recorded alongside a real-time ECG and ensembled using MatLab software. The 
intra-observer intra-session coefficients of variation for local wave speed and WI 
ranged between 3.7% and 19.6%. Local wave speed had the best reproducibility and 
the reflected WI (a relatively small signal) had the poorest reproducibility. The 
authors concluded that the method was therefore sufficiently reproducible to be used 
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in other research studies. This study also demonstrated that while the pattern of WI 
signals was similar in predominantly elastic or muscular arteries, the local wave 
speed and the magnitude of WI signals was not uniform through the arterial tree with 
higher values in muscular arteries. In addition, a mid-systolic expansion wave, 
largest in the muscular arteries, was described; this was attributed to re-reflection of 
the backward compression wave at the brachial bifurcation.  
In 2005, the same group applied this method to a small cohort of healthy adults 
(n=21, 14 men, mean age 44±6 years).
140
 The study confirmed that the pattern of WI 
signals was similar in the carotid, brachial and radial arteries (Figure 1-5). Again the 
local wave speed was higher in the muscular brachial artery compared with the 
elastic carotid artery (p=.01). In addition, this study was the first to report separated 
wave analysis at each arterial site using non-invasive methods. The finding that the 
FCW was higher in the muscular arteries (p<.01) despite similar heart rate and 
contractility, suggested that it was attributable to the differences in wave speed due 
to local structure, geometry and branching. This was expected because of the relation 
between wave speed and pressure in the waterhammer equation (dP ± = ρcdU ±).  
The relative timing of the FEW to the FCW was similar in all arteries supporting 
the theory that it originated from the LV. The amplitude of the FEW became smaller 
with distance from the heart and the authors suggested that this was due to arterial 
damping of the signal. Differences in impedance mismatching between arterial beds 
may account for the higher pressure reflected waves that were observed from the 
hand and forearm compared with the head; increased amounts of reflection from the 
hand may be due to vasoconstrictor tone or the anatomy of the circulation in the 
hand. Finally, the study confirmed the presence of a peripheral mid-systolic forward 
expansion wave in normal subjects which had not been documented in the ascending 
aorta in invasive studies.  
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Figure 1-5. Drawing showing the timing of simultaneous pressure, flow 
velocity, wave intensity and ECG signals. W1 occurs in early systole and is 
dominated by a forward compression wave. A small negative area can be seen 
following W1 because of a backward compression wave. W2 occurs towards 
the end of systole and is dominated by a forward expansion wave. Adapted 
from Hughes et al. 
140
  
 
Having described the haemodynamic variables obtained from WI, the authors 
applied the same non-invasive methods to a chronic heart failure population.
142
  
Using impedance methods, others had proposed that increased wave speed due to 
vasoconstriction and endothelial dysfunction in heart failure would result in earlier 
reflection of waves so that they arrived in systole, attenuating ejection,
154
 rather than 
in diastole. However, there was no conclusive evidence of this to date in the 
literature. Therefore, the aim of the study was to determine the effect of heart failure 
on the amplitude and timing of forward and backward components of waves. The 
study population comprised 67 patients with New York Heart Association (NYHA) 
class II or III heart failure and 29 healthy controls. The heart failure patients were 
older (66±10 years vs. 60±9 years, p=.004) and were all medicated with diuretics and 
an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker but the 
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groups were otherwise well matched. Heart failure patients had similar carotid 
pressure but reduced carotid flow velocity compared with controls. This was 
explained by a significantly reduced energy in the FCW (467±29 vs. 745±46 mJ/m
2
, 
p <.001). In addition, the time to peak of the wave was delayed in heart failure 
(0.15±0.01 vs. 0.12±0.01s, p<.001). The wave amplitude was progressively reduced 
in relation to NYHA class. Perhaps surprisingly, the wave amplitude was not 
associated with LV mass or ejection fraction.  
Although the FCW had reduced energy in heart failure, the proportion of energy 
reflected back from the periphery was higher. Since this reflection was in the form of 
a BCW it may contribute to the maintenance of mean arterial pressure at the expense 
of flow velocity. There was no difference in local wave speed or in the timing of the 
reflected wave in heart failure. Despite the altered proportion of reflected energy the 
augmentation index, a measure of arterial stiffness, was not significantly different 
between-groups.  
Simultaneous measures of diameter-derived pressure and flow 
The simultaneous method of measuring arterial pressure and flow at a single site was 
first described in 1999 by Niki et al. 
145
 and the literature is predominantly from the 
research groups based in Japan who developed the technology. The method used an 
ultrasound system (Hayashi Denki, Kanagawa, Japan) capable of automatically 
tracking changes in the carotid artery diameter and of simultaneously measuring 
blood velocity by Doppler at the same site. Others had previously shown that the 
diameter waveform was similar to an arterial pressure waveform in animal models, 
so the authors calibrated the diameter waveform with brachial systolic and diastolic 
blood pressure to derive an estimated pressure waveform. This technique was used to 
characterise the WI signals of 24 normal volunteers and of 11 patients with mitral 
valve regurgitation (before and after corrective surgery). The pattern of WI signals in 
normal volunteers was as described by other invasive and non-invasive methods. 
However, the second positive peak, W2, was significantly reduced or absent in the 
patients with mitral regurgitation but became significantly larger after corrective 
surgery. W2 is dominated by a forward expansion wave generated by the LV and the 
authors interpreted a very small or absent W2 as reflecting an inability of the LV to 
efficiently decelerate aortic blood at the end of ejection because of continued 
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emptying into the left atrium across the incompetent valve. This theory was 
supported by an increase in W2 after surgery.   
The same group validated the theory that carotid artery pressure could be derived 
from the arterial diameter waveform in 6 patients with heart disease.
155
 Invasive 
pressure in the left common carotid artery was compared with simultaneous arterial 
diameter changes at the same site, assessed using an ultrasound echo-tracking 
system. The relationship between pressure and diameter was relatively linear 
throughout the cardiac cycle (r
2
 ≥ 0.97). While there was slight non-linearity and 
hysteresis, the effects were considered to be minimal. There are few human studies 
to support this data and it is limited by the small sample size of diseased patients. 
However, the authors compared many data points on each wave through the cardiac 
cycle so that a significant volume of data was generated for statistical analysis.  
Normal values of WI measurements using the Aloka ultrasound system were 
established in 2002 by Niki et al. who studied 135 healthy volunteers (74 men) 
across a wide age range (25 years and over).
146
 The results can be found in Table 1-4 
and demonstrated that W1 was larger than W2 with neither of these parameters being 
correlated with age. The reproducibility of measures was reported in the same study 
and the mean coefficients of variation for intra-observer intra-session measures were 
reported to be 10% for W1 and 13% for both W2 and the negative area. As expected, 
the intra-observer inter-session reproducibility was poorer with confidence limits of 
17% for W1 and up to 36% for W2 and the negative area. While the values for W1 are 
clinically acceptable, those for the smaller waves (particularly the negative area) are 
large and this might preclude widespread adoption of the technique in the clinical 
environment.    
The physiological significance of W1 and W2 using this method was confirmed in 
a study of 64 patients with suspected coronary artery disease who underwent cardiac 
catheterization.
147
 The amplitude of W1 was strongly associated with the rate of LV 
pressure increase (r = .74, p<.001) and therefore it was confirmed as a measure of 
contractile performance.  The amplitude of W2 was inversely associated with the 
time-constant of LV relaxation (r = -.77, p<.001) suggesting that it provided 
information the transition between the end of systole and the beginning of diastole.   
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Table 1-4. Wave intensity values derived from healthy volunteers in a 
small study using the Aloka system. Adapted from Niki et al.
146
  Only 
the stiffness index, β, was correlated with age (r = 0.66, p<.0001 in men 
and r = 0.81, p<.0001 in women). 
 
 
 
 
 
 
 
 
Few studies have used WI to examine the effects of CV disease on ventricular-
arterial coupling. The Japanese group of Sugawara et al. have briefly reported the 
effects of dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM),  
and hypertension on WI signals compared with 170 controls.
150
 In control subjects 
(demographics not presented), neither W1 nor W2 depended on age. In the DCM 
group (n=36) W1 was significantly lower than in controls (mean ± SEM: 4,320 ± 420 
vs. 9,060 ± 330 mmHg ms
-3
, p<.001), and deteriorated with age. The smaller 
amplitude of W1 in DCM was expected since this is predominantly a disease which 
affects systolic function.  
In the HCM group (n=27), the values of W1 were similar to controls but declined 
with age. The values of W2 were significantly lower in subjects with HCM (875 ± 98 
vs. 1,793 ± 57 mmHg ms
-3
, p<.001). These results may be expected given that the 
hypertrophied LV in HCM causes ventricular stiffening and a significantly impaired 
ability to relax.  
 
Wave intensity parameters Mean ± SD 
W1 (mmHg ms
-3
) 8940 ± 3790 
W2 (mmHg ms
-3
) 1840 ± 880 
Negative area (mmHg ms
-3
) 27 ± 13 
Time from R wave to W1 (ms) 104 ± 14 
Time from W1 to W2 (ms) 270 ± 19 
Stiffness, β 10.4 ± 4.8 
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Separated wave intensity signals 
The commercially-available ultrasound system which can measure WI (Aloka) 
presents the net signals of W1, W2 and a negative area. These are summations of 
forward and backward waves arriving at an arterial site at a moment in time and 
show the dominant direction, energy and timing of the waves across the cardiac 
cycle. Some authors have suggested that a more precise assessment of ventricular-
arterial interaction is achieved by analyzing the separated forward and backward 
components of WI signals.
156
 This can be achieved by constructing a loop of the 
relationship between pressure and velocity across a cardiac cycle, then determining 
the local wave speed from the slope of the loop in early systole when the relationship 
is linear. The local wave speed can subsequently be used to calculate the separate 
forward and backward components of waves as described in the methods section of 
Chapter 5. This separation of waves is possible with both sequential and 
simultaneous methods of deriving WI signals. 
Separated WI signals appear to be sufficiently sensitive to detect changes in 
physiology associated with caffeine (increased FCW and wave speed) 
153
 and high 
dietary salt-intake (increased wave reflections) 
157
 in healthy volunteers. This 
suggests that the technique may be suitable for the detection of sub-clinical 
pathophysiology associated with obesity and pre-diabetic states.  
Wave intensity and obesity 
To the best of my knowledge there are no published papers detailing the effects of 
uncomplicated obesity on net WI or separated waves. There are brief reports from 
conference proceedings that obese subjects have higher carotid artery stiffness as 
measured by WI techniques 
158
 and that expansion wave reflections are associated 
with artery stiffness as well as measures of general and central obesity.
159
 
Given that elastance measures are related to body size in a lean, healthy 
population 
122
  and that augmentation index (a surrogate measure of wave reflection) 
is related to height,
144
 it would seem prudent to establish whether such relationships 
exist for WI measures, but such data are lacking. One study has shown that a wave 
reflection coefficient derived using different methods is not related to height 
144
 but it 
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is unclear whether WI variables should be scaled in cross-sectional studies where 
there are between-group differences in size.  
Wave intensity and pre-diabetic states 
I have been unable to find any published papers of WI in subjects with pre-clinical 
dysglycaemia or insulin resistance. One study has used measures of net WI to 
examine the relationships between type 2 diabetes and ventricular-arterial 
coupling.
148
 Sixty-five patients with diabetes were compared with 57 controls. All 
were free from overt coronary or peripheral vascular disease. Those with diabetes 
had higher amplitude W1 (11785±7491 versus 9191±4299 mmHg m/s
3
 in controls, 
p=.04) and greater beta stiffness index (11.5±4.6 versus 9.2±2.7, p=.002). There was 
no between-group difference in W2 despite evidence of worse diastolic function (e′ 
7.8±1.2 versus 9.5±1.6, p=.001). An increase in W1 is usually associated with 
increased ventricular inotropy but in this study those with diabetes also tended to 
have reduced systolic longitudinal function (s’ 7.5±1.1 versus 7.9±1.2 cm/s, p=.053).  
The authors suggest that the increase in W1 in diabetes was due to increased regional 
arterial stiffness since aortic pulse wave velocity was increased in those with the 
condition.   
Wave intensity and polycystic ovary syndrome 
To the best of my knowledge there are no published papers of WI, wave reflections 
or pulsatile loading in women with PCOS.  
Limitations of the current evidence-base 
WI analysis has not been widely adopted in clinical studies and while there is some 
evidence that the magnitude and timing of net WI signals may be altered in those 
with overt cardiovascular disease, it is unclear whether the technique is sufficiently 
sensitive to detect sub-clinical changes associated with obesity and pre-diabetic 
states. 
The separation of net WI signals into forward and backward components may 
provide more detailed information about the ventricular-arterial interaction, 
particularly in respect of the magnitude and timing of wave reflections which affect 
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the pulsatile load on the LV. The technique has the potential to add information 
about the mechanisms linking obesity, LV hypertrophy and diastolic information but 
this has yet to be studied in a young population with uncomplicated obesity or 
PCOS. 
The two methods of studying the ventricular-arterial interaction in this thesis (the 
ratio of end-systolic elastances and arterial WI signals) tend not to be applied 
together in other published studies so it is unclear whether they provide similar 
information i.e. whether they are equal in characterising arterial load and its impact 
on the LV. Elastance measures provide an assessment of ventricular-arterial coupling 
at a single point in the cardiac cycle and there is evidence that arterial elastance is 
predominantly affected by heart rate and resistive (static) vascular load.
160
 In 
contrast, arterial WI signals provide information about the time-course of loading, 
including pulsatile (dynamic) load across a cardiac cycle. These factors appear to be 
important in the development of left ventricular hypertrophy 
161
 which may 
ultimately lead to heart failure with preserved ejection fraction (HFpEF) 
50
 and 
increased mortality.
162
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Aims of this thesis 
This thesis has been designed to study the effect of obesity and pre-diabetic states on 
cardiovascular structure and function in young women. The work tests the 
hypothesis that quantitative measures of ventricular-arterial coupling will provide 
information about subclinical cardiovascular dysfunction that complements standard 
clinical measures. This may lead to an improved understanding of the 
pathophysiology of left ventricular hypertrophy and diastolic dysfunction which are 
common in older obese women. Such information could inform potential 
intervention studies which seek to reverse abnormal cardiovascular function before 
the development of diabetes or overt cardiovascular disease. 
The specific aims of the thesis are as follows. 
1. To examine whether non-invasive measures of ventricular-arterial 
coupling are sufficiently sensitive to detect sub-clinical changes in 
cardiovascular function associated with uncomplicated obesity and 
polycystic ovary syndrome in young women. 
2. To determine whether quantitative measures of ventricular-arterial 
coupling are more strongly associated with central obesity and insulin 
resistance than with general obesity. 
3. To determine whether non-invasive measures of ventricular-arterial 
coupling independently explain some of the variation in left ventricular 
mass and diastolic function in obese women. 
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2. General Methods 
The studies reported in this thesis were performed in collaboration with an MD 
student in endocrinology, Dr. Rose-Marie Coulson, who recruited the subjects and 
undertook their clinical evaluation, blood tests, obesity measurements and 
applanation tonometry. Computed tomographic measurements of abdominal fat areas 
were performed by the Medical Physics department at the University Hospital of 
Wales, Cardiff. I performed all echocardiograms and carotid ultrasound scans, whilst 
blind to the subjects’ status as patients with PCOS or controls.  
Detailed analyses of the associations between body composition and basic 
measures of cardiovascular function in women with PCOS are the subject of Dr. 
Coulson’s MD thesis and we have co-authored a publication of these data.163  
Subject recruitment 
The study was sponsored by Cardiff University and received ethical approval from 
South East Wales Regional Ethics Committee B. Each subject gave informed written 
consent before participation. 
Healthy volunteers were recruited from local staff and students of Cardiff 
University and University Hospital of Wales, Cardiff. In addition, advertisements 
were placed in the local media to recruit healthy women with dress size 14 or greater 
in order to match those with PCOS who tended to be obese. Two hundred and sixty 
nine healthy volunteers responded to advertisements. One hundred and seventy four 
were excluded because they failed to meet the inclusion criteria of regular menstrual 
cycles (27-32 days), normal history, clinical examination and hormone evaluation 
(testosterone, thyroid function, prolactin and 17-hydroxyprogesterone). The sample 
comprised 95 healthy control subjects. 
Five hundred and seventy women with potential PCOS were identified from a 
departmental database or from consecutive patients attending the endocrine clinic at 
the University Hospital of Wales Cardiff. A diagnosis of PCOS was made according 
to the Rotterdam criteria.
71
 Congenital adrenal hyperplasia, Cushing’s syndrome, 
androgen-secreting tumours, hyperprolactinaemia and thyroid disease were excluded 
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by biochemical testing. Those who were pregnant, breastfeeding and those who had 
used glucocorticoids, lipid-lowering agents, antihypertensives, antidiabetics or anti-
obesity drugs within three months of the study were also excluded. All women were 
free from overt cardiovascular disease and hypertension. 
Women with PCOS, mild oligomenorrhoea or eumenorrhoea were studied in the 
early follicular phase of their menstrual cycle but no temporal limitations were 
applied to women with severe oligomenorrhoea or amenorrhoea.  
Two hundred and twenty nine patients were excluded because of a different final 
diagnosis, co-existing diabetes, hypertension or hypercholesterolaemia, treatment 
with metformin, statins or anti-hypertensive medication. A further 257 were not 
contactable or declined to take part. The sample comprised 84 women with PCOS 
defined by the Rotterdam criteria; 62 had polycystic ovaries on ultrasound, 75 had 
oligo-/anovulation and 75 had clinical or biochemical hyperandrogenism. 
Study protocol 
All women attended the Clinical Research Facility at the University Hospital of 
Wales, Cardiff at 08:00 following an overnight fast. Dr. Coulson performed a 
pregnancy test on each woman and recorded a full medical history and physical 
examination prior to other investigations being performed. The study protocol 
comprised a number of investigations to be performed during the same visit in the 
order presented below in accordance with the study protocol (Figure 2-1). The oral 
glucose tolerance test was performed on a second separate visit.  
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Figure 2-1. Study protocol. 
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Body composition measurements 
For all subjects, anthropometric measurements included height to the nearest 0.1cm 
without shoes using a stadiometer, and weight to the nearest 0.5kg in light clothing 
without shoes (Omron Monitor BF500, Omron Corporation, Japan). Body mass 
index was calculated as weight divided by height in metres squared. Waist 
circumference was measured to the nearest 0.5cm from a position just above the iliac 
crest with a flexible tape (in a transverse plane) during minimal respiration. Hip 
circumference was measured in the same manner at the greatest protrusion of the 
buttocks.  
Biochemical measurements 
After basal sampling, subjects had a standard oral glucose tolerance test (113ml of 
Polycal® with 187ml of water). Blood samples were collected at 30 minute intervals 
until 120 minutes.  
Fasting venous blood samples were prepared by centrifugation at 4000rpm for 8 
minutes and serum was stored at -30°C prior to analysis. Table 2-1 details the 
method and equipment used to perform biochemical tests. Intra- and inter-assay 
coefficients of variation were all <9% according to laboratory data. 
The trapezoid method was used to calculate insulin and glucose areas under the 
curve (AUC). Insulin resistance was also assessed using the homeostatic model 
assessment method (HOMA-IR) 
164
. 
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Table 2-1. Biochemical assays. 
Variable (s) Method Equipment 
Total cholesterol, HDL, 
triglycerides 
Aeroset automated 
analyser 
Abbott Diagnostics, Berkshire, UK 
LDL 
Calculated by 
Friedewald’s formula 
 
Insulin 
Immunometric assay 
specific for human 
insulin 
Invitron, Monmouth, UK 
Glucose 
Aeroset chemistry 
system 
Abbott Diagnostics, Berkshire, UK 
High sensitivity c-reactive 
protein 
Nephelometry 
BN™ II System, Dade Behring, 
Milton Keynes, UK 
Total testosterone 
Liquid 
chromatography 
tandem mass 
spectrometer 
Quattro™ Premier XE triple 
quadrupole tandem mass 
spectrometer, Waters Ltd., Watford, 
UK 
High-molecular weight 
adiponectin 
ELISA EMD Millipore, Billerica, MA, USA 
 
 64 
 
 
Abdominal fat area measurement by computed tomography 
Abdominal subcutaneous and visceral fat areas were measured by x-ray computed 
tomography (CT) (Hawkeye, GE Medical Systems) on one cross-sectional scan at 
the level of L4-L5. Subjects were supine and standard acquisition parameters were 
used (140kV, 2.5mA, 10mm slice width, 13.6s rotation time, 256
2
 pixel matrix).  
A single operator, blind to the subject’s status, analysed the image using 
MATLAB. Fat was identified by using a fixed range of CT numbers (-120 to -80) 
defined by Watson et al..
165
 The visceral fat area was then calculated by segmenting 
the intraperitoneal region from the whole image. The subcutaneous fat area was 
calculated as the difference between the total and visceral fat areas (Figure 2-2). 
 
 
Figure 2-2. CT image demonstrating identification of visceral fat. The intraperitoneal region 
was defined by tracing its outline. Tissue within the intraperitoneal region with pixels having 
attenuation within the defined range of fat was depicted as white. Fat area was calculated by 
summation of the pixels in each area.   
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Applanation tonometry 
Applanation tonometry was performed by Dr. Coulson after a short period of 
training. Before the study began, the reproducibility of intra-operator intra-session 
duplicate measurements was established in 15 volunteers (age 21-45 years). The 
coefficients of variation were 18% for augmentation index and 4% for carotid-
femoral pulse wave velocity.   
Brachial blood pressure was measured after at least five minutes of rest from the 
left arm using a validated, automated device (Omron 7051T, Omron Corp.). An 
average of three measurements was used. A high-fidelity micromanometer 
(SPC-301, Millar Instruments, Houston, Texas) attached to a SphygmoCor MM3 
device (software version 8.0, AtCor Medical Ltd., Sydney, Australia) was used to 
obtain pulse wave analysis (PWA) of the radial artery waveform and carotid-femoral 
pulse wave velocity (PWV).  
Pulse wave analysis 
Subjects were asked to lie supine and allowed to rest for ten minutes. The wrist of 
the right hand was supported in a dorsi-flexed position to facilitate detection. The 
tonometer was placed on the wrist at a site where the radial pulse was best detected 
with the tonometer perpendicular to the artery. The tip of the tonometer was 
supported between two fingers to minimise movement. After 20 sequential 
waveforms the waveform was stored and a generalised transfer function was used to 
derive a central pressure waveform. Quality control indices were inspected and used 
to determine whether the recording was acceptable (Table 2-2). The recording was 
repeated and if the two measures of augmentation index (AIx) were within 5% the 
recordings were accepted and an average value noted for analysis. The augmentation 
index adjusted to a heart rate of 75 beats per minute was used in analyses. Central 
blood pressures were also derived from analysis of this waveform.  
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Table 2-2 Quality control indices used in pulse wave analysis. 
 Value 
Average pulse height >80 
Pulse height variation <5 
Diastolic variation <5 
Operator index >80 
  
Pulse wave velocity 
Carotid-femoral pulse wave velocity (PWV) was obtained directly after PWA 
measurement. The method followed international recommendations.
59
   
Electrocardiogram (ECG) leads were attached for continuous monitoring during 
acquisition of the arterial waveform. The carotid and femoral pulses were palpated 
and marked. The distance of each site from the suprasternal notch was measured in a 
direct line and entered into the software with the mean and diastolic brachial blood 
pressure. The carotid-femoral PWV (m/s) was calculated as the distance between 
measurement sites divided by the transit time. Transit time was the delay between 
the arrival of the pulse wave at the carotid artery and at the femoral artery. This was 
measured indirectly by subtracting the time from the R wave of the ECG to the peak 
pressure of the carotid recording from the same measurement taken at the femoral 
artery.  
The average of two measurements was used in analyses. The intra-session intra-
observer coefficient of variability for PWV was 4%.  
Echocardiography 
I performed all echocardiograms in the Wales Heart Research Institute at the 
University Hospital of Wales Cardiff. I was blind to each subject’s status.  
Left ventricular function was assessed by echocardiography (Vivid 7, GE 
Medical Systems, Horten, Norway) with a 2.5 MHz transducer and harmonic 
imaging. Images were acquired at passive end-expiration when possible. All 
measurements were performed during off-line analysis using EchoPAC PC software 
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version 110.0.0 (GE Healthcare). The mean measurement of three consecutive beats 
was used in analysis. 
Standard echo measurements and calculations were performed according to the 
joint recommendations of the American Society of Echocardiography and the 
European Association of Cardiovascular Imaging.
166
 Table 2-3 lists all 
echocardiographic measurements recorded in the study population.  Detailed 
methods for the key echo variables used in statistical analysis can be found below.   
 
Table 2-3. Resting echocardiographic measurements. 
Time intervals Left ventricular systolic function 
Heart rate (bpm) 
R wave to aortic valve opening (ms) 
R wave to aortic valve closure (ms)  
R wave to mitral valve opening (ms)  
R wave to mitral valve closure (ms) 
Fractional shortening (%) 
Ejection fraction (Teicholz) (%) 
Stroke volume  by Doppler (ml)  
Cardiac output by Doppler (L/min)  
Mean of lateral and septal s′ (cm/s)  
Mitral annular plane systolic excursion 
(average of 4 sites) (cm)  
Biplane LV end-diastolic volume (ml)  
Biplane LV end-systolic volume (ml)  
Biplane ejection fraction (%) 
Dimensions Left ventricular diastolic function 
Aortic root diameter (cm) 
LV outflow tract diameter (cm) 
Ventricular septum (diastole) (cm)  
LV internal dimension (diastole) (cm)  
Posterior wall (diastole) (cm)  
Ventricular septum (systole) (cm) 
LV internal dimension  (systole) (cm)  
Posterior wall (systole) (cm)  
Left ventricular  mass (ASE method) (g) 
Biplane LA volume (ml)  
Flow propagation velocity (cm/s)  
E (cm/s)  
E deceleration time (ms) 
A (cm/s)  
E:A  
Mean of lateral and septal e′ (cm/s)  
Mean of lateral and septal  a′ (cm/s)  
Mean of lateral and septal e′/a′ 
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Left ventricular dimensions 
Left ventricular wall thickness and internal dimensions were measured from m-mode 
recordings (leading-edge to leading-edge) (Figure 2-3) or from 2-dimensional 
images if a perpendicular alignment could not be obtained. Fractional shortening and 
ejection fraction (Teicholz method) were automatically calculated by EchoPac 
software using standard formulae.  
Left ventricular mass and identification of hypertrophy 
Left ventricular mass was automatically calculated by the Echopac software using 
the cube method which is recommended by the American Society of 
Echocardiography when there are no major distortions of ventricular geometry.
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Mass was subsequently indexed by height allometrically scaled to the power of 2.7 
since this has been shown to be the most accurate scaling method in obese 
subjects.
168
 A partition value of 44g/m
2.7 
was used to identify left ventricular 
hypertrophy.
169
 Relative wall thickness (RWT) was calculated by  
 
𝑅𝑊𝑇 =  
2 × 𝐿𝑉 𝑝𝑜𝑠𝑡𝑒𝑟𝑖𝑜𝑟 𝑤𝑎𝑙𝑙 𝑖𝑛 𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑒 
𝐿𝑉 𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑙 𝑑𝑖𝑚𝑒𝑛𝑠𝑖𝑜𝑛 𝑖𝑛 𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑒
 
 
A relative wall thickness partition value of 0.42 was used to identify a concentric 
pattern of remodelling or hypertrophy as described by the American Society of 
Echocardiography  (Table 2-4).
167
 
 69 
 
 
 
Figure 2-3. M-mode recording demonstrating measurement of left ventricular dimensions. 
 
Table 2-4. Criteria used to identify patterns of left ventricular remodelling and hypertrophy. 
 Relative wall thickness LV mass/height
2.7 
(g/m
2.7
) 
Normal ≤0.42 ≤44 
Concentric remodelling >0.42 ≤44 
Eccentric hypertrophy ≤0.42 >44 
Concentric hypertrophy >0.42 >44 
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Stroke volume 
Left ventricular stroke volume was measured using the Doppler method given by 
𝑆𝑡𝑟𝑜𝑘𝑒 𝑣𝑜𝑙𝑢𝑚𝑒 =  𝐿𝑉𝑂𝑇 𝐶𝑆𝐴 ×  𝐿𝑉 𝑣𝑡𝑖 
where LVOT CSA is the cross sectional area of the LV outflow tract found by  
0.785 ×  𝐿𝑉𝑂𝑇 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟2           (Figure 2-4), 
and LV vti is the velocity time integral of flow in the LV outflow tract (Figure 2-5).  
 
 
Figure 2-4. Two-dimensional left ventricular outflow tract measurement.  
Myocardial velocities  
Left ventricular longitudinal systolic function (s′) and diastolic function (e′, a′ and 
e′/a′) were assessed by pulsed myocardial velocity imaging. The mean of 
measurements from the lateral and septal mitral annulus over three consecutive 
cycles was used in analysis (Figure 2-6).  
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Figure 2-5. Pulsed-wave spectral Doppler recording showing measurement of the 
left ventricular outflow velocity time integral. 
 
 
Figure 2-6. Measurement of longitudinal myocardial tissue velocities. 
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Global longitudinal strain and strain rate imaging  
Global longitudinal strain was assessed by 2D strain analysis of the apical four-
chamber, apical two-chamber and apical long-axis views.  
The frame rate was typically 40-60fps. The endocardial border was defined by 
automated tracking software.  The width of the region of interest was adjusted 
manually, where necessary, to include only the myocardium. The accuracy of 
automated wall tracking through the cardiac cycle was visually inspected. The aim 
was to include an 18 segment model in the analysis which included basal-, mid- and 
apical- aspects of the septum, lateral, inferior, anterior, posterior and anteroseptal 
walls. However, only walls with good border detection and accurate tracking were 
approved for inclusion in quantitative analysis.   
Following approval of the segment, local strain curves were assessed for 
accuracy and artefact before use in analysis. The aortic valve closure time was 
detected automatically by the software but adjusted manually if necessary. The 
average global longitudinal strain was derived from bulls-eye plots.
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Carotid ultrasound 
I performed each carotid ultrasound scan immediately after the echocardiogram. The 
right and left common carotid artery (CCA) were scanned consecutively using an 
Aloka Prosound SSD-5500 with 7.5MHz linear array transducer.  
Carotid intima media thickness  
Common carotid intima-media thickness (ccIMT) of the far artery wall was assessed 
in a 1cm segment of the left and right common carotid artery 1cm proximal to the 
bulb (Figure 2-7). The method followed international recommendations.
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Measurements were made offline using automated wall tracking and analysis 
software (Carotid Analyser, Medical Imaging Applications). The software measures 
ccIMT at each pixel within the 1cm region of interest at every end-diastolic frame 
(~140 measurement points). A minimum of five end-diastolic frames were studied 
and a mean of left and right ccIMT was used in analyses. The reproducibility of 
intra-observer analysis from stored images was 5% for the right and 6% for the left 
common carotid artery.  
 
Figure 2-7 Longitudinal image of left common carotid artery.  
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Data analysis 
In the study design phase, power calculations had suggested that recruiting 80 
women with PCOS and 80 controls would yield an 80% power to detect a difference 
of 0.45m/s in PWV and 0.25 in eʹ/aʹ - these were considered to be clinically different 
changes to key outcome measures based on the work by Cruickshank et al. 
171
 and  
Mogelvang et al. 
172
. The likely power for the regression analyses was harder to 
estimate without detailed knowledge of the relationships but a statistician estimated 
there to be 80% power for detecting partial correlation coefficients of around 0.25. 
Despite attempts to match age and BMI during recruitment, women with PCOS 
enrolled in the study were younger and heavier than controls. Therefore, groups were 
matched for age and BMI after enrollment which resulted in a final sample of 86 
controls and 73 women with PCOS.  
Data are expressed as mean ± standard deviation unless otherwise stated. 
Distributions were checked for normality by visual inspection of histograms and use 
of the Kolmogorov-Smirnov statistic. Univariate correlations were assessed with 
Spearman’s Rho because of the high number of skewed distributions; these were 
transformed by taking the natural logarithm prior to between-group comparisons.  
Between-group comparisons were assessed using one-way ANOVA with Welch’s 
robust test of equality of means when group variances were significantly different 
(Levene’s test) and with Tukey post-hoc correction. Between-group comparisons of 
categorical data were assessed using the chi-squared statistic. 
The stepwise method of multivariate regression was used to derive basic 
predictive models for arterial and ventricular end-systolic elastance. These were 
followed by separate hierarchical models to assess whether measures of general and 
central obesity made significant independent contributions which improved the basic 
model. Only significant univariate correlates were used in multivariate models and 
care was taken to select independent variables that were not highly correlated e.g. 
multiple measures of central obesity were not included in the models. The β weights 
and standard errors were considered to be accurate i.e. not influenced by 
multicolinearity, when the tolerances were greater than .200. Tables report 
standardised β weights because of the inclusion of measures with significantly 
different units and standard deviations.  
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In all cases p<.05 was considered statistically significant and significant results 
have bold type-face in all tables.   
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3. Obesity, polycystic ovary syndrome and standard 
measures of cardiovascular function 
There is considerable evidence of the effects of obesity on cardiovascular risk factors 
and on cardiovascular function, but the majority of studies include patients with 
confounding factors such as hypertension, diabetes or those who are taking 
cardiovascular medication. There is some evidence of the effects of uncomplicated 
obesity in children but very few studies of uncomplicated obesity in adults, 
particularly concerning the independent effects of general obesity, central obesity 
and insulin resistance.  
There are also significant gaps in the literature concerning the effects of PCOS 
on cardiovascular function and it is unclear whether PCOS, with its associated high 
rates of obesity and insulin resistance, can be used as a pre-diabetic model for other 
groups of young women.   
Aims of this chapter 
The primary aim of this chapter is to present the clinical characteristics of the study 
population and to confirm the effects of general obesity, central obesity and insulin 
resistance on standard measures of cardiovascular function. The secondary aim is to 
establish whether women with PCOS have similar cardiovascular risk factors and 
function as age- and BMI-matched controls.   
Hypotheses 
In young women who are free from cardiovascular symptoms 
1. uncomplicated obesity (regardless of PCOS status) will be associated 
with increased cardiovascular risk factors and altered cardiovascular 
structure and function; 
2. there will be a higher prevalence of insulin resistance, impaired glucose 
tolerance and type 2 diabetes in those with PCOS compared with age- 
and BMI- matched controls; and 
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3. women with PCOS will have comparable cardiovascular risk factors and 
cardiovascular function as age- and BMI-matched controls. 
Specific methods 
Women with PCOS and control volunteers were recruited from local clinics and the 
general community. Full details of recruitment, exclusion criteria and general 
methods are described in Chapter 2. 
Data analysis 
To understand the independent and potential additive effects of obesity and PCOS on 
cardiovascular function, women were grouped according to PCOS status defined by 
the Rotterdam criteria, and by obesity status using a BMI partition value of 
≥27kg/m2 since this has been shown to identify abnormal glucose handling. There 
were four groups - lean control, lean PCOS, obese control, and obese PCOS. 
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Results 
The sample sizes per group were as follows: (i) lean control = 44; (ii) lean PCOS = 
20; (iii) obese control = 42; and (iv) obese PCOS = 53.  
Abnormal glucose handling 
Table 3-1 shows the proportions of women with undiagnosed insulin resistance, IGT 
and type 2 diabetes. Sixteen percent of lean control women had insulin resistance. As 
expected the prevalence was higher in lean women with PCOS than without (p=.003, 
odds-ratio 6:1 for women with PCOS). Obese women with PCOS had the highest 
prevalence of insulin resistance but the rate was not significantly higher than for 
obese controls (p= .230). 
The prevalence of impaired glucose tolerance was higher in all other groups 
compared with lean controls. In this study, obese women with PCOS were not more 
likely to have IGT than lean women with PCOS or obese controls. Eight of the 11 
patients with IGT were overweight or obese and the majority had waist 
circumference greater than 88cm.  
There were no cases of impaired fasting glucose (IFG) but five cases of 
undiagnosed type 2 diabetes in obese PCOS subjects; all were excluded from 
subsequent analyses since the aim of this thesis was to establish the effect of pre-
diabetic status on cardiovascular function. The remaining obese PCOS group 
comprised 48 women. Three of the cases of diabetes would have been missed had an 
oral glucose-tolerance test not been performed. All five patients had class II or III 
obesity (BMI 37-42.7 kg/m
2
) and waist circumference significantly greater than 
88cm (112-139cm).  
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Table 3-1. Proportions of women with undiagnosed abnormalities of glucose handling. 
 Lean 
Control 
Lean 
PCOS 
Obese 
Control 
Obese 
PCOS 
     
Insulin resistance 7/44(16%) 11/20 (55%) 26/42 (62%) 40/53 (83%) 
     
Impaired glucose 
tolerance 
1/44 (2%) 2/20 (10%) 3/42 (7%) 5/53 (6%) 
     
Type 2 diabetes 0/44 0/20 0/42 5/53 (6%) 
 
 
Clinical characteristics of the study population 
Table 3-2 shows the clinical characteristics of the final studied population. By 
design, age was similar across the groups and all measures of obesity were higher in 
obese compared with lean groups. In addition, the mean testosterone of lean women 
with PCOS was 34% higher than that of lean controls but this was not statistically 
significant. However, the result may be affected by the distribution of data in 
controls; the technique used to assess testosterone could not discriminate between 
values less than 0.7nmol/l. Therefore, a value of 0.69 was ascribed to all women 
having testosterone level categorised as <.7 nmol/l.  Obese women with PCOS had 
the highest testosterone levels. 
Body composition was similar in women with PCOS and BMI-matched controls. 
Obesity, regardless of PCOS status, was associated with higher levels of fasting 
insulin, insulin area under the curve, lower HDL cholesterol, higher triglycerides and 
higher hs-CRP. Obesity tended to be associated with reduced adiponectin but only 
the difference between lean and obese PCOS groups was statistically significant. The 
mean adiponectin for lean women with PCOS was 56% higher than the mean for 
lean controls although there was significant variation within the group and this did 
not reach significance after applying post-hoc corrections for multiple group 
comparisons
a
. 
                                                 
a
 The distribution of adiponectin in lean controls was significantly different from that of lean women 
with PCOS when assessed using the non-parametric Man-Whitney U test (p=.022). 
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Table 3-2. Clinical characteristics (mean ± s.d.) of the final studied population.  
 Lean  
Control  
 
 
(n=44) 
Lean  
PCOS  
 
 
(n=20) 
Lean  
Control  
vs. 
Lean  
PCOS 
Obese 
Control 
 
 
(n=42) 
Lean  
Control 
vs.  
Obese 
Control 
Obese  
PCOS  
 
 
(n=48) 
Lean  
PCOS 
vs. 
Obese 
PCOS 
Obese 
Control 
vs.  
Obese 
PCOS 
Age (years)* 30  ± 7 29 ± 7 .911 33  ± 7   .364 31  ± 7  .775  .559 
BMI (kg/m
2
)* 23  ± 2 23  ± 3 .840 33  ± 5  <.0001 35 ± 5  <.0001  .134 
Weight (kg)* 61 ± 7 64 ± 10 .905 89 ± 15  <.0001 95 ± 19  <.0001  .381 
Waist (cm)* 75  ± 6 77  ± 9 .784 96 ± 10  <.0001 102  ± 13  <.0001  .111 
Waist/hip* 0.79  ± 0.05 0.80  ± 0.05 .780 0.82 ± 0.05  .006 0.84  ± 0.05  .019  .445 
TFA (cm
2
)* 185  ± 62 200  ± 75 .887 400  ± 72  <.0001 417  ± 75  <.0001  .925 
SFA (cm
2
) 169 ± 58 184  ± 69 .852 358 ± 65  <.0001 372 ± 70  <.0001  .758 
VFA (cm
2
)* 15  ± 8 16  ± 8 .994 42 ± 19  <.0001 44  ± 27  <.0001  .999 
Cholesterol (mmol/l) 4.6  ± 0.9 4.4  ± 0.9 .884 4.7  ± 0.9  .921 4.9  ± 0.6  .096  .547 
HDL (mmol/l)* 1.5  ± 0.3 1.6  ± 0.4 .961 1.3  ± 0.3  .001 1.3  ± 0.3  .002  1.0 
LDL (mmol/l) 2.6  ± 0.8 2.5 ± 0.7 .802 2.9  ± 0.8  .322 3.1  ± 0.6  .007  .637 
Triglycerides (mmol/l)* 0.9  ± 0.4 0.8  ± 0.2 .977 1.1  ± 0.5  .023 1.2 ± 0.5  .005  .858 
Glucose (mmol/l)* 4.5  ± 0.3 4.6  ± 0.3 .901 4.7  ± 0.4  .050 4.7  ± 0.4  .443  1.0 
Gluc AUC (mmol min/l)  660  ± 122 733  ± 135 .196 739  ± 135  .038 777  ± 137  .613  .533 
Insulin (pmol/l)* 53 ± 28 72  ± 31 .145 88 ± 39  <.0001 134  ± 9  <.0001  .010 
Ins AUC (pmol min/l)* 42789 ± 31999 58387 ± 35196 .312 61150 ± 37886  .033 107507  ± 65098  .003  .001 
HOMA-IR* 1.7  ± 1.0 2.4  ± 1.1 .106 3.0  ± 1.5  <.0001 4.7  ± 3.5  <.0001  .019 
hs-CRP (mg/l)* 1.3  ± 1.4 2.4  ± 5.8 .851 3.9  ± 3.9  <.0001 4.6  ± 4.9  .001  .679 
Testosterone (nmol/l)†* 0.9 ± 0.3 1.2  ± 0.8 .194 0.9  ± 0.3  1.0 1.6  ± 0.8  .047  <.0001 
Adiponectin (µg/ml)* 11 ± 6 18 ± 11 .120 9 ± 8  .105 9 ± 7  .001  .984 
 
TFA: total fat area, SFA: subcutaneous fat area, VFA: visceral fat area, HDL: high-density lipoproteins, LDL: low-density lipoproteins, AUC: Area under the curve 
(during oral glucose tolerance test), HOMA-IR: homeostasis model assessment of insulin resistance, hs-CRP: high sensitivity c-reactive protein.  
† The mass spectrometry technique was unable to discriminate between results <0.7nmol/l. *Variables were transformed using natural log before use in ANOVA. 
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Obese women with PCOS did not have lower levels of adiponectin than obese 
controls despite having higher levels of insulin. 
In controls obesity was associated with higher fasting glucose and glucose area 
under the curve, but this finding was not evident in women with PCOS. 
The mean fasting insulin of lean women with PCOS was 36% higher than the 
mean of lean controls, and a similar finding was evident in HOMA-IR, but the 
differences did not reach statistical significance. The combination of obesity and 
PCOS resulted in the highest levels of insulin resistance and hyperinsulinemia 
(p=.001 for HOMA-IR and fasting insulin). The between-group differences in 
HOMA-IR, testosterone and adiponectin are shown in Figure 3-1.   
 
Cardiovascular function by study group 
Table 3-3 shows standard measures of cardiovascular structure and function in the 
four groups. Obesity, regardless of PCOS status, resulted in higher peripheral and 
central systolic BP, LV mass and lower eʹ/aʹ. Obese subjects tended to have higher 
stroke volume than controls but this difference was not statistically significant.  In 
controls, obesity was associated with increased PWV and LV relative wall thickness 
but this difference was not evident in obese compared with lean PCOS subjects. 
Measurements of augmentation index, LV systolic function, global LV strain and 
strain rate (data not presented) were not different between groups in this study. Due 
to a technical problem with storage there was a small sample size for strain and 
strain rate measurements (n = 33 lean control, n = 9 lean PCOS, n = 31 obese 
control, n= 22 obese PCOS).  
In lean women, a diagnosis of PCOS did not affect any standard measure of 
cardiovascular function. In addition, a combined diagnosis of PCOS and obesity did 
not result in worse cardiovascular function than obesity alone despite women with 
PCOS having worse endocrine function than controls. 
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Figure 3-1. Median HOMA-IR, testosterone and adiponectin by 
subject group. Error bars give 95% confidence interval.
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Table 3-3. Selected measures (mean ± s.d.) of cardiovascular function in the studied population. 
 
Lean 
Control 
Lean 
PCOS 
Lean 
Control 
vs. 
Lean 
PCOS 
 
Obese 
Control 
 
Lean 
Control 
vs. 
Obese 
Control 
Obese 
PCOS 
Lean 
PCOS 
vs. 
Obese 
PCOS 
Obese 
control 
vs. 
Obese 
PCOS 
 Heart rate (bpm) 69 ± 10 71  ± 12  .895 72 ± 12 .715 75 ± 10 .604  .543 
bSBP (mmHg) 108 ± 8 108  ± 6  .996 116 ± 11 <.0001 115 ± 9 .026  .759 
bDBP (mmHg) 62 ± 9 63  ± 6  .942 66 ± 9 .083 67 ± 10 .472  1.0 
cSBP (mmHg) 92  ± 9 91  ± 6  .998 99 ± 11 <.0001 98 ± 9 .042  .693 
cDBP (mmHg) 63 ± 9 65 ± 6  .857 67  ± 9 .070 69 ± 10 .455  .989 
ccIMT (mm)* 0.492 ± 0.048 0.473  ± 0.063  .529 0.524 ± 0.064 .100 0.507  ± 0.063 .102  .630 
Aortic PWV (m/s)* 5.96  ± 0.75 5.91  ± 0.71  .997 6.74  ± 0.90 <.0001 6.42 ± 0.87 .133  .190 
AIx-75 (%) 1.14 ± 14.73 1.75 ± 10.28  .998 7.63 ± 14.73 .124 4.31 ± 11.63 .891  .666 
RWT* 0.35 ± 0.06 0.35 ± 0.06  1.0 0.39  ± 0.07 .024 0.35 ± 0.05 .997  .047 
LVIDd (cm) 4.52  ± 0.37 4.51 ± 0.40  1.0 4.73  ± 0.39 .144 4.73 ± 0.36 .108  .962 
LV mass (g/m
2.7
)* 30  ± 6 30 ± 7  .998 39 ± 7 <.0001 36 ± 5 .003  .325 
FS (%) 33 ± 5 34  ± 5  .916 35 ± 6 .140 36  ± 5 .294  .844 
Stroke volume (ml) 61  ± 10 60 ± 12.3  .988 67 ± 12 .127 67 ± 12 .130  1.0 
S’ (cm/s)* 9.8  ± 1.5 9.6  ± 1.1  .986 10  ± 2.1 .974 9.8 ± 1.6 .990  .970 
MAPSE (cm) 1.3 ± 0.1 1.3 ± 0.1  .576 1.4 ± 0.2 .090 1.4 ± 0.1 .970  .996 
e' (cm/s)* 15 ± 2 17 ± 2  .446 14 ± 3 .081 14 ± 3 .014  .999 
a' (cm/s) 7.7 ± 1.5 8.1 ± 1.7  .922 9.2 ± 2.0 .004 9 ± 1.9 .408  .960 
e'/a'*  (cm/s) 2.1  ± 0.5 2.1  ± 0.5  .973 1.6 ± 0.6 .001 1.7 ± 0.5 .024  .914 
IVRT (ms) 81 ± 8 80 ± 11  .896 87 ± 11 .023 82 ± 12 .879  .072 
FPV (cm/s) 54 ± 8 56 ± 11  .996 60 ± 12 .130 58 ± 10 .884  .902 
b: brachial, c: central, SBP: systolic blood pressure, DBP: central diastolic blood pressure, ccIMT: common carotid intima-media thickness, PWV: pulse wave 
velocity, AIx-75: augmentation index corrected for a heart rate of 75bpm, RWT: relative wall thickness, LVIDd: left ventricular internal dimension in diastole, FS: 
fractional shortening, sʹ: longitudinal systolic myocardial velocity, eʹ/aʹ: ratio of early to late diastolic myocardial tissue velocity, IVRT: isovolumic relaxation 
time. *Variables were transformed using natural log before use in ANOVA.
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Left ventricular geometry by study group 
Frequencies of concentric remodelling, concentric hypertrophy and eccentric 
hypertrophy are shown in Table 3-4. In controls, obesity was associated with an 
increased prevalence of ventricular remodelling and hypertrophy with evidence of 
both eccentric and concentric patterns. The prevalence of concentric remodelling 
was higher in lean women with PCOS than in lean controls but the numbers were 
small in both groups. The prevalence of hypertrophy in obese women with PCOS 
was significantly lower than in obese controls. The difference in frequency of 
hypertrophy was related to the study group (χ2 = 32.32, p=.000183) with an odds 
ratio of 18:1 for hypertrophy in obese control versus obese PCOS subjects. 
 
Table 3-4. Frequency of left ventricular remodelling and hypertrophy by study group. 
 
Lean 
Control 
Lean 
PCOS 
Obese 
Control 
Obese 
PCOS 
Unable to determine 2/44 (4.5%) 1/20 (5%) 2/40 (5%) 4/47 (8.5%) 
Normal geometry 39/44 (89%) 16/20 (80%) 22/40 (55%) 39/47 (83%) 
Concentric remodelling 2/44 (4.5%) 3/20 (15%) 5/40 (12.5%) 3/47 (6.4%) 
Concentric hypertrophy 1/44 (2%) 0/20 (0%) 4/40 (10%) 1/47 (2.1%) 
Eccentric hypertrophy 0/44 (0%) 0/20 (0%) 7/40 (17.5%) 0/47 (0%) 
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Univariate correlates of key cardiovascular function variables 
Table 3-5 shows univariate correlations between metabolic variables and key 
measures of cardiovascular structure and function in the pooled data.  
The most important correlate of ccIMT was age. There were weaker but 
significant direct associations with measures of general and central obesity (except 
WHR), central systolic BP and aortic PWV, and an inverse association with 
adiponectin. There were no significant associations of ccIMT with measures of 
insulin resistance (except glucose AUC), cholesterol, testosterone or inflammation.  
The most important correlate of aortic PWV was central systolic blood pressure 
(which can be a cause and effect of increased PWV, a pressure dependent measure of 
aortic stiffness). Associations also existed with age, measures of general and central 
obesity, fasting measures of glucose handling, diastolic blood pressure, 
inflammation, LDL and total cholesterol, ccIMT, mitral annular plane systolic 
excursion (all direct) and adiponectin (inverse). There was no association of aortic 
stiffness with testosterone.   
The most important correlate of LV mass was weight. There were also 
associations with age, other measures of general and central obesity, stroke volume, 
inflammation, fasting measures of glucose handling, systolic and diastolic BP, aortic 
stiffness, LDL and triglycerides (all direct). LV mass was also inversely associated 
with adiponectin and HDL. There was no association of LV mass with testosterone. 
There was a direct association of LV mass with ccIMT which may be partly due to a 
shared association with body size, particularly with lean mass. 
The most important correlate of the diastolic function measure, eʹ/aʹ, was age 
(inverse). There were also inverse associations with aortic PWV, ccIMT, LV mass, 
all measures of general and central obesity, all measures of glucose handling, 
cholesterol, inflammation, brachial and central BP, stroke volume, and fractional 
shortening. The ratio of eʹ/aʹ was also directly associated with HDL. There was no 
significant association of eʹ/aʹ with testosterone or with adiponectin. 
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Table 3-5. Univariate correlates [Spearman’s Rho (p-value)] of key cardiovascular variables 
in the pooled data.  
 ccIMT Aortic PWV LV mass eʹ/aʹ 
 
Age  .44   (<.0001)  .56  (<.0001)  .32  (.0001)  −.60  (<.0001) 
Weight  .26   (.001)  .40  (<.0001)  .62  (<.0001)  −.45   (<.0001) 
BMI  .26   (.001)  .47  (<.0001)  .58  (<.0001)  −.51   (<.0001) 
Waist  .28   (.001)  .47  (<.0001)  .58  (<.0001)  −.57   (<.0001) 
Waist/hip  .10   (.243)  .23  (.006)  .23  (.006)  −.38  (<.0001) 
TFA  .24   (.004)  .41  (<.0001)  .47  (<.0001)  −.44   (<.0001) 
SFA  .22   (.008)  .38  (<.0001)  .46  (<.0001)  −.40   (<.0001) 
VFA  .27   (.001)  .42  (<.0001)  .50  (<.0001)  −.54   (<.0001) 
Cholesterol  .03   (.713)  .17  (.049)  .13  (.123)  −.23  (.012) 
HDL  −.12   (.151)  −.15  (.069)  −.26  (.003)  .25  (.006) 
LDL  .07   (.406)  .19  (.022)  .20  (.021)  −.26  (.003) 
Triglycerides  .13   (.117)  .15  (.070)  .25  (.003)  −.21  (.018) 
Glucose  .13   (.112)  .20  (.018)  .18  (.031)  −.30   (.001) 
Gluc AUC   .20   (.017)  .17  (.051)  .11  (.188)  −.37   (<.0001) 
Insulin  .02   (.807)  .20  (.018)  .23  (.006)  −.20   (.030) 
Ins AUC  .03   (.724)  .15  (.097)  .01  (.875)  −.29   (.003) 
HOMA-IR  .03   (.685)  .24  (.004)  .25  (.001)  −.23   (.013) 
hs-CRP  .12   (.141)  .26  (.001)  .30  (<.0001)  −.19   (.032) 
Testosterone  −.14   (.099)  .02  (.849)  .05  (.583)  −.05   (.605) 
Adiponectin  −.26   (.002)  −.18   (.039)  −.26  (.002)  .16   (.091) 
Heart rate  −.05  (.530)  .11  (.193)  .00  (.995)  −.19  (.035) 
bSBP  .10  (.214)  .43  (<.0001)  .36  (<.0001)  −.22  (.013) 
bDBP  .03  (.775)  .48  (<.0001)  .22  (.008)  −.35  (<.0001) 
cSBP  .20  (.015)  .62  (<.0001)  .36  (<.0001)  −.43  (<.0001) 
cDBP  .02  (.775)  .46  (<.0001)  .25  (.003)  −.37  (<.0001) 
SV  .27  (.001)  .16  (.062)  .44  (<.0001)  −.28  (.002) 
sʹ  −.01  (.951)  .06  (.515)  −.16  (.094)  .02  (.817) 
MAPSE  .06  (.452)  .18  (.033)  .12  (.153)  −.14  (.115) 
FS  .15  (.081)  .14  (.096)  .08  (.323)  −.39  (<.0001) 
ccIMT  1  .28  (.001)  .38  (<.0001)  −.36  (<.0001) 
aPWV    1  .32  (<.001)  −.54  (<.0001) 
LV mass    
 
 1  −.39  (<.0001) 
 
TFA: total fat area, SFA: subcutaneous fat area, VFA: visceral fat area, HDL: high-density lipoproteins, 
LDL: low-density lipoproteins, AUC: Area under the curve (during oral glucose tolerance test), HOMA-IR: 
homeostasis model assessment of insulin resistance, hs-CRP: high sensitivity c-reactive protein, b: brachial, 
c: central, SBP: systolic blood pressure, DBP: central diastolic blood pressure, SV: stroke volume, s’: 
longitudinal systolic myocardial velocity, MAPSE: mitral annular plane systolic excursion, FS: fractional 
shortening, ccIMT: common carotid intima-media thickness, aPWV: pulse wave velocity,  eʹ/aʹ: ratio of early 
to late diastolic myocardial tissue velocity.
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Independent contributors of common carotid intima-media thickness 
The variation in ccIMT was explained reasonably well by a basic model comprising 
age and a measure of body size. Separate regression models for each measure of 
body size are shown in Table 3-6. The combination of age and weight resulted in the 
best model. 
Glucose AUC and adiponectin were added to the second block of a hierarchical 
model using a stepwise method. Adiponectin emerged as a significant explanatory 
variable and improved the model (r
2
 change 4%, p=.003) while the measure of body 
size became non-significant.  
In the next step central systolic blood pressure, aortic pulse wave velocity and 
LV stroke volume were added using the same method. Stroke volume emerged as a 
significant explanatory variable and improved the model (r
2
 change 5%, p=.003). 
The final model therefore included age, adiponectin and stroke volume which 
together explained 32% of the variation in carotid intima-media thickness (p<.0001) 
(Table 3-7). 
Age explained most of the variation in ccIMT in this population but a significant 
proportion of the variation was independently explained by adiponectin, suggesting 
that the hormone may represent a link between obesity and increased intima-media 
thickening in the young women in this study.  Left ventricular stroke volume, which 
tended to be increased in obese subjects, was also an independent explanatory 
variable for ccIMT. 
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Table 3-6. Separate basic multivariate regression models for common carotid intima-media 
thickness. 
Dependent variable = ccIMT* r
2
 value Model p-value 
Age* + weight* .233 <.0001 
Age* + BMI* .223 <.0001 
Age* + waist circumference* .220 <.0001 
Age* + visceral fat area* .222 <.0001 
*Variables were transformed by taking the natural logarithm prior to use in multivariate regression. 
 
 
Table 3-7. Final multivariate regression model for common carotid intima-media thickness. 
Dependent variable = ccIMT* Standardised β P-value 
Part 
correlation 
Age* .383 <.0001 .373 
HMW adiponectin* −.286 <.0001 −.285 
LV stroke volume .231 .005 .226 
Model r
2
 = .323, p<.0001 
*Variables were transformed by taking the natural logarithm prior to use in multivariate regression. 
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Independent contributors of aortic pulse wave velocity 
The variation in aortic PWV was explained reasonably well by a basic model 
comprising age, central systolic blood pressure and a measure of body size. Although 
PWV is a measure of aortic stiffness and a rise in PWV would result in higher 
systolic blood pressure, PWV is also dependent on systolic blood pressure because 
the aorta becomes functionally stiffer at higher blood pressures. Separate regression 
models for each measure of body size are shown in Table 3-8. The use of waist 
circumference or BMI resulted in an improved model compared with visceral fat. 
HOMA-IR, hs-CRP, adiponectin, ccIMT, cholesterol, LDL and MAPSE were 
added to the second hierarchical block using a stepwise method but these did not 
independently contribute to aortic PWV and did not improve the model.  
The final model therefore included age, central systolic blood pressure and waist 
circumference which together explained 54% of the variation in aortic pulse wave 
velocity (p<.0001) (Table 3-9). Central systolic blood pressure and age explained 
most of the variation in aortic pulse wave velocity in this population with a small 
proportion of the variation independently explained by waist circumference.   
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Table 3-8. Separate basic multivariate regression models for aortic pulse wave velocity. 
Dependent variable = aortic PWV* r
2
 value Model p-value 
Age* + cSBP + weight* .529 <.0001 
Age* + cSBP + BMI* .543 <.0001 
Age* + cSBP + waist circumference* .544 <.0001 
Age* + cSBP + visceral fat area* .517 <.0001 
cSBP: central systolic blood pressure. *Variables were transformed by taking the natural logarithm 
prior to use in multivariate regression. 
 
Table 3-9. Final multivariate regression model for aortic pulse wave velocity. 
Dependent variable = aortic PWV* Standardised β P-value 
Part 
correlation 
Age* .353 <.0001 .322 
Central systolic blood pressure .399 <.0001 .337 
Waist circumference* .195 .003 .172 
Model r
2
 = .544, p<.0001 
 *Variables were transformed by taking the natural logarithm prior to use in multivariate regression. 
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Independent contributors of left ventricular mass  
The variation in LV mass was explained reasonably well by a basic model 
comprising age, central systolic blood pressure and a single measure of body size. 
Separate regression models for measures of body size are shown in Table 3-10. 
Weight explained more of the variation in ventricular mass than did the other basic 
measures of body size.  
Measures of glucose handling were added to the second block of a hierarchical 
model using a stepwise method but these did not independently explain a significant 
proportion of the variation in LV mass and did not improve the model. 
Aortic pulse wave velocity and ccIMT were added to the second block of the 
hierarchical model using a stepwise method. ccIMT emerged as an independent 
contributor to LV mass and resulted in a small but significant improvement in the 
model (r
2
 change 6%, p <.0001).  
The final model for the dependent variable LV mass is shown in Table 3-11. The 
model explained 50% of the variation in LV mass and weight was the most 
important independent contributor. The introduction of ccIMT had the effect of 
reducing the beta value of age and central systolic blood pressure to a non-significant 
value.  
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Table 3-10. Separate basic multivariate regression models for left ventricular mass. 
Dependent Variable = LV Mass* r
2
 value Model p-value 
Age* + cSBP + weight  .466 <.0001 
Age* + cSBP + BMI* .401 <.0001 
Age* + cSBP + waist circumference* .381 <.0001 
Age* + cSBP + visceral fat area* .289 <.0001 
cSBP = central systolic blood pressure. *Variables were transformed by taking the natural logarithm 
prior to use in multivariate regression. 
 
Table 3-11. Final multivariate regression model for left ventricular mass. 
Dependent variable = LV mass* Standardised β P-value 
Part 
correlation 
Weight* .558 <.0001 .490 
ccIMT* .214 .002 .188 
cSBP .096 .191 .080 
Age* .040 .583 .034 
Model r
2
 = .501, p<.0001 
cSBP = central systolic blood pressure. *Variables were transformed by taking the natural logarithm 
prior to use in multivariate regression.  
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Independent contributors of diastolic function 
The variation in diastolic function (eʹ/aʹ) was explained reasonably well by a basic 
model comprising age, central systolic blood pressure and a measure of body size. 
Separate regression models for measures of body size are shown in Table 3-12. 
Among the measures of obesity, visceral fat area appeared to explain more of the 
variation in diastolic function. LV mass did not independently explain any of the 
variation in diastolic function when measures of obesity were included.  
A hierarchical approach was used to test whether the model was improved by the 
addition of any of the following variables (in separate blocks); measures of glucose 
handling, ccIMT and aortic PWV. Insulin area under the curve emerged as an 
independent contributor of diastolic function explaining a further 7% of its variation 
(Table 3-13).  
The final model is shown in Table 3-14. Age was the most important 
independent determinant of reduced diastolic function, followed by insulin area 
under the curve and visceral fat area. Central systolic blood pressure did not 
independently explain a significant proportion of the variation in eʹ/aʹ in the final 
model.   
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Table 3-12. Separate basic multivariate regression models for the eʹ/aʹ. 
Dependent variable = eʹ/aʹ* r2 value Model p-value 
Age* + cSBP + weight* .428 <.0001 
Age* + cSBP + BMI* .458 <.0001 
Age* + cSBP + waist circumference* .480 <.0001 
Age* + cSBP + visceral fat area* .511 <.0001 
cSBP = central systolic blood pressure. *Variables were transformed by taking the natural logarithm 
prior to use in multivariate regression. 
Table 3-13. Separate hierarchical multivariate regression block for eʹ/aʹ. 
Dependent variable = eʹ/aʹ* r2 change Cumulative r2 F change statistic 
Basic model + insulin AUC* .066 .577 
F (1, 91) = 14.22, 
p<.0001 
Basic model included age*, central systolic blood pressure and visceral fat area. *Variables were 
transformed by taking the natural logarithm prior to use in multivariate regression. 
Table 3-14. Final multivariate regression model for eʹ/aʹ. 
Dependent variable = eʹ/aʹ* Standardised β P-value 
Part 
correlation 
Age* −.491 <.0001 −.419 
Insulin AUC* −.262 .001 −.241 
Visceral fat area* −.209 .011 −.179 
cSBP −.147 .068 −.128 
Model r
2
 = .577, p<.0001 
cSBP = central systolic blood pressure. *Variables were transformed by taking the natural log prior 
to use in multivariate regression.
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The effects of obesity and PCOS on the relationship between age and 
cardiovascular function 
Common carotid intima-media thickness and aortic PWV are known to increase with 
age, while eʹ/aʹ decreases. Scatterplots and linear regression were used to determine 
whether the relationship between these measures and age was affected by obesity 
and PCOS status (Figure 3-2).  
The effect of obesity in controls: Comparison of the solid lines shows the effect of 
obesity on the relationship between age and cardiovascular function. The slope 
tended to be steeper in obese (red line) compared with lean (black line) controls for 
each of the three variables although the differences in regression coefficients did not 
reach statistical significance (p= .184 for ccIMT, p= .085 for PWV and p= .247 for 
eʹ/aʹ).  
The effect of obesity in women with PCOS: Comparison of the broken lines shows 
the effect of obesity on the relationship between age and cardiovascular function in 
women with PCOS.  Those who were obese (red) appeared to have higher PWV and 
lower eʹ/aʹ than those who were lean (black) across the age-range because of a 
tendency for different intercepts but these differences were not statistically 
significant (p= .469 for PWV and p= .513 for eʹ/aʹ). The slopes were very similar 
between lean and obese women with PCOS (p= .689 for ccIMT, p= .793 for PWV 
and p= .877 for eʹ/aʹ). 
The effect of PCOS in lean women: Comparison of the solid and broken black lines 
shows the effect of PCOS on the relationship between age and cardiovascular 
function in lean women. The intercept between age and ccIMT appeared lower in 
those with PCOS (broken line) (p=.150) but the slope tended to be increased 
compared with lean controls (solid line) (p=.225) so that the lines crossed at around 
age 35 years. A diagnosis of PCOS had no effect on the relationship between age and 
aortic PWV in lean women (p=.907 for differences in slope and p=.969 for 
differences in intercept). The decline in diastolic function with age appeared 
marginally steeper in those with PCOS (p=.463) so that the lines separated at higher 
ages. 
 96 
 
The effect of PCOS in obese women: Comparison of the solid and broken red lines 
shows the effect of PCOS on the relationship between age and cardiovascular 
function in obese women. The age-related change in ccIMT tended to be steeper in 
obese women with PCOS compared to obese controls (p=.180). However, the 
intercept was lower (p=.160) so that only women with PCOS who were older than 35 
years had higher ccIMT than controls. A higher intercept (p=.190) but shallower 
slope (p=.142) meant that after age 30 years obese women with PCOS tended to 
have lower PWV than obese controls. Similarly, the eʹ/aʹ intercept and slope were 
more similar in obese women with and without PCOS (p=.559 and p=.696 
respectively).   
These trends, coupled with inconclusive evidence for altered cardiovascular 
outcome data in women with PCOS, led to the generation of a new hypothesis that 
HMW adiponectin may be more important in mitigating the effects of obesity and 
insulin resistance in PCOS than in healthy women.  
HMW Adiponectin 
Table 3-15 shows univariate correlations between HMW adiponectin and other 
cardio-metabolic variables by PCOS status. HMW adiponectin was negatively 
associated with obesity, fasting insulin and HOMA-IR, ccIMT and LV mass in 
subjects with and without PCOS. However, the correlation coefficients for measures 
of obesity were significantly greater in women with PCOS compared with controls. 
Furthermore, adiponectin was negatively associated with central systolic blood 
pressure in those with PCOS but not in controls.  
There was no association of testosterone with HMW adiponectin when groups 
were split by PCOS diagnosis. However, in a separate analysis for lean subjects 
(regardless of PCOS status) there was a weak association of testosterone with HMW 
adiponectin (r=.270, p=.032).  
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Figure 3-2. The relationship of age with pulse wave velocity, common carotid intima-media thickness and diastolic function by subject group. 
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Table 3-15.  Univariate correlations [Spearman’s Rho (p-value]) of HMW-adiponectin with 
cardio-metabolic variables. 
 
   Control       PCOS 
Fisher 
Z 
p-value 
Weight −.22 (.049) −.56 (<.0001)  2.52 .006 
BMI −.23 (.035) −.57 (<.0001)  2.55 .005 
Waist circumference −.25 (.028) −.50 (<.0001)  1.81 .035 
Visceral fat area −.21 (.062) −.56 (<.0001)  2.59 .005 
Glucose −.03 (.805) −.09 (.489)  0.37 .356 
Glucose AUC −.17 (.132) −.05 (.683)  −0.75 .227 
Insulin −.38 (<.0001) −.43 (.001)  0.37 .711 
Insulin AUC −.35 (.002) −.26 (.056)  −0.61 .271 
HOMA-IR −.37 (.001) −.43 (<.0001)  0.44 .330 
Hs-CRP −.17 (.130) −.32 (.010)  0.99 .161 
Testosterone −.01 (.996) −.10 (.439)  0.56 .288 
Heart rate −.14 (.221) −.08 (.561)  −0.37 .356 
Central SBP −.05 (.681) −.34 (.006)  1.87 .031 
Central DBP −.02 (.854) −.18 (.144)  1.0 .159 
ccIMT −.23 (.044) −.29 (.020)  0.40 .345 
Aortic PWV −.13 (.260) −.22 (.084)  0.57 .284 
LV mass −.24 (.035) −.30 (.020)  0.40 .345 
eʹ/aʹ .17 (.154) .17 (.268) 0 .500 
 
AUC: area under the curve, HOMA-IR: homeostasis model assessment of insulin resistance, hs-CRP: 
high sensitivity c-reactive protein, SBP: systolic blood pressure, DBP: diastolic blood pressure, 
ccIMT: common carotid intima-media thickness, PWV: pulse wave velocity.
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Discussion 
Undiagnosed abnormalities of glucose metabolism 
Impaired fasting glucose and type 2 diabetes: There were no cases of IFG in any 
group and no cases of undiagnosed type 2 diabetes in control subjects. In contrast, 
five women with PCOS had undiagnosed type 2 diabetes. These figures are 
comparable to the 4-10% quoted by other studies,
173-175
  which is 7.5-10 times higher 
than the prevalence for women of a similar age without PCOS.
173
 All those with 
diabetes in my study were drawn from the obese PCOS group which may also be 
more likely to contain those with the most severe reproductive forms of the 
syndrome. Three of the five cases of diabetes were only evident when the post-
prandial glucose response was assessed. This finding is not unique to this study and 
the Androgen Excess Society has recommended screening women with PCOS for 
diabetes using an oral glucose tolerance test.
176
  
Impaired glucose tolerance: There were very small numbers of women with IGT in 
all categories. Perhaps surprisingly, the rate was not higher in women with PCOS 
who were obese than for those who were lean.  The prevalence of IGT in women 
with PCOS in my study (6-10%) is lower than the 20-35% quoted by others.
173-175, 
177
.  This may be related to the use of the Rotterdam criteria although 79% of women 
with PCOS in my study also met the NIH criteria that requires a diagnosis of 
hyperandrogenism and chronic anovulation.  
Insulin resistance: Insulin regulates blood glucose levels by stimulating glucose 
uptake by tissues, adipocytes, skeletal and cardiac muscle. It also suppresses glucose 
production in the liver. The term insulin resistance is used to describe a decreased 
ability of insulin to mediate these actions so that more insulin is required to achieve 
any given effect. Therefore, insulin resistance results in elevated basal insulin and 
elevated post-prandial insulin when pancreatic β-cells are intact. The 
hyperinsulinaemic-euglycaemic clamp technique is considered the gold standard for 
assessing insulin resistance in vivo but this method is complex and expensive, 
rendering it unsuitable for many larger studies. I used fasting insulin and glucose 
measures, the HOMA-IR index, and OGTT-derived parameters as surrogate 
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measures of insulin resistance. While these are less precise assessments of insulin 
sensitivity, they do correlate with clamp methods.
178, 179
  
Two-thirds of obese controls had undiagnosed insulin resistance according to a 
HOMA-IR result of 2.5 or greater. It is unclear whether this partition value 
represents the most sensitive and specific threshold for the diagnosis of insulin 
resistance but I used it because of the absence of a clear definition in guidelines and 
because it allowed a direct comparison between my results and those of another 
group who also studied cardiovascular function in women with and without PCOS.
98
  
As expected, the rates of insulin resistance were higher in women with PCOS. 
Insulin resistance affected around half of those who were lean and 83% of those who 
were obese. Others have reported a prevalence of 44-95% for insulin resistance in 
women with PCOS, with rates likely affected by the diagnostic method, partition 
value and reproductive phenotype.
74, 76
  
In 1980 Burghen et al. were the first to report that women with PCOS had 
increased insulin responses during oral glucose-tolerance testing that were not solely 
attributable to obesity.
180
 This triggered an exponential rise in the number of studies 
on insulin resistance associated with the syndrome. While there is a general 
consensus that obese women with PCOS are insulin resistant,
72
 some studies using 
the clamp method in lean women with PCOS have failed to demonstrate insulin 
resistance.
181
  
I found a trend towards an intrinsic level of basal hyperinsulinemia and elevated 
HOMA-IR in lean women with PCOS but the differences were not statistically 
significant after corrections for multiple post-hoc comparisons. Fasting insulin levels 
are affected by insulin production, insulin clearance and insulin sensitivity, but our 
study was not designed to determine the precise mechanism for these findings. 
Others have demonstrated, using clamp studies, that lean women with PCOS have 
hyperinsulinemia due to increased insulin secretion and not as a consequence of 
insulin resistance.
181
 However, postprandial dysglycaemia was also evident in our 
study and this suggests peripheral, mainly skeletal muscle, insulin resistance.
182
 
Fasting glucose levels were normal reflecting endogenous glucose production (in the 
liver) that was similar to controls. 
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Insulin resistance and body composition 
Visceral fat is more metabolically active than subcutaneous fat and is strongly 
associated with insulin resistance. In my study visceral fat area was measured from 
CT scans and was similar among controls and age- and BMI-matched women with 
PCOS. These results are similar to other studies using MRI which is considered the 
gold-standard method of quantifying visceral and subcutaneous fat.
183, 184
  
There is speculation in the literature that the insulin resistance in PCOS is 
attributable to increased visceral fat rather than global obesity. This is based on an 
increased frequency of upper body obesity (the so-called ‘android shape’) in those 
with hyperandrogenemia,
185
 and a positive association between exogenous androgen 
levels (nandrolone) and visceral fat.
186
  The data in the present study suggest that 
body composition and in particular visceral fat levels, are not different in women 
with PCOS and controls so this is unlikely to be the cause of higher rates of insulin 
resistance in the former.  
The addition of obesity to PCOS was associated with insulin resistance beyond 
the ‘intrinsic’ level of hyperinsulinemia. The relationship between visceral fat area 
and insulin resistance was similar in PCOS and in controls suggesting that obesity is 
linked to extrinsic insulin resistance in a similar manner in both groups. This is 
relevant to management strategies since therapies designed to target insulin 
resistance (such as metformin) may be more successful in treating the extrinsic 
insulin resistance in PCOS.
187
 Given this, it would be useful to have a better 
understanding of the associations between obesity, insulin resistance and 
cardiovascular function in women with PCOS. 
Metabolic phenotype mirrors reproductive phenotype in PCOS 
Not all women with PCOS defined by the Rotterdam criteria have insulin resistance. 
There are two reproductive phenotypes with normal or near normal insulin 
sensitivity; these are (i) anovulatory women with polycystic ovaries but normal 
androgen levels (ii) women with hyperandrogenaemia and polycystic ovaries but 
normal ovulation.
177, 188
 These women are often leaner than those diagnosed by NIH 
criteria who have both anovulation and hyperandrogenemia. Since I was interested in 
the effects of insulin resistance and obesity on cardiovascular function I did not 
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characterize subjects by reproductive phenotype. However, lean women with PCOS 
in my study had better insulin sensitivity and lower testosterone levels than obese 
women with PCOS i.e. the metabolic phenotype appeared to mirror the reproductive 
phenotype as noted by others.
76
 There is evidence for a mechanistic link between the 
reproductive phenotype and insulin since it decreases hepatic production of the sex 
hormone binding globulin (SHBG) which results in elevated levels of circulating 
testosterone.
189
 
There are no detailed longitudinal studies which explore the natural history of 
PCOS and it is unclear whether the milder reproductive phenotypes are an 
intermediate stage between normality and the more severe form of the syndrome 
with progression triggered by weight gain. 
Cardiovascular function 
Common carotid intima-media thickness: Obesity tended to be associated with 
increased ccIMT but the differences were not significant. In addition, women with 
PCOS had similar ccIMT to age- and BMI-matched controls.  
The study population was aged 16 to 45 years and it may be that significant 
increases in ccIMT are not evident until later in life. One study has demonstrated that 
only women aged >45 years with PCOS had thicker ccIMT than controls after 
adjustment for BMI.
190
 Subtle differences in a small measurement are also difficult 
to detect without very large sample sizes. A systematic review and meta-analysis in 
2012 combined 19 studies for meta-analysis (1123 women with PCOS and 923 
controls in total) and found that ccIMT was increased by 0.072 - 0.084mm (p<.0001) 
for good and high quality studies.
93
 The authors suggested that the difference in 
ccIMT equates to ~7 years of ageing since the average change in ccIMT for women 
is reported to be 0.009 – 0.015mm per year.191, 192 The review was unable to 
determine which cardiovascular risk factors or reproductive phenotypes were 
associated with increased ccIMT but many of the studies used NIH criteria to 
diagnose PCOS.  
A key finding of this study is that age, adiponectin and LV stroke volume were 
the only independent contributors to ccIMT in this young population who were free 
from overt cardiovascular disease.  
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This suggests that obesity and increased ccIMT may be linked through a 
reduction in adiponectin (which has anti-inflammatory and anti-atherogenic effects) 
and an increase in body size and circulating volume. The data support a recent large 
study by Kozakova et al. who found that the increased thickening of the common 
carotid wall in an uncomplicated obese population may be predominantly due to 
adaptive remodelling to normalise arterial wall stress.
94
 Wall stress increases in 
obesity because the persistently increased circulating volume causes an increased 
luminal diameter. This suggests that the increase in ccIMT in subjects with 
uncomplicated obesity may be reversible.   
Despite the lack of between-group difference in mean ccIMT in the present 
study, I found a potentially different relationship between age and ccIMT in those 
with and without PCOS. Even lean women with PCOS appeared to have increased 
age-related thickening of the ccIMT than did controls. The results did not reach 
statistical significance and this could be due to the small sample size in each group. 
Since ccIMT was not associated with measures of insulin resistance it is unlikely that 
the basal hyperinsulinemia in PCOS is influencing the relationship. In contrast, 
adiponectin was a significant negative independent predictor of ccIMT and others 
have suggested that it is selectively reduced in PCOS diagnosed by NIH criteria 
regardless of BMI and insulin resistance.
193
 I did not find lower adiponectin 
associated with PCOS in this study but it is tempting to speculate that reduced 
adiponectin may be a link between PCOS and accelerated ageing of the ccIMT. 
Aortic stiffness (pulse wave velocity): My data confirm that young women with 
uncomplicated obesity have increased aortic PWV even in the absence of 
hypertension. Others have reported similarly increased PWV in obese young adults 
194
 and in obese children.
56
 In my study central obesity (waist circumference) was an 
independent predictor of the variation in aortic PWV. These data are similar to the 
study of Wohlfahrt et al. who found that central obesity was a more important 
determinant of PWV than BMI in a large study of the general population.
195
 I did not 
find stronger associations of PWV with visceral fat than with waist circumference as 
others have reported,
196
 but the subjects in my study were considerably younger and 
it may be that obesity has different short- and long-term effects on arterial stiffness. 
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The mechanisms linking obesity to increased PWV are not well defined but may 
include insulin resistance. In healthy individuals an infusion of insulin within the 
physiological range decreases arterial stiffness with vessel tone altered via actions on 
endothelial nitric oxide synthesis. However, this does not appear to happen in those 
with obesity and insulin resistance, reflecting an impaired large conduit artery 
response to insulin.
197
 Basal hyperinsulinemia also promotes vascular smooth muscle 
hyperplasia 
198
 and collagen production,
199
 which may also contribute to increased 
arterial stiffness.  
While insulin resistance was associated with PWV in my study, it was not an 
independent contributor to multivariate regression. This may explain why the 
relationship between arterial stiffness and age was very similar for lean women with 
and without PCOS, despite the latter having evidence of insulin resistance. It may be 
that the mechanism linking obesity and increased aortic PWV is not related to 
hyperinsulinemia.  
A key finding of this study is that women with PCOS had similar aortic stiffness 
(PWV) to age- and BMI-matched controls. 
This finding is comparable with other small studies of aortic PWV in young 
women with PCOS 
88, 90, 91
 but differs from Meyer at al. who found increased PWV 
in 100 overweight young women with PCOS compared with 20 overweight 
controls.
87
 In the latter study, PCOS was diagnosed by NIH criteria and therefore all 
subjects had the more severe reproductive phenotype of hyperandrogenemia and 
anovulation; it may be that increased arterial stiffness is most evident in this 
phenotype which is associated with a constellation of cardiovascular risk factors 
including dyslipidemia and inflammation. I did not classify subjects by reproductive 
phenotype because I was interested in the effects of metabolic presentation on 
cardiovascular disease. While I have evidence of hyperandrogenemia in the obese 
PCOS group, I am unable to retrospectively identify who had anovulatory cycles.  
I found that the relationship between age and PWV may be different for obese 
women with and without PCOS. According to my data, obese women with PCOS 
younger than ~30 years old may have higher PWV than BMI- and age-matched 
controls. However, the relationship with age was less steep and the lines crossed 
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such that older obese women with PCOS had increasingly lower PWV than 
comparable controls.  The differences did not reach statistical significance and this is 
probably because of the small sample size in each group. Nevertheless, by including 
women across a wide age range in the study I may have unwittingly negated any 
difference between PCOS and controls.  
It is unclear why obese control women tended to have a steeper rise in PWV with 
age than did obese women with PCOS. There was a weak negative association 
between HMW adiponectin and aortic PWV but the former was not an important 
predictor in multivariate analysis. 
Left ventricular mass: The data from my study confirm that young women with 
obesity have increased LV mass compared with lean controls, even in the absence of 
hypertension. This finding is similar to other published studies in obese young 
women 
200
 and obese children.
61
 In addition, I found that LV mass was more strongly 
associated with general obesity (BMI) than with central obesity. The Strong Heart 
Study also reported that LV mass was more strongly related to general obesity 
(particularly relative fat-free mass deficiency) than to central obesity and that this 
effect was particularly evident in women.
46
 In contrast, data from the Multi-Ethnic 
Study of Atherosclerosis showed that insulin resistance and waist-hip ratio were 
associated with concentric LV remodelling after adjusting for BMI, suggesting that 
body size (haemodynamic load) and metabolic health may both be important 
contributors to the development of LV hypertrophy.
47
 Therefore, it will be 
interesting to discover whether the quantification of ventricular-arterial coupling can 
provide additional information about the mechanisms liking uncomplicated obesity 
and increased left ventricular mass. 
A key finding of this study is that women with PCOS had similar LV mass to 
age- and BMI-matched controls. However, obese women with PCOS had a 
significantly lower relative wall thickness and lower prevalence of LV hypertrophy 
compared with obese controls (2% vs. 28% respectively, p<.001, odds ratio of 18:1 
for controls). 
These findings differ from other studies which have reported a 10-40% higher 
LV mass in women with PCOS compared with age- and BMI-matched controls.
99, 100
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The difference in magnitude may be due to the inconsistent use of indexing methods. 
There is considerable debate in the literature regarding the best method of scaling 
echocardiographic dimensions and volumes for body size. I used the allometric 
scaling of LV mass by height
2.7
. This has been shown to identify the 
pathophysiological increase in LV mass associated with obesity 
168
 and has been 
used in other studies of women with PCOS.
98, 99
  
The studies reporting increased LV mass associated with obesity cited above 
used the NIH criteria for defining PCOS and it may be that only the most severe 
reproductive phenotype has evidence of increased LV mass beyond that associated 
with obesity.  Like me, Kosmala et al. used the Rotterdam criteria and found that 
PCOS had no effect on LV mass in obese women compared with BMI matched 
controls.
98
 
The lower relative wall thickness or lower rate of hypertrophy in PCOS did not 
appear to be explained by other differences in standard measures of cardiovascular 
function. This suggests that there may be elements of ventricular loading which are 
not fully described by the basic dataset.  
Diastolic function: As expected, obesity was associated with impaired ventricular 
relaxation (a lower passive filling tissue velocity and higher atrial component to 
filling). These data are comparable with Wong et al. 
201
 and Peterson et al.
200
 who 
studied subjects of a similar age with uncomplicated obesity and also found a 
reduction in eʹ across categories of obesity. This finding has prognostic significance 
since tissue Doppler measurements, particularly the early diastolic velocity (eʹ), are 
significantly associated with outcome providing information that is independent 
from and incremental to clinical data even after adjustment for left ventricular 
hypertrophy.
202
  
I found that visceral fat area was a stronger independent associate of diastolic 
function than was BMI. Libhaber et al. reported that waist circumference was an 
independent associate of E/A in a community sample with a high prevalence of  
obesity,
203
 but this ratio of early to late diastolic flow is more sensitive to the 
changes in loading which are found obesity than is eʹ/aʹ. In addition, waist 
circumference includes lean mass and subcutaneous fat so is less specific a measure 
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of ectopic fat accumulation than visceral fat measured by CT or MRI. Data from the 
Baltimore Longitudinal Study of Ageing (n=843) measured visceral fat by CT and 
eʹ/aʹ and also found that visceral fat was more strongly associated with diastolic 
function than other measures of obesity.
204
  
A key finding of this study is that women with PCOS had similar diastolic 
function (eʹ/aʹ) to age- and BMI-matched controls.  
My results are similar to those of Kosmala et al. 
98
 and Wang et al. 
99
 but differ 
from those of Erdogan 
205
 who found worse diastolic function in a small group of 
Turkish women with PCOS defined by Rotterdam criteria, and Orio et al. 
100
 who 
found worse diastolic function in a small group of women with PCOS defined by 
NIH criteria. Once again, discrepant results may be influenced by the reproductive 
phenotype and by the age of subjects. 
The mechanistic links between insulin resistance or diabetes and diastolic 
dysfunction are multiple, complex and the subject of active research. Myocytes 
demonstrate reduced glucose uptake when glucose levels are higher in insulin 
resistant states leading to the theory that the heart, like skeletal muscle, becomes 
insulin resistant.  There is evidence from animal models of intramyocardial effects 
such as altered calcium handling (reduced deactivation of cross-bridges), altered 
myocyte substrate metabolism, impaired bioenergetics, myocyte steatosis, pro-
inflammatory and pro-fibrotic states, increased myocyte necrosis and apoptosis. In 
addition, hyperglycaemia can cause endothelial dysfunction, oxidative stress, altered 
collagen metabolism and ultimately increased artery stiffness which would lead to 
hypertrophy and altered diastolic function.
206
 
Is there a specific phenotype of PCOS that is associated with 
hyperadiponectinaemia? 
The finding of hyperadiponectinaemia in some lean women with PCOS was 
unexpected. This has not been reported by other studies and it is unclear whether I 
have unintentionally uncovered a phenotype with a compensatory response to the 
intrinsic insulin resistance associated with the syndrome. There was evidence of a 
weak negative association of adiponectin with ccIMT, aortic PWV and LV mass in 
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my data and adiponectin emerged as an independent predictor of ccIMT in 
multivariate analysis.  
I would have liked to explore whether reproductive phenotype was relevant to 
adiponectin levels but the study was not designed to collect this data and it was not 
available retrospectively. It may be that women with PCOS who have normal length 
ovulatory cycles have higher levels of adiponectin. There is evidence that ~20% of 
women with PCOS defined by the Rotterdam criteria report a cycle length of fewer 
than 35 days and these do not have overt insulin resistance on oral glucose-tolerance 
testing.
207
 It would be interesting to evaluate the HMW adiponectin in these women 
to determine whether the lack of overt insulin resistance is as a result of elevated 
levels of this insulin-sensitising adipokine.    
Limitations 
The main limitation of this study is that I did not adequately record details about 
reproductive phenotype. I was primarily concerned with the cardio-metabolic effects 
of PCOS and therefore focused my attention on comprehensive cardiovascular 
measure and detailed measures of obesity, as well basic measures of insulin 
resistance and androgen levels. At the time of study design, there was less evidence 
of the importance of reproductive phenotype on cardiovascular risk factors. It is clear 
from my data and from other publications since the inception of the study, that 
information relating to ovarian ultrasound, ovulation status and cycle length may 
have improved my understanding of the effects of PCOS on the cardiovascular 
system. Future studies should routinely record this information and analyse results 
by reproductive phenotype. 
The case-control, observational nature of the study means that I cannot determine 
causal relationships between obesity, insulin resistance and cardiovascular function. 
Furthermore, there were complex relationships between key variables with many of 
them demonstrating inter-dependence. This rendered statistical analysis difficult and 
it may have been beneficial to approach a statistician to explore interaction effects 
particularly in respect of androgen levels and HMW adiponectin. 
Given the lack of difference between fat distribution in women with PCOS and 
controls, I controlled for obesity by BMI. However, this does not take into account 
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the effects of aberrant adipocyte function which has been shown in women with 
PCOS.
183
 Nevertheless, those with PCOS did not have significantly worse 
cardiovascular function than controls.  
I did not analyse lean muscle mass in this study and this could have been 
considered to accurately assess insulin action since androgens lead to increased 
muscle mass and muscle is a major site of insulin-mediated glucose use.
54
 Women 
with PCOS may have worse levels of insulin resistance than my data suggest if they 
have higher levels of lean muscle mass than controls. Furthermore, increases in LV 
mass and ccIMT may simply reflect increases in lean mass rather than pathologic 
effects of obesity and insulin resistance.  
Echocardiographic measures of strain and strain rate were not among the primary 
outcome measures when the study was designed. I attempted to measure these 
retrospectively from stored data but this was not possible for all subjects and this 
limits the power to detect between-group differences in these variables. In addition, 
the high levels of obesity meant that the apical echo views were frequently not of 
sufficient quality to accurately measure ventricular volumes or perform the 
Simpson’s biplane calculation of ejection fraction.  Nevertheless, the parasternal 
views used to estimate LV mass were typically of sufficient quality and the 
myocardial velocity measures of systolic and diastolic function were feasible in the 
majority of subjects. These measures are well-validated and proven to add prognostic 
information to clinical data.  
Conclusions 
Young women with uncomplicated obesity had increased aortic stiffness (PWV), 
increased LV mass and worse diastolic function (eʹ/aʹ) even in the absence of 
hypertension or diabetes. There was a tendency for ccIMT to be increased in those 
who were obese but this did not reach statistical significance.  
General obesity (weight) was more important than central obesity in the 
development of increased LV mass which suggests that haemodynamic factors 
related to whole body size are among the key mechanisms. This means that even 
those who are obese but metabolically healthy are likely to have increased LV mass. 
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In contrast, central obesity (waist circumference) was more important in the 
development of increased aortic stiffness, and visceral fat was more important in the 
development of impaired diastolic function. These findings suggest that those who 
are obese with abnormal glucose handling may be more likely to have altered arterial 
stiffness and diastolic dysfunction.  
Stroke volume was more important than measures of obesity in explaining the 
variation in ccIMT which supports a theory put forward by others that this might 
represent vascular remodelling to reduce arterial wall stress associated with a 
persistently increased circulating volume. However, adiponectin was also an 
independent predictor suggesting that low adiponectin levels might also be a link 
between obesity and increased ccIMT, perhaps because of inflammation.  
The trend for basal hyperinsulinemia and insulin resistance which is considered 
intrinsic to PCOS was not associated with significant subclinical cardiovascular 
dysfunction in lean women below age 45 years. Furthermore, the combination of 
PCOS and obesity did not have an additive effect on cardiovascular dysfunction 
beyond obesity alone. In fact, obese women with PCOS had a significantly lower LV 
relative wall thickness and lower prevalence of left ventricular hypertrophy than 
obese controls; there may be an as yet unappreciated element of PCOS which 
mitigates the effects of obesity on LV geometry.  
The influence of PCOS reproductive phenotype on subclinical cardiovascular 
function requires further study. I found that lean women with PCOS had a trend 
towards higher adiponectin levels than controls and that obese women with PCOS 
had similar adiponectin levels as obese controls despite worse insulin resistance and 
similar levels of obesity. In addition, adiponectin was a significant univariate 
correlate (inverse) of ccIMT, aortic stiffness and LV mass. Furthermore, the 
relationship between obesity and adiponectin was significantly stronger in those with 
PCOS than in controls. Together, these findings suggest that there may be a 
phenotype of PCOS with hyperadiponectinaemia and that this might be among the 
mechanisms which mitigate the effects of obesity on the cardiovasculature in those 
with PCOS. This could have direct relevance to the lack of evidence for altered 
cardiovascular outcomes in women with PCOS despite increased risk factors.  
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It is clear that the measures of cardiovascular structure and function in this 
chapter are affected differently by general obesity and central obesity. However, it is 
less clear whether LV mass and impaired diastolic function occur mainly as a 
consequence of haemodynamic factors such as increased sympathetic nervous 
system activity and loading, or as a direct result of non-haemodynamic factors such 
as hyperinsulinemia. Subsequent chapters will focus on integrated measures of 
ventricular-arterial coupling to define the effects of obesity, insulin resistance and 
PCOS on static and pulsatile loading, in an effort to understand the pathophysiology.  
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4. Obesity, polycystic ovary syndrome and end-systolic 
elastance 
Measurements of arterial and cardiac function are frequently considered in isolation 
but the interaction between the two is also an important determinant of effective 
cardiovascular performance.
102
  
This interaction, called ventricular-arterial coupling, can be simply and non-
invasively assessed using pressure-volume analysis derived from echocardiographic 
and blood pressure measurements.  A detailed description of the development of this 
method is given in the general introduction. In essence, the method involves 
calculating the end-systolic elastance of the arteries and LV and expressing these as 
a ratio. Elastance is the reciprocal of compliance and considers how a given change 
in volume affects blood pressure. Higher values of elastance represent a stiffer 
system.  
It is unclear whether non-invasive pressure-volume analysis is feasible in an 
obese, female population, or whether these methods are sufficiently sensitive to 
detect any subclinical cardiovascular dysfunction which may be associated with 
obesity and PCOS prior to the development of hypertension or clinical 
dysglycaemia. 
Aims of this chapter 
The primary aim of this chapter is to determine whether uncomplicated obesity and 
PCOS affect unscaled and scaled non-invasive measures of arterial elastance, 
ventricular end-systolic elastance, and the ratio of these measures (ventricular-
arterial coupling).  
The secondary aim is to establish whether central obesity and insulin resistance 
are more important contributors to arterial and ventricular elastance than general 
obesity.  
The final aim is to explore potential mechanisms linking obesity and altered 
elastance by examining the components which determine these measures.  
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Hypotheses 
In young women who are free from diabetes, hypertension and overt cardiovascular 
disease 
1. obesity will be associated with increased arterial elastance and a matched 
increase in ventricular end-systolic elastance so that the coupling ratio will be 
similar to lean controls, but at the expense of elevated systolic blood 
pressure; 
2. visceral fat area and/or insulin resistance will independently explain more of 
the variation in arterial or ventricular end-systolic elastance than will BMI  
3. women with PCOS will have similar arterial and ventricular elastance to 
BMI- and age-matched controls; and 
4. increases in arterial and ventricular elastance will be predominantly driven by 
the increased circulating volume and sympathetic nervous system activity 
associated with obesity, rather than intrinsic structural changes.
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Specific methods 
Women with PCOS and control volunteers were recruited from local clinics and the 
general community. Full details of recruitment, exclusion criteria and general 
methods are described in Chapter 2. 
Single beat method of estimating ventricular end-systolic elastance 
Ventricular end-systolic elastance (Ees) was calculated according to the single-beat 
method described by Chen  as detailed in Chapter 1.
121
 Briefly, the calculation is as 
follows 
𝐸𝑒𝑠  =  
𝑃𝑑  –  (𝐸𝑁𝐷 ×  𝑃𝑒𝑠) 
𝐸𝑁𝐷 ×  (𝑉𝑑 − 𝑉𝑒𝑠)
 
where Pd is the brachial diastolic blood pressure which is often similar to the central 
diastolic pressure, and Pes is the estimated central systolic blood pressure given by  
𝑃𝑒𝑠  =  0.9 ×  𝑏𝑟𝑎𝑐ℎ𝑖𝑎𝑙 𝑠𝑦𝑠𝑡𝑜𝑙𝑖𝑐 𝑏𝑙𝑜𝑜𝑑 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒 
Vd – Ves is the stroke volume of the LV which is measured by echocardiography 
using the Doppler method, given by 
𝑆𝑡𝑟𝑜𝑘𝑒 𝑣𝑜𝑙𝑢𝑚𝑒 =  𝐿𝑉𝑂𝑇 𝐶𝑆𝐴 × 𝐿𝑉 𝑣𝑡𝑖 
where LVOT CSA is the cross sectional area of the LV outflow tract found by  
0.785 × 𝐿𝑉𝑂𝑇 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟2 (Figure 4-1) 
LV vti is the velocity time integral of flow in the LV outflow tract (Figure 4-2). 
Finally, the normalised elastance, END, is found by 
𝐸𝑁𝐷  =  0.0275 – (0.165 × 𝐸𝐹)  +  (0.3656 × 𝑃𝑑 𝑃𝑒𝑠⁄ )   +  (0.515 × 𝐸𝑁𝐷𝐴𝑉𝐺) 
where ejection fraction (EF) is derived using the Teicholz formula below to estimate 
ventricular volumes from internal dimensions measured by m-mode 
echocardiography (Figure 4-3). 
 
 115 
 
𝐿𝑉𝐸𝐷𝑉 =  [ 
7
2.4 +  𝐿𝑉𝐼𝐷𝑑
 ] × 𝐿𝑉𝐼𝐷𝑑3 
𝐿𝑉𝐸𝑆𝑉 =  [ 
7
2.4 +  𝐿𝑉𝐼𝐷𝑠
 ] × 𝐿𝑉𝐼𝐷𝑠3 
𝐸𝐹 =  
𝐿𝑉𝐸𝐷𝑉 –  𝐿𝑉𝐸𝑆𝑉
𝐿𝑉𝐸𝐷𝑉
 
ENDAVG is an empirically derived polynomial function found by 
𝐸𝑁𝐷𝐴𝑉𝐺 =  0.35695 +  (−7.2266 × 𝑇𝑁𝐷)  +  (74.249 × 𝑇𝑁𝐷
2)  + (−307.39
× 𝑇𝑁𝐷
3)  +  (684.54 × 𝑇𝑁𝐷
4)  +  (−856.92 × 𝑇𝑁𝐷
5)  +  (571.95
× 𝑇𝑁𝐷
6)  +  (−159.1 × 𝑇𝑁𝐷
7) 
where   𝑇𝑁𝐷  =
 𝑇𝑖𝑚𝑒 𝑓𝑟𝑜𝑚 𝑅 𝑤𝑎𝑣𝑒 𝑡𝑜 𝐴𝑉 𝑜𝑝𝑒𝑛𝑖𝑛𝑔
 𝑇𝑖𝑚𝑒 𝑓𝑟𝑜𝑚 𝑅 𝑤𝑎𝑣𝑒 𝑡𝑜 𝐴𝑉 𝑐𝑙𝑜𝑠𝑢𝑟𝑒
 
Arterial elastance 
Arterial elastance (Ea) was calculated by 
𝐸𝑎  =  
𝑃𝑒𝑠 
𝑆𝑉
 
Normalisation of elastances for body size 
Ea and Ees were scaled allometrically for body surface area (BSA) following the 
method of Chirinos et al. 
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𝐸𝑎𝐼 =  
𝐸𝑎 
𝐵𝑆𝐴−1.18
           𝐸𝑒𝑠𝐼 =  
𝐸𝑒𝑠 
𝐵𝑆𝐴−1.05
  
𝐵𝑆𝐴 (𝐺𝑒ℎ𝑎𝑛 𝑚𝑒𝑡ℎ𝑜𝑑)  =  0.0235 × ℎ𝑒𝑖𝑔ℎ𝑡 (𝑐𝑚)0.42246 × 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑘𝑔)0.51456 
Coupling ratio 
The ratio of ventricular-arterial coupling (VAC) was found by 
𝑉𝐴𝐶 =  
𝐸𝑎  
𝐸𝑒𝑠
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Figure 4-1. Two-dimensional image demonstrating measurement of left ventricular 
outflow tract diameter in mid-systole (used in the calculation of stroke volume). 
 
Figure 4-2. Spectral Doppler recording demonstrating measurement of left 
ventricular outflow tract velocity-time integral (used in the calculation of stroke 
volume). 
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Figure 4-3. M-mode recording demonstrating measurement of left ventricular wall 
thickness and chamber dimensions used in the calculation of mass, fractional shortening 
and ejection fraction (Teicholz method). 
Reproducibility of elastance methods 
Reproducibility of elastance methods was established prior to the study by inviting 
six healthy volunteers to attend for testing on two occasions, under similar 
conditions, separated by at least 10 weeks. Subjects were aged 23-49 years (5 male) 
with BMI 20-27. The coefficient of variation (CV) was used to quantify the intra-
observer inter-session reproducibility according to the formula 
𝐶𝑉 (%)  =  
𝑆. 𝐷. 𝑜𝑓 𝑤𝑖𝑡ℎ𝑖𝑛 𝑠𝑢𝑏𝑗𝑒𝑐𝑡 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒𝑠 
𝐺𝑟𝑜𝑢𝑝 𝑚𝑒𝑎𝑛 𝑜𝑓 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑚𝑒𝑛𝑡𝑠
    
The intra-observer inter-session CV was 11 % for Ea and 16% for Ees, which is 
similar to other published studies (detailed in Chapter 1). 
Systemic arterial compliance 
Systemic arterial compliance was used as a surrogate of pulsatile afterload and was 
found by 
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𝑆𝐴𝐶 =  
𝑆𝑡𝑟𝑜𝑘𝑒 𝑣𝑜𝑙𝑢𝑚𝑒
𝑆𝑦𝑠𝑡𝑜𝑙𝑖𝑐 𝐵𝑃 –  𝐷𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐 𝐵𝑃
 
Systemic vascular resistance 
Systemic vascular resistance (SVR) was used as a measure of static afterload and 
was estimated by 
𝑆𝑉𝑅 =  
𝑀𝐴𝑃
𝐶. 𝑂.
 
where mean arterial pressure (MAP) was found by 
𝑀𝐴𝑃 =  
2. 𝑏𝐷𝐵𝑃 +  𝑏𝑆𝐵𝑃
3
 
and cardiac output (C.O.) was calculated using the Doppler method. The result was 
converted into Dynes/s/cm
5
 by multiplying by 80.  
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Results 
Feasibility of elastance calculations  
Measurement of arterial elastance was feasible in 97% of subjects and depended on 
whether the left ventricular outflow tract could be measured. There was no 
difference in feasibility between lean and obese subjects. 
Ventricular elastance was obtained in 95% of lean subjects and 88% of obese 
subjects. Feasibility was limited by the ability to accurately measure left ventricular 
dimensions in the parasternal long-axis view (Teicholz method).  
Calculation of ventricular-arterial coupling was therefore feasible in 94% of lean 
and 88% of obese subjects. 
Unscaled elastances and the coupling ratio 
Table 4-1 shows the unscaled values of arterial elastance, ventricular elastance and 
coupling ratio by group. There were no significant between-group differences.  
Elastances scaled for body size 
Table 4-2 shows the mean arterial and ventricular elastance after allometric scaling 
for the normal relationship with body surface area. In control subjects, obesity 
resulted in higher scaled arterial and ventricular end-systolic elastance but increases 
were matched so that there was no significant effect on ventricular-arterial coupling 
(Figure 4-4).  
In women with PCOS, obesity resulted in a higher scaled arterial elastance but a 
non-significant trend for increased ventricular elastance. This appeared to be because 
lean women with PCOS had marginally higher ventricular elastance than lean 
controls. As a result, women with PCOS tended to have lower ventricular-arterial 
coupling ratios than controls but this difference was not statistically significant. The 
combination of obesity and PCOS did not have an additive effect on arterial or 
ventricular elastance. 
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Table 4-1. Arterial elastance, ventricular end-systolic elastance and ventricular arterial 
coupling (mean ± s.d.) by subject group. 
 Lean 
Control 
Lean 
PCOS 
Obese 
Control 
Obese 
PCOS 
ANOVA  
p-value 
Ea (mmHg/ml)* 1.65  ± 0.27 1.61 ± 0.34 1.65 ± 0.34 1.57 ± 0.29 .533 
Ees (mmHg/ml)* 1.49 ± 0.35 1.55 ± 0.37 1.45 ± 0.32 1.49 ± 0.34 .873 
VAC (Ea/Ees) 1.15 ± 0.23 1.07 ± 0.16 1.16 ± 0.26 1.08 ± 0.20 .412 
Ea: Arterial end-systolic elastance, Ees: Ventricular end-systolic elastance, VAC: Ventricular-arterial 
coupling. *Variables were transformed with natural logarithm prior to use in ANOVA. 
 
 
 
Table 4-2. Scaled arterial and ventricular end-systolic elastance (mean ± s.d.) by subject 
group. 
 Lean 
Control 
Lean 
PCOS 
Obese 
Control 
Obese 
PCOS 
ANOVA  
P-value 
EaI (mmHg/ml/m
2.4
)* 3.03 ± 0.43 3.06 ± 0.53 3.80 ± 0.81 3.75 ± 0.86 <.0001 
EesI (mmHg/ml/m
2.1
)* 2.55 ± 0.55 2.69 ± 0.49 3.03 ± 0.74 3.18 ± 0.81 <.0001 
EaI: Allometrically scaled arterial end-systolic elastance, EesI: Allometrically scaled ventricular end-
systolic elastance. *Variables were transformed with natural logarithm prior to use in ANOVA.
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Figure 4-4. Median scaled arterial elastance, ventricular elastance and 
mean ventricular-arterial coupling ratio by subject group. Error bars 
show 95% confidence intervals. 
  
 
1
2
3
 
Table 4-3. Univariate correlates [Spearman’s rho (p-value)] of arterial elastance, LV end-systolic elastance and ventricular-arterial coupling.  
 Arterial elastance,  
 
 
Ea 
Scaled arterial 
elastance, 
 
EaI 
Ventricular end-
systolic elastance,  
 
Ees 
Scaled ventricular 
end-systolic elastance,  
 
EesI 
Ventricular-arterial  
coupling,  
 
Ea/Ees  
Age  −.15  (.079) .03  (.767) −.04  (.632) .07  (.431) −.09  (.285) 
BMI −.11  (.182) .54  (<.0001) −.04  (.629) .38  (<.0001) −.05  (.531) 
Waist  −.09  (.282) .56  (<.0001) <.01  (.987) .42  (<.0001) −.09  (.276) 
Waist/hip  .13  (.116) .35  (<.0001) .12  (.170) .26  (.002) −.05  (.573) 
TFA −.09  (.298) .52  (<.0001) −.05  (.558) .34  (<.0001) <.01  (.952) 
SFA −.09  (.286) .50  (<.0001) −.06  (.526) .32  (<.0001) <.01  (.975) 
VFA −.08  (.364) .47  (<.0001) −.02  (.860) .37  (<.0001) −.05  (.540) 
Glucose  −.16  (.050) .05  (.564) −.06  (.495) .18  (.038) −.20  (.019) 
Gluc AUC   .05  (.558) .18   (.032) .26  (.003) .33  (<.0001) −.27  (.001) 
Insulin  .04  (.625) .43   (<.0001) .14  (.100) .40  (<.0001) −.13  (.131) 
Ins AUC  .18  (.036) .41   (<.0001) .31  (.001) .45  (<.0001) −.18  (.045) 
HOMA-IR  <.01  (.966) .40   (<.0001) .14  (.112) .41  (<.0001) −.16  (.058) 
hs-CRP  .08  (.338) .39  (<.0001) .04  (.634) .24  (.004) .02  (.806) 
Testosterone  .03  (.757) .12  (.174) .11  (.230) .20  (.018) −.13  (.129) 
Adiponectin  −.18  (.029) −.40  (<.0001) .02  (.860) −.18  (.034) −.20  (.025) 
Cholesterol  .10  (.219) .16  (.056) .01  (.895) .09  (.286) .13  (.131) 
HDL  .03  (.736) −.38  (<.0001) <.01  (.975) −.20  (.018) −.06  (.464) 
LDL  .12  (.157) .26  (.002) −.02  (.835) .13  (.146) .18  (.043) 
Triglycerides  −.01  (.951) .23  (.006) <.01  (.931) .17  (.048) .04  (.615) 
 
TFA: total fat area, SFA: subcutaneous fat area, VFA: visceral fat area, AUC: Area under the curve (during oral glucose tolerance test), HOMA-IR: homeostasis 
model assessment of insulin resistance, hs-CRP: high sensitivity c-reactive protein,  HDL: high-density lipoproteins, LDL: low-density lipoproteins.
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Associations of elastance measurements with cardiovascular risk factors 
Table 4-3 shows univariate correlates of unscaled and scaled elastances and the 
dimensionless ratio of ventricular-arterial coupling.  None of the measures was 
significantly associated with age in this young population.  
Unscaled elastances: There were few significant associations of cardiovascular risk 
factors with unscaled elastance measures. Unscaled arterial elastance was inversely 
associated with fasting glucose and adiponectin, and directly associated with insulin 
area under the curve. Unscaled ventricular elastance was directly associated with 
glucose and insulin area under the curve.  
Scaled elastances: Scaled measures of elastance were associated with many of the 
cardiovascular risk factors in this study including direct associations with all 
measures of obesity and many of the measures of glucose handling. The strongest 
associations were with waist circumference and insulin area under the curve. In 
addition, scaled arterial and ventricular elastance were inversely associated with 
adiponectin and HDL and directly associated with hs-CRP and triglycerides. 
Interestingly, there was a weak direct association of scaled ventricular elastance with 
testosterone and this may account for the trend towards higher values (and lower 
coupling ratio) in women with PCOS.  
Ventricular-arterial coupling ratio: There were few significant associations with 
the ventricular-arterial coupling ratio. Fasting glucose, glucose area under the curve 
and insulin area under the curve were all inversely associated with the coupling ratio. 
This suggests that only obesity associated with significant dysglycaemia will result 
in altered ventricular-arterial coupling. In addition, there was an inverse association 
of coupling with adiponectin and a direct association with low-density lipoproteins.  
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Relationship of arterial and ventricular end-systolic elastance 
There was a linear relationship between arterial and ventricular end-systolic 
elastance (regardless of whether the variables were scaled) (Figure 4-5).  Arterial 
elastance accounted for 34% of the variation in ventricular end-systolic elastance.   
Given this finding I repeated the testing for univariate associations of risk factors 
with scaled ventricular elastance, adding an adjustment for scaled arterial elastance 
(Table 4-4). The relationships with obesity became weaker, with the association of 
visceral fat changing the least. The positive association of glucose with ventricular 
elastance remained largely unchanged suggesting that this relationship is not 
significantly driven by an effect on arterial elastance.  
 
 
Figure 4-5. Relationship between unscaled arterial and ventricular end-systolic 
elastance. 
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Table 4-4. Univariate correlates [Pearson’s R (p-value)] of allometrically 
scaled LV end-systolic elastance after adjustment for scaled arterial 
elastance.  
 
 
Ventricular end-systolic elastance,  
EesI 
 Age* .17 (.059) 
 BMI* .14 (.128) 
 Waist*  .19 (.037) 
 Waist/hip*  .11 (.241) 
 TFA* .12 (.195) 
 SFA .09 (.311) 
 VFA* .20 (.021) 
 Glucose* .16 (.100) 
 Gluc AUC  .29 (.003) 
 Insulin* .11 (.257) 
 Ins AUC* .25 (.010) 
 HOMA-IR* .13 (.195) 
 hs-CRP* .03 (.728) 
 Testosterone* .13 (.189) 
 Adiponectin* .07 (.448) 
 Cholesterol −.18 (.065) 
 HDL* −.02 (.866) 
 LDL −.16 (.098) 
 Triglycerides* −.02 (.816) 
 
TFA: total fat area, SFA: subcutaneous fat area, VFA: visceral fat area, 
AUC: Area under the curve (during oral glucose tolerance test), HOMA-IR: 
homeostasis model assessment of insulin resistance, hs-CRP: high sensitivity 
c-reactive protein, HDL: high-density lipoproteins, LDL: low-density 
lipoproteins.  *Variables were transformed using the natural logarithm 
before use in partial correlation.
1
2
7
 
 
 
 
Table 4-5. Univariate echocardiographic and tonometric correlates [Spearman’s Rho (p-value)] of unscaled and scaled elastances. 
  Unscaled 
arterial 
elastance, 
Ea 
 Scaled 
arterial 
elastance, 
EaI 
 Unscaled 
ventricular 
elastance, 
Ees 
 Scaled 
ventricular 
elastance, 
EesI 
 Ratio of arterial 
to ventricular 
elastance, 
Ea/Ees 
 Heart rate .24 (.003)  .36 (<.0001)  .20 (.016)  .27 (.001)  .02 (.852) 
 SVR .67 (<.0001)  .38 (<.0001)  .45 (<.0001)  .29 (.001)  .11 (.194) 
 SAC −.70 (<.0001)  −.49 (<.0001)  −.33 (<.0001)  −.21 (.013)  −.32 (<.0001) 
 ccIMT  −.15  (.064)  .07 (.372)  −.11 (.187)  .03 (.737)  −.01 (.935) 
 AIx-75  .03 (.743)  .13 (.115)  .15 (.086)  .21  (.016)  −.17  (.053) 
 aPWV  .04  (.599)  .32  (<.0001)  .07 (.405)  .29  (.001)  −.03 (.690) 
 RWT .22 (.010)  .35 (<.0001)  .15 (.071)  .27 (.001)  .01 (.866) 
 LV mass  −.26  (.002)  .22  (.009)  −.36  (<.0001)  −.01 (.873)  .18  (.040) 
 FS  −.16  (.052)  .02 (.775)  .32  (<.0001)  .41  (<.0001)  −.53  (<.0001) 
 sʹ  .01  (.902)  .09 (.300)  .21  (.024)  .29 (.002)  −.30  (.001) 
 MAPSE  −.35  (<.0001)  −.10 (.239)  −.06 (.496)  .12 (.163)  −.35 (<.0001) 
 eʹ  −.05  (.581)  -.25  (.006)  <.01 (.969)  −.14 (.140)  −.08 (.382) 
 aʹ  −.19  (.035)  .06 (.507)  .14 (.131)  .34 (<.0001)  −.37  (<.0001) 
 eʹ/aʹ  .11  (.233)  −.17  (.058)  −.09 (.318)  −.29 (.002)  .20  (.037) 
 FPV  .08  (.397)  .17 (.073)  .03 (.740)  .12 (.219)  .01 (.940) 
 IVRT  <.01  (.934)  .11 (.198)  −.23 (.008)  −.10 (.246)  .21 (.018) 
SVR: systemic vascular resistance, SAC systemic arterial compliance, ccIMT: common carotid intima-media thickness, AIx-75bpm: 
augmentation index corrected for heart rate of 75bpm, aPWV: aortic pulse wave velocity, RWT: left ventricular relative wall thickness, FS: 
fractional shortening, MAPSE: mitral annular plane systolic excursion, FPV: flow propagation velocity, IVRT: isovolumic relaxation time.
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Relationship of elastance with other measures of cardiovascular structure and 
function 
Table 4-5 shows the association of elastances with heart rate, measures of systemic 
vascular resistance and compliance, and echocardiographic and tonometric measures 
of structure and function.  
Unscaled elastances:  unscaled arterial and ventricular elastance was associated 
with heart rate, systemic vascular resistance, LV mass (all direct) and systemic 
arterial compliance (inverse). In addition, unscaled arterial resistance was associated 
with the mitral annular plane systolic excursion and the late diastolic tissue velocity 
(both inverse), brachial but not aortic pulse wave velocity. Unscaled ventricular 
elastance was associated with fractional shortening and the systolic myocardial 
velocity (direct) as well as the isovolumic relaxation time (inverse). The strongest 
associations of arterial elastance were systemic vascular resistance and arterial 
compliance. The strongest association of ventricular elastance was systemic vascular 
resistance. There were no associations of unscaled ventricular elastance with global 
strain and strain rate (data not presented). 
Scaled elastances: The associations of elastance measures with heart rate, systemic 
vascular resistance and arterial compliance remained significant after scaling, as did 
the association of arterial elastance with LV mass and relative wall thickness. In 
contrast, the association of ventricular elastance with LV mass was no longer evident 
after scaling, but the association with relative wall thickness increased in strength. 
The associations of ventricular elastance with measures of contractile function 
remained after scaling but new associations emerged with the late diastolic tissue 
velocity (direct) and the ratio of early to late diastolic tissue velocities (inverse).   
Ventricular-arterial coupling: ventricular-arterial coupling was negatively 
associated with systemic arterial compliance, LV mass (but not relative wall 
thickness), measures of contractile function, the late diastolic tissue velocity and the 
ratio of early to late diastolic tissue velocities.  
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Independent contributors of scaled arterial elastance 
Arterial elastance has been proposed as a composite measure of afterload which 
integrates arterial stiffness. I tested whether arterial elastance could be explained by 
a basic model that included heart rate, systemic vascular resistance (a measure of 
resistive load), systemic arterial compliance (a basic measure of pulsatile load) and 
aortic pulse wave velocity (a measure of regional arterial stiffness). Table 4-6 shows 
the results of the basic model; systemic vascular resistance and heart rate contributed 
most towards the variation in arterial elastance. Aortic stiffness (PWV) and pulsatile 
load (systemic arterial compliance) were also independent contributors but explained 
less of the variation in arterial elastance.  
Separate hierarchical multivariate regression models were used to determine 
whether adding measures of general and central obesity resulted in an improved 
ability to explain arterial elastance (Table 4-7). The addition of waist circumference 
resulted in a significant improvement in the model with this measure of central 
obesity independently explaining a further 33% of the variation in arterial elastance.  
In separate models, general obesity (BMI) resulted in a similar but a marginally 
smaller improvement (31%), while visceral fat area and insulin resistance each 
explained to 19% and 13% of the variation in arterial elastance.  
Table 4-8 shows the final multivariate regression model for scaled arterial 
resistance. The model was able to explain 84% of the variation in arterial elastance. 
The inclusion of waist circumference in the model supplanted the effect of aortic 
pulse wave velocity.  
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Table 4-6. Initial stepwise multiple regression model for scaled arterial elastance (EaI). 
Dependent variable: EaI* Standardised β P-value Part correlations 
Systemic vascular resistance .410 <.0001 .329 
Heart rate .382 <.0001 .314 
Aortic PWV * .276 <.0001 .264 
Systemic arterial compliance −.260 .001 −.214 
Model r
2 
= .505, p<.0001 
PWV: pulse wave velocity.  *Variables were log-transformed prior to use in inferential statistics.  
 
Table 4-7. Separate hierarchical multiple regression models for scaled arterial elastance 
(EaI) and measures of obesity. 
Dependent variable: EaI* 
Change 
in r
2
  
Cumulative 
r
2
 
F change statistic 
P-value for 
model 
Basic model  
 
 .505  <.0001 
Basic model  
+ BMI* 
.313 .818 
F (1, 131) = 225.14, 
p<.0001 
<.0001 
Basic model  
+ waist circumference 
.334 .839 
F (1, 130 ) = 272.93, 
p<.0001 
<.0001 
Basic model  
+ visceral fat area* 
.187 .692 
F (1, 123) = 77.41, 
p<.0001 
<.0001 
Basic model + HOMA-IR .127 .632 
F (1, 131) = 37.21, 
p<.0001 
<.0001 
HOMA-IR: homeostasis model of assessment for insulin resistance. *Variables were log-transformed 
prior to use in inferential statistics.  
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Table 4-8. Final multiple regression model for scaled arterial elastance (EaI). 
Dependent variable: EaI* 
Standardised 
β 
P-value 
Part 
correlations 
Waist circumference* .681 <.0001 .578 
Systemic vascular resistance .482 <.0001 .385 
Systemic arterial compliance -.340 <.0001 -.277 
Heart rate  .292 <.0001 .238 
Aortic PWV * -.043 .304 -.036 
Model r
2 
= .841, p<.0001 
 
PWV: pulse wave velocity. *Variables were log-transformed prior to use in inferential statistics.  
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Independent contributors of scaled ventricular end-systolic elastance 
Ventricular end-systolic elastance reflects systolic stiffness which, in steady states, is 
affected by ventricular geometry, diastolic stiffness, biochemical properties and 
contractile function. Multiple regression was used to test whether ventricular 
elastance could be explained by a model that included fractional shortening (a 
measure of circumferential contractile function), heart rate, systemic vascular 
resistance, systemic arterial compliance, relative wall thickness and aʹ (a measure of 
late diastolic function).  The stepwise model identified that, from these variables, 
fractional shortening, systemic vascular resistance, heart rate and late diastolic 
function were the largest independent contributors of scaled ventricular elastance, 
together accounting for 64% of its variation (Table 4-9).  Systemic arterial 
compliance and LV geometry were not independent predictors of ventricular systolic 
stiffness in this population.  
 Table 4-10 shows the results of multivariate regression analysis when systemic 
vascular resistance and heart rate were replaced by scaled arterial elastance. The use 
of this composite measure of afterload resulted in a small but significant 
improvement in the model, explaining 3% more of the variation in ventricular 
systolic elastance.  
Separate hierarchical multivariate regression models were used to test whether 
adding measures of obesity or hyperinsulinaemia to the basic model resulted in a 
significant improvement (Table 4-11). The addition of waist circumference resulted 
in a small but significant improvement, explaining 3% more of the variation in 
ventricular elastance. The use of BMI or visceral fat resulted in smaller or non-
significant changes. Insulin resistance had no effect on the model.  
The final model is shown in Table 4-12 and explained 70% of the variation in 
scaled ventricular elastance. Waist circumference had a negative independent 
association with ventricular elastance after adjustment for arterial elastance, 
fractional shortening and late diastolic function. This contrasts with the positive 
univariate association. 
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Table 4-9. Initial stepwise multiple regression model for scaled ventricular elastance (EesI). 
Dependent variable: EesI Standardised β P-value Part correlations 
Fractional shortening .520 <.0001 .478 
Systemic vascular resistance .605 <.0001 .316 
Heart rate .446 <.0001 .292 
aʹ .190 .005 .342 
Model r
2 
= .639,
 
p<.0001 
 
*Variables were transformed using the natural logarithm prior to use in inferential statistics.  
 
 
 
Table 4-10. Stepwise multiple regression model for scaled ventricular elastance (EesI) using 
scaled arterial elastance in place of heart rate and systemic vascular resistance. 
Dependent variable: EesI Standardised β P-value Part correlations 
EaI* .673 <.0001 .636 
Fractional shortening .370 <.0001 .343 
aʹ .175 .003 .163 
Model r
2 
= .672,  p<.0001 
 
EaI: scaled arterial elastance. *Variables were transformed using the natural logarithm prior to use 
in inferential statistics.   
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Table 4-11. Hierarchical separate multiple regression models for scaled ventricular elastance 
(EesI). 
Dependent variable: EesI 
Change 
in r
2
 
Cumulative 
r
2
 
F change statistic 
P-value for 
model 
Basic model  
 
 .672  <.0001 
Basic model 
+ BMI* 
.015 .687 
F (1, 110) = 5.41, 
p=.022 
<.0001 
Basic model  
+ visceral fat area* 
.009 .681 
F (1, 103) = 2.63, 
p=.108 
<.0001 
Basic model  
+ waist circumference* 
.026 .698 
F (1, 110) = 9.45, 
p=.003 
<.0001 
 
*Variables were transformed using the natural logarithm prior to use in inferential statistics.  
 
 
 
 
Table 4-12. Final multiple regression model for scaled ventricular elastance (EesI). 
Dependent variable: EesI 
Standardised 
β 
P-value 
Part 
correlations 
EaI* .746 <.0001 .618 
Fractional shortening .421 <.0001 .375 
aʹ .259 <.0001 .217 
Waist circumference* −.229 .003 −.161 
Model r
2
= .698, p<.0001 
 
EaI: scaled arterial elastance. *Variables were transformed using the natural logarithm prior to use 
in inferential statistics. 
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Independent contributors of ventricular-arterial coupling 
Measures of obesity were not associated with ventricular-arterial coupling in this 
study but there were significant negative univariate correlations with other 
cardiovascular risk factors (see Table 4-3). Hierarchical multivariate regression was 
used to test which factors were the most important independent determinants of 
ventricular-arterial coupling.  
The first block of the model included the variables glucose AUC, adiponectin, 
insulin AUC and LDL; these were inserted using the stepwise method. The second 
block of the model included measures of cardiovascular function. These were 
fractional shortening, MAPSE, sʹ, aʹ and IVRT (Table 4-13). 
Ventricular-arterial coupling is inversely related to contractile function and the 
final model (Table 4-14) confirmed inverse independent contributions of fractional 
shortening and mitral annular plane systolic excursion. Increased LV mass is a 
consequence of increased afterload (and therefore a higher coupling ratio). A direct 
association of LV mass and ventricular-arterial coupling was evident in this 
population. Finally, dysglycaemia, reflected by glucose AUC, independently 
explained some of variation in ventricular-arterial coupling. The inverse association 
between glucose AUC and the coupling ratio (Ea/Ees) suggests that dysglycaemia 
may affect the ventricular elastance more than arterial elastance. 
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Table 4-13. Hierarchical multivariate regression for ventricular-arterial coupling. 
Dependent variable: VAC 
Change 
in r
2
 
Cumulative 
r
2
 
F change statistic 
P-value for 
model 
Fractional shortening  .399  <.0001 
LDL .033 .431 
F (1, 84) = 4.80, 
p=.031 
<.0001 
Glucose AUC* .036 .468 
F (1, 83) = 5.69, 
p=.019 
<.0001 
MAPSE .057 .525 
F (1, 82) = 9.82, 
p=.002 
<.0001 
LV mass* .071 .595 
F (1, 81) = 14.20, 
p<.0001 
<.0001 
LDL: low-density lipoproteins, AUC: area under the curve, MAPSE: mitral annular plane systolic 
excursion. *Variables were transformed using the natural logarithm prior to use in inferential 
statistics. 
Table 4-14. Final multivariate regression model for ventricular-arterial coupling. 
Independent variables Standardised β P-value Part correlation 
Fractional shortening −.485 <.0001 −.439 
MAPSE −.292 <.0001 −.277 
LV mass* .274 <.0001 .266 
Glucose AUC* −.250 .002 −.228 
LDL .126 .085 .123 
Model r
2
= .595, p<.0001 
LDL: low-density lipoproteins, AUC: area under the curve, MAPSE: mitral annular plane systolic 
excursion. *Variables were transformed using the natural logarithm prior to use in inferential 
statistics 
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Discussion 
Feasibility 
According to published data, non-invasive measurement of arterial and ventricular 
elastance is feasible in 56-95% of subjects depending on the characteristics of the 
sample population and whether there was a prospective aim to collect this data.
115, 
116, 122, 125-127
 My study was designed to look for sub-clinical dysfunction in subjects 
who were likely to be obese and I chose not to exclude subjects with poor acoustic 
views since this would have introduced selection bias. Nevertheless, it was feasible 
to derive paired arterial and ventricular elastance in 94% of lean and 88% of obese 
female subjects.  
The feasibility of arterial elastance was dependent on whether the left ventricular 
outflow tract could be adequately visualised to measure its diameter. Similarly, the 
feasibility of the ventricular elastance calculation was dependent on whether the LV 
cavity could be adequately visualised to measure dimensions. This method is 
considered to be less accurate at deriving left ventricular volumes and ejection 
fraction than is the Simpson’s Biplane method but the latter requires excellent apical 
acoustic windows. If I had chosen to use the latter method the feasibility would have 
been reduced to 64% because the obese women in this study frequently had poor 
apical acoustic windows.  
My data confirm that non-invasive assessment of arterial and ventricular 
elastance is feasible in the majority of young, obese women.   
Elastance values in healthy subjects 
Published unscaled elastance values in healthy subjects are 1.3-1.43 mmHg/ml for 
arterial elastance and 1.4-2.2 mmHg/ml for ventricular elastance, depending on the 
age and characteristics of the study population and the methods used to derive these 
measures.
116, 122, 124, 127, 160, 208
 
The study of Chirinos et al. had a large sample size (n=612 in reference group) 
and a population with characteristics similar to subjects in this thesis, but they found 
a lower median arterial elastance than in my study (1.43 vs. 1.67 mmHg/ml for 
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unscaled arterial elastance and 2.89 vs. 3.10 mmHg/ml/m
2.4
 for scaled arterial 
elastance).
122
 It is possible that the higher values in this thesis may be influenced by 
the all-female population. There is evidence that women have higher arterial 
elastance than men due to increased heart rate and pulsatile arterial load.
124
 However, 
between-study differences may also be related to different methods of estimating 
central end-systolic pressure rather than to true differences in elastance. While 
Chirinos et al. derived central end-systolic blood pressure from arterial tonometry, I 
used the equation 0.9*brachial cuff systolic pressure because it was used in the key 
validation paper describing the single-beat method.
121
 This may have resulted in an 
overestimate of central end-systolic pressure and therefore a higher arterial elastance 
value.  
The measure of end-systolic pressure is also used in the calculation of ventricular 
end-systolic elastance but the normal values published by Chirinos et al. were higher 
than for lean controls in my study (1.73 vs. 1.49 mmHg/ml for unscaled and 3.28 vs. 
2.55 mmHg/ml/m
2.1 
for scaled ventricular elastance).
122
 There is evidence that 
unscaled ventricular elastance tends to be higher in females so it is unlikely that the 
all-female population explains this difference.
124, 208
 Between-study differences may 
not necessarily reflect worse contractile function or lower ventricular stiffness but 
may be due to the different method of estimating ejection fraction (used in the 
calculation of systolic elastance using the single-beat method). Chirinos et al. used 
the area-length method but I used the Teicholz method used in the validation paper 
by Chen et al.
121
 The Teicholz method uses linear dimensions to derive three-
dimensional volumes and therefore makes certain geometric assumptions. This 
method is not recommended to derive ejection fraction in clinical practice 
169
 but 
sample population in my study were young, free from overt cardiovascular disease, 
and unlikely to have significantly distorted or asymmetric geometry.  In addition, 
this study was designed to look for between-group differences associated with 
obesity and/or PCOS, rather than to establish normal values. Therefore, the method 
would not affect the outcome unless the methods of estimating end-systolic pressure 
and ejection fraction were less accurate for obese than for lean subjects. 
Having higher arterial elastance and lower ventricular elastance necessarily 
resulted in subjects having higher mean ventricular-arterial coupling ratio than 
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published by Chirinos et al. (1.14 vs. 0.82).
122
 Some reviews state that energy 
efficiency and stroke work are maximised at coupling ratios of 0.7 and 0.8 
respectively, commenting that values above one represent ‘ill-matched’ ventricular 
and arterial systems.
209
 However, there is evidence from animal and human studies 
that coupling ratios of 0.6-1.2 may be observed without evidence of pathology.
109, 116, 
118, 210, 211
 In addition, changes in loading which alter the coupling ratio within the 
range 0.3-1.3 seem to have little effect on stroke work or energy efficiency which 
remain at >90% of their optimal values.
210
  
No association of age with elastances 
There is evidence from invasive and non-invasive studies that arterial elastance and 
ventricular elastance increase in tandem with healthy ageing so that the coupling 
ratio remains unchanged.
113, 212
 I did not find an association of age with arterial or 
ventricular end-systolic elastance but this may be because subjects were relatively 
young (16-45 years) and free from hypertension.  
Obesity affects scaled arterial systolic elastance 
A key finding of this study is that obesity was associated with a significantly 
increased scaled but not unscaled arterial elastance.  
The data in this thesis confirm the findings of Chirinos et al. that obesity exerts 
adverse effects on arterial load beyond the normal relationship of elastance with 
body size.
122
 Furthermore, this was evident in a younger population who were 
normotensive.  
The relationship between obesity and arterial elastance is likely to be complex 
and may be influenced by haemodynamic factors such as altered resistive load, 
pulsatile load, or heart rate, as well as by non-haemodynamic factors such as 
adipokines, hyperinsulinemia, low-grade inflammation and lipids. Indeed, I found 
that these were all significant univariate correlates of scaled arterial elastance. 
Fat location may not be important for altered arterial elastance 
A key finding of this study is that visceral fat area was not a stronger correlate of 
arterial elastance than general obesity.  
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Adding waist circumference or BMI to the basic model for arterial elastance 
resulted in a greater improvement than did adding visceral fat area or insulin 
resistance. Waist circumference was the largest contributor to the final model, 
independently explaining 58% of the variation in arterial elastance. It is worth noting 
that waist circumference, while used as a measure of central obesity, is determined 
by visceral fat, subcutaneous fat and lean mass. Therefore, these data suggest that the 
increased arterial elastance in obese women may be driven by a general increase in 
lean and fat mass in all compartments, rather than specifically by visceral fat and 
insulin resistance. This interpretation is supported by evidence from the Olmsted 
study, which reported that weight loss was associated with a reduction in arterial 
elastance in an older, mixed population (n=788, mean age 60±9 years, 48% men) but 
that central obesity (waist circumference) was not an independent predictor of the 
change.
116
 
This thesis adds to current data by demonstrating that even young women with 
obesity, who are free from hypertension and dysglycaemia, have an increase in 
arterial elastance. In addition, the inclusion of a detailed measurement of visceral fat 
area helped to identify that fat location was not an important factor for altered 
arterial elastance.   
Contributions of heart rate, resistive load and pulsatile load to arterial elastance 
Arterial elastance was originally proposed as a useful composite measure of pulsatile 
and resistive afterload and in this thesis 51% of the variation in scaled arterial 
elastance could be predicted by a model comprising heart rate, systemic vascular 
resistance (a measure of resistive load), systemic arterial compliance (a measure of 
pulsatile load) and aortic pulse wave velocity (a measure of regional arterial 
stiffness). Resistive load and heart rate independently contributed more to the 
variation in arterial elastance than did pulsatile load or regional arterial stiffness (part 
correlations of .329 for systemic vascular resistance, .314 for heart rate, -.214 for 
systemic arterial compliance and .264 for pulse wave velocity).  
Others have published invasive data demonstrating that arterial elastance was 2.5 
times more sensitive to a change in the ratio of systemic vascular resistance and 
cardiac interval than to a similar change in the reciprocal of compliance.
213
 In 
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addition, investigations of the sensitivity of arterial elastance to changes in pulsatile 
load associated with isometric exercise showed that a combination of systemic 
vascular resistance and heart rate predicted ~96% of the variation in elastance, with 
detailed measures of pulsatile load together accounting for <1%.
160
 These authors 
have suggested that the interpretation of arterial elastance as a composite measure of 
pulsatile and resistive load should be reconsidered.  
Taken together, these findings suggest that arterial elastance may not fully 
describe the influence of pulsatile load and the latter may be better represented by 
wave reflections and their timing.  
Obesity affects ventricular end-systolic elastance 
A key finding of this study is that obesity was associated with significantly increased 
scaled but not unscaled ventricular end-systolic elastance.  
My data confirm the findings of Chirinos et al. that obesity exerts adverse effects 
on left ventricular systolic stiffening beyond the normal relationship with body size. 
122
 Furthermore, this was evident in our younger population, the majority of whom 
did not have altered left ventricular geometry.   
The increase in ventricular elastance is largely driven by the increase in arterial 
elastance  
Ventricular end-systolic elastance is considered to be a load-independent measure of 
contractility, but at rest it is also influenced by geometric and passive structural 
factors as well as diastolic function.
214
 Therefore, the increase associated with 
obesity may be due to a change in one or more of these factors. I did not find a 
significant association of ventricular elastance with LV mass in this population of 
young women but there was an association with relative wall thickness which is a 
reflection of concentric remodelling. Ventricular elastance was positively associated 
with measures of arterial stiffness, contractile function and late diastolic function. 
The associations of cardiovascular risk factors with ventricular elastance were 
similar to those for arterial elastance so I examined whether the increase in one was 
driven by an increase in the other; there was a linear relationship between the 
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elastance measures, with arterial elastance explaining one third of the variation in 
ventricular elastance. However, visceral fat, post-prandial glucose and insulin, and 
central blood pressures remained significant correlates of ventricular elastance after 
adjustment for arterial elastance.  
Ventricular end-systolic elastance could be explained reasonably well with a 
multivariate model that comprised scaled arterial elastance, fractional shortening, 
and aʹ (r-square .672, p<.0001).  Scaled arterial elastance explained the majority of 
the variation in ventricular elastance (part correlation .636) but fractional shortening 
and aʹ were independent contributors (part correlations .343 and .163 respectively).  
Adding BMI or waist circumference to this basic model made small but significant 
improvements but the visceral fat did not make a significant contribution despite 
having the largest univariate association. This suggests that visceral fat might exert 
its effects on ventricular elastance through changes in fractional shortening, diastolic 
function or both.   
A key finding of this study is that uncomplicated obesity predominantly affects 
ventricular elastance through its effects on arterial elastance but there may be direct 
effects of visceral fat and abnormal glucose metabolism on ventricular systolic 
stiffness. 
Obesity did not affect ventricular-arterial coupling 
A key finding of this study is that the increase in arterial elastance associated with 
uncomplicated obesity is matched by an increase in ventricular elastance so that the 
system remains closely coupled.  
These data support the work of Chirinos et al. who also reported matched 
increases in elastance associated with obesity.
122
 This thesis adds to the current 
understanding by extending the work to a younger population who were free from 
hypertension and diabetes.  
According to the experimental work of Sunagawa et al. (discussed in the 
introduction) an unchanged coupling ratio suggests that stroke volume is not 
significantly altered.
109
 Instead, the stiffer ventricular-vascular system is operating at 
higher blood pressures. I confirmed this finding (see Table 3-3); while obese women 
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had a mean stroke volume which was ~10% higher (6ml) than the mean for lean 
women, there was a wide range of measures within each group so the difference was 
not statistically significant. In contrast, the 8% (7mmHg) increase in central systolic 
blood pressure was highly significant (p<.0001) because of a narrower data range 
within groups. 
In this thesis, dysglycaemia (reflected by glucose area under the curve) was 
independently and inversely associated with the ventricular-arterial coupling ratio. 
This may suggest that, in the absence of hypertension, an increase in blood glucose is 
associated with a larger increase in ventricular systolic elastance than arterial 
elastance. The effect of glucose on ventricular elastance was not entirely explained 
by altered contractility and it is possible that the effect is mediated by structural 
changes that increase stiffness.  
Potential consequences of an elevated arterial and ventricular elastance 
The potential haemodynamic consequences of ‘coupled’ increases in arterial and 
ventricular elastance are suggested in the simplified pressure-volume diagrams in 
Figure 4-6. The diagrams illustrate the hypothetical effects of an isolated increase in 
ventricular preload (end-diastolic volume) which has the effect of shifting the arterial 
elastance curve to the right without altering its slope (Ea). Changes from the basal 
state are depicted in red. Diagram [A] reflects a closely coupled and compliant (low 
elastances) ventricular-arterial system typical of the lean subjects in this study. The 
increase in end-diastolic volume leads to a 10ml augmentation of stroke volume 
which is associated with a 10mmHg change in end-systolic blood pressure and an 
increase in the area within the box, which represents stroke work. This can be 
contrasted with [B], which reflects a closely-coupled but stiffer system typical of the 
obese women in my study. The same basal volumes ejected into a stiffer arterial 
system, result in a higher basal end-systolic pressure. In addition, the increase in end-
diastolic volume results in a greater change in systolic blood pressure and stroke 
work for the same augmentation in stroke volume. Since the ratio of arterial to 
ventricular elastance is unchanged, the higher elastances may not adversely affect the 
augmentation of stroke volume at rest.  
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Figure 4-6. Suggested consequence of the same increase in preload on haemodynamic 
variables in lean [A] and obese [B] subjects.  In both subjects an isolated increase in preload 
causes the arterial elastance curve to shift to the right but the slope (Ea) remains the same. In 
[A] the elastances are low and the ratio is ~1. Stroke volume (SV) is augmented by 10ml (for 
example) and this is associated with a 10mmHg (for example) increase in end-systolic 
pressure (Pes) and an increase in stroke work (area shaded within box). In [B] the elastances 
are higher but the ratio remains ~1. The higher basal elastances result in a higher basal Pes. 
The same augmentation of SV is associated with a larger increase in Pes and stroke work. 
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The effect of PCOS on scaled arterial and ventricular systolic elastance 
To the best of my knowledge this is the first study of arterial and ventricular end-
systolic elastance in women with PCOS. The data suggest that increased arterial 
stiffness in PCOS is mediated by the increase in obesity and not by other hormonal 
changes associated with the syndrome.  
Women with PCOS tended to have a higher ventricular elastance than controls 
and this was weakly associated with testosterone. As a result the coupling ratio 
tended to be lower in those with PCOS. The results were not statistically significant 
and this may be a result of the small sample size. Since there was a weak direct 
association of the coupling ratio with mass (Table 4-5) it is tempting to speculate 
that the lower coupling ratio may help to explain the finding of a lower rate of LV 
hypertrophy in obese women with PCOS in my study.  
A key finding of this study is that young women with PCOS who are free from 
comorbidities have similar arterial elastance to age- and BMI-matched controls. The 
trend towards higher ventricular elastance and lower coupling ratio needs to be 
confirmed in other studies.  
The prognostic value of elastances and their ratio 
Ejection fraction is a widely used measure of systolic function with proven 
prognostic importance at values less than 45% in a wide range of cardiovascular 
disease.
215
 Its strength as a prognostic marker may be underpinned by the fact that it 
is a composite measure which is affected by loading as well as by ventricular 
contractility. This means it is actually a measure of ventricular-arterial coupling, 
rather than a pure measure of contractile function, but this factor also hampers its 
usefulness in unpicking the pathophysiology associated with disease. Elastance 
measures are determinants of ejection fraction (the relationship is shown below), and 
may help to explain which elements of pathophysiology are best targeted by 
therapeutic strategies. 
𝐸𝑗𝑒𝑐𝑡𝑖𝑜𝑛 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 =  
1
1 +  𝐸𝑎/𝐸𝑒𝑠
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There are few studies which consider whether elastance measures have 
prognostic significance. In the Penn heart failure study, LV end-diastolic volume, 
increased arterial elastance and a high coupling ratio were associated with increased 
risk of death, cardiac transplantation or requirement for a mechanical assist device, 
and increased rates of hospitalization.
126
 Surprisingly, LV end-systolic elastance was 
not an independent predictor of outcomes in the same study. This seems 
counterintuitive given that all patients had heart failure with reduced ejection 
fraction (HFrEF) but the authors emphasise that ventricular elastance is the slope of 
the end-systolic pressure-volume relationship and only fully describes contractile 
function when considered alongside its volume intercept (V0) which was related to 
poorer outcomes. These data help to explain why aggressive afterload reduction is 
important in patients with HFrEF and suggest that the coupling ratio may be more 
important in predicting outcomes that individual elastance values.  
Similar results have been described in a small study of women with systemic 
lupus erythematosus (SLE) who were free from overt cardiovascular disease and had 
normal ejection fraction.
216
 Women with SLE (n=48) had higher arterial elastance 
and higher coupling ratio than controls (n=20) and these variables were significantly 
elevated in those with SLE who had a cardiovascular event in a three year follow-up 
period.   
Exercise capacity is an accepted prognostic measure of cardiovascular mortality 
even in low-risk populations,
217
 and women who are obese often have exertional 
dyspnea and reduced exercise capacity.
218
 The mechanisms linking these findings 
with obesity are likely to be multifactorial but one study of U.S. patients with 
exertional dyspnea and a high burden of obesity (BMI 30.9 ± 6.8kg/m
2
) found that 
arterial elastance independently explained reduced exercise capacity (workload less 
than eight metabolic equivalents) after adjustment for age, hypertension, LV strain 
and ejection fraction.
125
 None of the measures of ventricular function, including 
ventricular elastance, were independent predictors of exercise capacity in this 
population but that might be expected given that they had normal ventricular 
function. There were no significant between-group differences in resting indices of 
diastolic function (with the exception of left atrial volume) suggesting that arterial 
elastance may be better than these measures at predicting exercise tolerance in an 
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obese population. A strength of this study is that those with reduced ejection fraction 
and exercise-induced ischaemia were excluded from the study. However, the obesity 
was complicated by hypertension in 58%, diabetes in 23% and obstructive lung 
disease in 19% of patients so it is unclear whether the results can be generalised to a 
population with uncomplicated obesity.  
Intervention studies and elastance 
A sub-study of the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine 
Trial (SHIFT) has shown the value of elastance measures in understanding the 
effects of therapy on cardiovascular physiology. Ivabradine is an If channel inhibitor 
which selectively affects the spontaneous activity of the sinoatrial node, leading to a 
reduction in heart rate without a negative inotropic effect. Patients with HFrEF 
frequently have increased resting heart rate which is related to worse cardiovascular 
outcomes. The SHIFT study found that Ivabradine improved outcomes in patients 
with HFrEF with resting heart rate over 70 bpm as well as improving quality of life. 
Patients were already optimally medicated at the start of the trial but the 
improvements were directly related to the magnitude of heart rate reduction 
associated with Ivabradine. The sub-study (n=275) showed that, after 8 months of 
treatment with Ivabradine, a significant reduction in heart rate was accompanied by a 
decrease in arterial elastance and ventricular-arterial coupling ratio compared with 
the placebo group (p-values <.0001, <.0001 and .002 respectively). In addition, 
systemic vascular resistance was unchanged but arterial compliance, a surrogate 
measure of pulsatile load was improved (p=.004). There was no change in 
ventricular elastance but the decrease in ventricular-arterial coupling ratio led to an 
increase in stroke volume. The authors suggest that an isolated reduction in heart rate 
appears to result in systolic unloading of the LV which improves stroke volume in 
those with systolic heart failure.
219
  
Women with obesity and insulin resistance are more likely to develop HFpEF 
than HFrEF, but I have been unable to find a similar study of elastance in this 
population. There is evidence from one small, randomised trial (n=61) that short-
term treatment (7 days) with Ivabradine resulted in increased exercise capacity and a 
slower baseline heart rate as well as a slower increase in exercise heart rate 
compared with those in the placebo group.
220
 The patients were predominantly 
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female, overweight, middle-aged (67±8years) and hypertensive with no significant 
between-group differences in clinical characteristics. The authors report improved 
diastolic filling in the Ivabradine group, reflected in higher eʹ, but the effects of 
altered afterload are not considered in this study so it is unclear whether the results 
can be solely attributed to increased diastolic filling time because of slower heart rate 
or whether reduced afterload was also a contributing factor to improved exercise 
capacity.  
Together these data suggest that the increase in arterial elastance in women with 
uncomplicated obesity may result in reduced exercise capacity. It would be 
interesting to conduct a study to confirm this and to examine the relative 
contributions of heart rate, static load and pulsatile load to reduced exercise capacity. 
Whatever the haemodynamic mechanisms involved, prognosis may not be affected 
until the arterial and ventricular elastances become uncoupled but there are no 
longitudinal studies which confirm this.  
Limitations 
Cardiovascular risk factors such as cholesterol were not added to multivariate 
models for elastance because the sample size limited the number of independent 
variables which could be included and because the close correlation of these risk 
factors with obesity may have produced problems with multicollinearity. Despite 
this, the regression models explained a significant proportion of the variability in 
elastance. 
I considered whether the associations of elastance with obesity and with insulin 
resistance were a function of using body surface area in the scaling method, itself a 
surrogate measure of obesity. However, the associations remained significant when 
analyses were adjusted for body surface area (data not presented) so this is unlikely. 
Scaling elastance to lean mass may be preferable in future studies, since this would 
provide greater confidence in the results relating to the effects of obesity. 
The lack of difference in arterial elastance between women with PCOS and 
matched controls may be affected by the sample size since the initial power 
calculation for the study did not include measures of elastance. Nevertheless, this is 
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one of the largest studies of its type in women with PCOS and the data suggest that 
any between-group differences are likely to be subtle. 
Finally, the study population comprised young women with uncomplicated 
obesity and the results may not be generalizable to males, an older population or 
those with co-existing hypertension or diabetes.  
Conclusions 
The data from this study confirm that young women with uncomplicated obesity 
have evidence of increased scaled arterial and ventricular elastance compared with 
lean controls, but these increases are matched so that the cardiovascular system 
remains closely-coupled and stroke volume at rest is not significantly altered. 
However, obese women have higher peripheral and central blood pressure as a result 
of increased arterial elastance, and this is more sensitive to changes in preload.  
These data add to the current literature by extending the findings to a younger 
population who were free from confounding factors such as hypertension and 
diabetes.  
To the best of my knowledge this study represents the most comprehensive 
assessment of body composition, glucose handling and elastance measures in a 
young female population with obesity. A novel finding of this study is that increases 
in arterial elastance were not particularly affected by fat location since visceral fat 
and insulin resistance were not stronger associates of elastance than BMI and waist 
circumference. In addition, the increase in ventricular elastance associated with 
obesity appears to be driven by the increase in arterial elastance but visceral fat may 
have a small direct effect on ventricular function. 
I have been unable to find other published studies of elastance and ventricular-
arterial coupling in women with PCOS. A novel finding of this thesis is that women 
with PCOS have similar arterial elastance as age- and BMI-matched controls. This 
confirms that increased afterload in women with PCOS is attributable to the obesity 
associated with the syndrome. There was a trend towards a higher ventricular 
elastance and lower ventricular arterial coupling ratio in women with PCOS and this 
might be related to testosterone levels. It is unclear whether this finding is relevant to 
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the lower rates of LV hypertrophy in obese women with PCOS and this is worthy of 
further study.  
The principle determinant of arterial elastance in this study was waist 
circumference which independently explained a significant proportion of arterial 
elastance after adjustment for systemic vascular resistance, heart rate and systemic 
arterial compliance (a measure of pulsatile load). The principle determinant of 
ventricular end-systolic elastance was arterial elastance but after adjustment for this, 
contractile function, late diastolic function and waist circumference remained 
independent contributors to the model.  Interestingly, a direct univariate association 
between ventricular elastance and waist circumference became an inverse 
association after adjustment for arterial elastance. It is unclear whether this reflects 
an early negative effect of obesity on ventricular contractility but other measures of 
contractile function were not significantly altered. Together these findings suggest 
that both haemodynamic and non-haemodynamic factors are important contributors 
to ventricular-arterial coupling in this population.  
 
It is unclear whether arterial elastance fully describes pulsatile afterload. I found 
that it was significantly affected by heart rate and static load but that arterial 
compliance was also a significant contributor. Others have found that arterial 
elastance is a poor measure of pulsatile load and this is a key factor in the 
development of LV hypertrophy. For this reason a comparison of elastance and WI 
measures of loading is included in Chapter 5. 
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5. Obesity, polycystic ovary syndrome and arterial waves 
The study of arterial waves provides an additional opportunity to quantify the 
ventricular-arterial interaction. One non-invasive method of studying these waves 
involves using ultrasound to detect simultaneous changes of diameter-derived blood 
pressure and velocity in the common carotid artery. A detailed description of the 
development of this method is given in the general introduction. Briefly, the product 
of the change in blood pressure and velocity is called WI and this reflects the energy 
or power carried by a longitudinal wave as it moves through blood. A commercially 
available system generates net WI signals but it is possible to separate these into 
forward and backward components of the wave using mathematical software. The 
separated waves are considered to provide more detailed information about the time-
course of the ventricular-arterial interaction.  
Waves travelling forward from the heart into the circulation have positive values 
of WI while backward waves reflected from the circulation have negative values. In 
addition, waves that increase pressure are considered to be ‘compression’ in nature 
and those that decrease pressure are ‘expansion’ in nature. In summary, a forward 
compression wave (FCW) generated by the heart causes an increase in arterial blood 
pressure and velocity i.e. it may be considered as having a ‘pushing’ effect. This is 
reflected back from the circulation as a backward compression wave (BCW) which 
increases backward pressure but opposes the velocity of blood. In contrast, the 
forward expansion wave (FEW) generated by the LV at the end of systole has a 
‘pulling’ effect, causing a reduction of arterial blood pressure and decelerating blood 
velocity. This is reflected from the circulation as a backward expansion wave (BEW) 
which also reduces blood pressure but pulls the flow towards the circulation.  
Whereas elastance measures represent end-systolic stiffness of the ventricular-
arterial system, WI measures may provide more detailed information about the time-
course of ventricular-arterial coupling. This may have relevance to the timing and 
quantification of pulsatile loading which may be particularly relevant to the 
development of LV hypertrophy. 
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It is unclear whether WI analysis is feasible in an obese, female population, or 
whether these methods are sufficiently sensitive to detect subclinical dysfunction 
associated with uncomplicated obesity or PCOS. 
Aims of this chapter 
The primary aim of this chapter is to establish the effect of uncomplicated obesity 
and PCOS on net WI and separated waves. Wave intensity signals are said to provide 
a more comprehensive means of assessing pulsatile load so the data should 
complement the results detailed in Chapter 3 which characterised ventricular-arterial 
coupling using elastance methods.  
The secondary aim is to establish whether central obesity and insulin resistance 
independently contribute more to the variation in WI than general obesity.  
The final aim is to establish whether detailed quantitative measures of 
ventricular-arterial coupling can independently explain the variation in LV mass and 
diastolic function in this study population.  
Hypotheses 
In young women who are free from diabetes, hypertension and cardiovascular 
disease 
1. those who are obese will have wave intensity signals that are altered in 
magnitude compared with lean controls but a similar reflection co-
efficient,  
2. those with PCOS will have similar wave intensity signals to age- and 
BMI-matched controls, 
3. central obesity will independently explain more of the variation in key 
measures of wave intensity than BMI, and 
4. quantitative measures of ventricular-arterial coupling will help to explain 
the finding of increased left ventricular mass and worse diastolic function 
in obese subjects.
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Specific methods 
Women with PCOS and control volunteers were recruited from local clinics and the 
general community. Full details of recruitment, exclusion criteria and general 
methods are described in Chapter 2. 
Net wave intensity 
Subjects were studied in the supine position after resting for at least 10 minutes. WI 
signals were derived using a commercially available ultrasound system (Aloka 
Prosound SSD-5500, Tokyo, Japan).  
A perpendicular scan line was applied to a longitudinal view of the common 
carotid artery ~1cm from the bulb, to acquire changes in diameter through the 
cardiac cycle using an echo-tracking subsystem (Figure 5-1) which has been 
described elsewhere.
146
 Arterial pressure waveforms were derived from diameter 
waveforms and calibrated by automated sphygmomanometer measurement of 
brachial systolic and diastolic blood pressure from the ipsilateral arm as previously 
validated.
155
 The design of the ultrasound system allows for a second, steerable 
pulsed-wave Doppler beam to be aligned to the vessel walls in order to 
simultaneously acquire velocity data and diameter-derived pressure. Colour-flow 
Doppler over the vessel lumen allowed the angle of incidence to be more closely 
aligned with blood flow and the sample volume was altered to encompass ~70-80% 
of the lumen diameter. Arterial diameter and flow velocity were continuously 
recorded for 20 seconds.  
During off-line analysis, individual beats affected by artefact or ectopics were 
rejected. The aim was to include at least 10 consecutive beats which were signal-
averaged to derive a single waveform of diameter and velocity (Figure 5-2). Wave 
intensity was calculated as the product of the time-derivatives of pressure and flow 
velocity [(dP/dt) x (dU/dt)]. A simultaneous electrocardiogram (ECG) was used as a 
time reference for the cardiac cycle.  
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Figure 5-1. Simultaneous recordings of velocity and diameter-derived pressure used 
to derive wave intensity signals. The vertical cursor on the longitudinal image shows 
the m-mode recording position (displayed on the right). Echo-tracking software 
follows diameter changes of the near and far carotid adventitia (orange and green 
lines). From this a diameter waveform is constructed (shown in pink) which can be 
calibrated with brachial systolic and diastolic blood pressure. The flow velocity 
waveform derived from Doppler information is shown in blue.  
 
Figure 5-2. Screenshot from Aloka showing diameter-derived pressure (green), Doppler 
derived flow velocity (orange) and net wave intensity (yellow). 
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Separated wave analysis 
A customised programme (MATLAB, MathWorks Inc., Natick, Massachusetts) was 
used to calculate the local wave speed and the intensity of separated forward and 
backward travelling waves as previously described by our lab.
149
 Briefly, the time-
course of simultaneous changes in pressure and velocity across the cardiac cycle was 
displayed as a loop as shown in Figure 5-3; the onset of systole is in the bottom left 
corner. In early systole there is a linear relationship between pressure and velocity. 
Local wave speed was calculated by  
𝑐 =  
𝑑𝑃
𝑑𝑈
 × 
1
𝜌
 
where c is the local wave speed, dP is the change in pressure in early systole, dU is 
the change in velocity in early systole and ρ is the density of blood (1040kg/m3).  
The programme uses formulae described by Jones et al. 
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 to separate forward 
and backward waves using net WI signals and the local wave speed in early systole 
as follows 
𝑃𝑓 =  
(𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒 − 𝑃𝑜) + (𝜌. 𝑐. 𝑣𝑒𝑙𝑜𝑐𝑖𝑡𝑦)
2
 
𝑃𝑏 =  
(𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒 − 𝑃𝑜)  − (𝜌. 𝑐. 𝑣𝑒𝑙𝑜𝑐𝑖𝑡𝑦)
2
 
where Pf is the part of artery pressure from a forward travelling wave, Pb is the part 
of artery pressure from a backward travelling wave, pressure is the net pressure, 
velocity is the net velocity, Po is the diastolic blood pressure, ρ is the density of 
blood and c is the local wave speed in early systole. For the forward and backward 
components of velocity: 
𝑈𝑓 =  
𝑃𝑓 
𝜌. 𝑐
 
𝑈𝑏 =  −
𝑃𝑏 
𝜌. 𝑐
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where Uf is velocity of a forward travelling wave and Ub is the velocity of a 
backward travelling wave.  Finally,  
𝑊𝐼𝑓 =  𝑑𝑃𝑓. 𝑑𝑈𝑓 
𝑊𝐼𝑏 =  𝑑𝑃𝑏. 𝑑𝑈𝑏 
where WIf is the wave intensity of the forward travelling wave and WIb is the wave 
intensity of the backward travelling wave.  
Figure 5-4 shows separated forward and backward components of pressure and 
velocity obtained using this method and the final separated forward and backward 
wave intensity signals are shown in Figure 5-5. 
 
 
Figure 5-3. Example of a pressure-velocity loop across the cardiac cycle generated by 
customised software. The onset of systole occurs in the bottom left corner. The first red 
section marked by asterisks represents the linear portion in early systole used to calculate 
local wave speed.  
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Figure 5-4. Example of the total (black), forward (blue) and backward (red) components of 
pressure and velocity which were separated using the method described. Note that the net 
pressure represents the addition of the forward and backward pressure (it is augmented by 
the backward pressure). Whereas the net flow velocity represents the subtraction of the 
backward from the forward flow velocity. 
 
 
Figure 5-5. Final separated forward (blue) and backward (red) wave intensity signals.  
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Local artery stiffness was calculated using established formulae and the changes 
in common carotid diameter and diameter-derived pressure. 
β stiffness index = ln [(Ps/Pd) / ((Ds-Dd)/Ds)] 
Peterson’s elastic modulus, ε = [(Ps – Pd) / (Ds – Dd)] . Dd 
Reproducibility of wave intensity measures 
The intra-observer inter-session repeatability of WI measures using an Aloka 
prosound SSD-5500 and these methods of wave separation has previously been 
established and published by a member of our group.
149
 The mean (s.d.) differences 
of two measurements taken from the right common carotid artery, separated by at 
least one week were as follows; epsilon 13(10)%, beta stiffness index 12(9)%, wave 
speed 8(8.3)%, augmentation index 14(7)%, forward compression wave 12(6)%, 
backward compression wave 21(11)%.  
Data analysis 
I analysed the effects of obesity and PCOS on the following measurements (the 
average of left and right common carotid artery measures was used for net and 
separated WI analysis): 
 net wave intensity  
o W1 amplitude, 
o W2 amplitude, 
o negative area, 
 separated wave intensity 
o local wave speed, 
o forward compression wave amplitude (FCW) and integral, 
o backward compression wave (BCW) amplitude and integral, 
o time from the R wave of the ECG to BCW, 
o forward expansion wave (FEW) amplitude and integral, 
o reflection coefficient (BCWintegral/FCWintegral x 100), 
o local beta stiffness index, and 
o local Peterson’s elastic modulus. 
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Results 
Feasibility 
Net WI analysis was feasible in 90% of subjects and was limited by the ability to 
obtain high quality and stable images of both the left and right common carotid 
artery since I elected to use the average of these measurements in analyses. The 
feasibility was not worse in obese subjects.  
Wave intensity measures were not related to body size  
In the lean control subjects there were no associations of body size with net WI 
measures but this was a small group (n=56). I assessed the relationship of height 
with WI measures in the pooled sample (n=127) but there were no significant 
associations. 
Association of net wave intensity measures with cardiovascular risk factors 
Table 5-1 shows univariate correlations of net WI measures with cardiovascular risk 
factors. There were few significant associations and none of the measures was 
related to BMI.  
There was a weak direct association of age with the amplitude of W1 (originating 
from the LV) and with the negative area (representing reflections). In addition, there 
was a weak but direct association of the negative area with visceral fat and an 
inverse association with HDL cholesterol. 
 160 
 
Table 5-1. Univariate correlates [Spearman’s rho (p-value)] of net wave intensity measures 
with cardiovascular risk factors. 
 W1 W2 NA 
Age .18  (.048) .11  (.218) .21  (.020) 
BMI −.03  (.733) −.06  (.531) .10  (.290) 
Waist  .02  (.805) −.04  (.690) .09  (.312) 
Hip  .05  (.545) .01  (.906) .18  (.039) 
Waist/hip  −.09  (.321) −.14  (.125) −.09  (.328) 
TFA −.04  (.696) −.02  (.862) .16  (.093) 
SFA −.04  (.690) −.03  (.716) .15  (.116) 
VFA .01  (.941) .01  (.943) .19  (.043) 
Glucose  .10  (.271) −.02  (.867) .06  (.509) 
Glucose AUC  −.04  (.627) <.01  (.987) −.02  (.844) 
Insulin −.13  (.157) −.04  (.637) −.01  (.956) 
Insulin AUC −.03  (.753) −.06  (.516) .04  (.700) 
HOMA-IR −.11  (.227) −.07  (.456) <.01  (.981) 
hs-CRP .07  (.439) -.05  (.588) .09  (.302) 
Testosterone −.01  (.931) .02  (.830) .06  (.530) 
Adiponectin .08  (361) .10  (.266) −.07  (.417) 
Cholesterol .02  (.844) −.08  (.375) −.01  (.938) 
HDL −.04  (.671) .01  (.922) −.18  (.045) 
LDL .05  (.605) −.06  (.532) −.01  (.960) 
Triglycerides −.04  (.685) −.14  (.126) .05  (.595) 
 
TFA = total abdominal fat area, SFA = subcutaneous fat area, VFA = visceral fat area, AUC = area 
under the curve. 
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Local artery stiffness and cardiovascular risk factors 
Table 5-2 shows univariate correlations of cardiovascular risk factors with measures 
of local carotid artery stiffness. There was a direct association of age with the local 
beta stiffness index, epsilon and the augmentation index, but not with local wave 
speed which is an important determinant of wave intensity. There were no 
associations of obesity or insulin resistance with the beta stiffness index in this 
young female population. In contrast, both general and central obesity were directly 
associated with local wave speed, epsilon and the local augmentation index. The 
local augmentation index was directly associated with the post-prandial glucose 
levels and triglycerides. There was an unexpected direct association of wave speed 
with HDL cholesterol.  
Separated wave intensity measures and cardiovascular risk factors 
Univariate correlations of cardiovascular risk factors with separated WI measures are 
shown in Table 5-3. The first two columns show the relationships with waves 
generated by the LV. There was a direct association of visceral fat area and HOMA-
IR with the forward compression wave. The correlations of this wave with other 
measures of obesity were weaker and, in most cases, not significant. Age tended to 
be inversely associated with the energy in the FCW but this did not reach statistical 
significance. The forward expansion wave was directly associated with all measures 
of obesity and with HOMA-IR; the strongest association was with visceral fat area.  
The next column shows the relationships with the reflected wave from the 
cerebrovascular circulation. Age was inversely associated with the reflected 
compression wave. Central obesity was directly associated with the reflected wave.  
When the reflected wave was normalised for the energy in the preceding forward 
travelling wave (to produce a reflection coefficient), only the inverse association 
with age remained.   
The final column shows the data for the timing of the reflected wave. This was 
most strongly associated with age, visceral fat and fasting glucose levels (all 
inverse).  
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Table 5-2. Univariate correlates [Spearman’s Rho (p-value)] of carotid artery stiffness 
measures with cardiovascular risk factors. 
 
Local wave 
speed 
Local β 
stiffness index 
Local Epsilon 
Local 
Augmentation 
index 
Age .02  (.859) .47  (<.0001) .54  (<.0001) .49  (<.0001) 
BMI −.20  (.021) −.05  (.599) .17  (.051) .34  (<.0001) 
Waist  −.21  (.017) −.03  (.757) .20  (.019) .32  (<.0001) 
Hip  −.22  (.011) −.05  (.590) .18  (.041) .33  (<.0001) 
Waist/hip  −.04  (.634) .08  (.358) .19  (.032) .16  (.064) 
TFA −.17  (.060) −.08  (.392) .12  (.183) .22  (.015) 
SFA −.17  (.059) −.10  (.269) .09  (.331) .18  (.041) 
VFA −.17  (.055) .03  (.775) .23  (.011) .34  (<.0001) 
Glucose −.03  (.699) .16  (.071) .17  (.055) .16  (.063) 
Glucose AUC .05  (.581) .04  (.693) .06  (.500) .19  (.029) 
Insulin −.02  (.829) −.08  (.333) .03  (.748) .10  (.263) 
Insulin AUC −.04  (.698) −.10  (.286) −.02  (.816) .02  (.798) 
HOMA-IR −.05  (.606) −.07  (.417) .05  (.578) .14  (.112) 
hs-CRP −.10  (.234) −.06  (.473) .10  (.268) .15  (.075) 
Testosterone .09  (.298) −.02  (.864) −.03  (.759) .02  (.809) 
Adiponectin .04  (.652) .07  (.438) −.05  (.570) −.10  (.280) 
Cholesterol .03  (.706) .12  (.167) .22  (.011) .11  (.223) 
HDL .22  (.012) .13  (.128) .08  (.368) <.01  (.976) 
LDL −.07  (.442) .05  (.570) .17  (.049) .08  (.383) 
Triglycerides .01  (.937) <.01  (.979) .08  (.375) .26  (.002) 
 
TFA = total abdominal fat area, SFA = subcutaneous fat area, VFA = visceral fat area, AUC = area 
under the curve. 
 163 
 
Table 5-3. Univariate correlates [Spearman’s rho (p-value)] of separated wave intensity 
measures with cardiovascular risk factors.  
 
 
FCWi FEWi BCWi BCWi/FCWi R-BCW 
Age −.15  (.077) .02  (.795) −.24  (.006) −.19  (.026) −.24  (.004) 
BMI .10  (.252) .18  (.032) .09  (.327) .04  (.627) −.13  (.143) 
Waist  .15  (.089) .19  (.028) .13  (.129) .05  (.563) −.14  (.102) 
Hip  .12  (.177) .17  (.048) .11  (.226) .05  (.552) −.13  (.130) 
Waist/hip  .11  (.195) .09  (.327) .10  (.273) .01  (.956) −.11  (.203) 
TFA .19  (.037) .24  (.006) .17  (.050) .07  (.421) −.10  (.256) 
SFA .17  (.055) .24  (.008) .17  (.051) .09  (.304) −.07  (.448) 
VFA .22  (.014) .25  (.005) .19  (.033) .02  (.800) −.25  (.005) 
Glucose .03  (.718) .10  (.249) −.02  (.845) −.06  (.464) −.24  (.006) 
Gluc AUC .02  (.828) −.07  (.423) −.05  (.606) −.13  (.141) −.19  (.034) 
Insulin .16  (.068) .17  (.044) .09  (.331) −.05  (.547) −.13  (.141) 
Ins AUC .10  (.296) .05  (.619) .07  (.464) .01  (.897) −.15  (.106) 
HOMA-IR .20  (.028) .21  (.014) .11  (.190) −.04  (.610) −.15  (.082) 
hs-CRP .17  (.055) .16  (.067) .16  (.072) .07  (.429) −.09  (.309) 
Testosterone .01  (.937) −.02  (.801) −.02  (.784) −.06  (.529) .03  (.744) 
Adiponectin −.07  (.451) −.04  (.673) −.05  (.543) −.03  (.724) .03  (.765) 
Cholesterol .03  (.751) .10  (.256) <.01  (.994) −.06  (.508) −.05  (.536) 
HDL −.12  (.179) −.11  (.227) −.11  (.231) −.02  (.782) .10  (.271) 
LDL .07  (.444) .15  (.093) .05  (.547) −.02  (.854) −.05  (.599) 
Triglycerides .08  (.337) .03  (.704) .05  (547) −.05  (.569) −.07  (.424) 
 
FCWi = forward compression wave integral, BCWi = backward compression wave integral, 
R-BCW = time from R wave to backward compression wave peak, BCWi/FCWi = 
compression wave reflection coefficient, FEWi = forward expansion wave integral, TFA = 
total abdominal fat area, SFA = subcutaneous fat area, VFA = visceral fat area, AUC = 
area under the curve.
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These data suggested that WI measures of pulsatile loading were more strongly 
influenced by central obesity and metabolic health than by general obesity. As a 
result, I tested the effect of a diagnosis of PCOS and/or insulin resistance on 
separated waves.  
Clinical characteristics of the population when grouped by insulin resistance and 
PCOS status 
The clinical characteristics of the study population when stratified by PCOS and 
insulin resistance are presented in Table 5-4. Women in the ‘control’ group were free 
from PCOS and insulin resistance (PCOS-IR-). There were only 12 subjects with a 
diagnosis of PCOS but without insulin resistance, this group size was significantly 
smaller than the others and was not considered in further inferential statistics. 
Women in the ‘insulin resistance’ group were obese but free from PCOS (PCOS-
IR+). Women in the ‘PCOS’ group had both PCOS and insulin resistance 
(PCOS+IR+). 
As expected, the insulin resistance group had higher levels of general and central 
obesity than the metabolically healthy controls, with lower levels of HDL and 
adiponectin, and higher levels of inflammation.  
By design, women with PCOS had higher testosterone levels than the other two 
groups. Women with PCOS had similar levels of obesity as the group with insulin 
resistance. Measures of glucose handling were also similar with the exception of 
insulin area under the curve, which was higher in those with PCOS.  
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Table 5-4. Clinical characteristics (mean ± s.d.) of the study population when grouped by PCOS status and HOMA-IR >2.5. 
 
 
Control 
(PCOS-IR-) 
(n=50) 
Insulin Resistance 
(PCOS-IR+) 
(n=29) 
IR vs. 
Control 
p-value 
PCOS 
(PCOS+IR+) 
(n=43) 
PCOS vs. 
Control 
p-value 
PCOS vs. 
IR 
p-value 
Age (years) 31 ± 8 32  ± 7 .947 30  ± 6 .614 .374 
BMI (kg/m
2
)* 25 ± 4 32  ± 6 <.0001 32  ± 7 <.0001 .977 
Waist (cm)* 79 ± 10 94  ± 13 <.0001 96  ± 17 <.0001 .969 
Hip (cm) 100 ± 11 115  ± 15 <.0001 115  ± 17 <.0001 .996 
Waist-hip ratio 0.80 ± 0.05 0.82  ± 0.05 .296 0.83  ± 0.05 0.12 .762 
TFA (cm
2
) 224 ± 105 380  ± 90 <.0001 362 ± 127 <.0001 .896 
SFA (cm
2
) 204 ± 97 339 ± 78 <.0001 327 ± 113 <.0001 .925 
VFA (cm
2
)* 19 ± 13 42  ± 21 <.0001 38  ± 27 <.0001 .640 
Glucose (units) 4.5 ± 0.4 4.8  ± 0.3 .047 4.7 ± 0.4 .037 .995 
Gluc AUC (mmol min/l)*  670 ± 120 743 ± 145 .066 775 ± 141 .001 .738 
Insulin (units) 45 ± 19 107 ± 28 <.0001 132 ± 91 <.0001 .239 
Ins AUC (pmol min/l)* 36460 ±16357 73478 ± 45023 <.0001 105583 ±61173 <.0001 .021 
HOMA-IR* 1.4 ± 0.6 3.8 ± 1.1 <.0001 4.6 ± 3.3 <.0001 .759 
hs-CRP (mg/l)* 1.6 ± 2.1 3.8 ± 3.4 <.0001 3.8 ± 4.6 <.0001 .990 
Testosterone (nmol/l)* 0.92 ± 0.28 0.88 ± 0.27 .944 1.52 ± 0.86 <.0001 <.0001 
Adiponectin (µg/ml)* 12 ± 7 7 ± 6 .002 11 ± 9 .207 .179 
Cholesterol (mmol/l) 4.6 ± 0.8 4.7 ± 0.9 .989 4.8 ± 0.7 .856 .981 
HDL (mmol/l) 1.5 ± 0.4 1.2 ± 0.2 .003 1.3 ± 0.3 .023 .714 
LDL (mmol/l) 2.7 ± 0.7 3.0 ± 0.9 .248 2.9 ± 0.7 .375 .969 
Triglycerides (mmol/l) 0.9 ± 0.5 1.0 ± 0.4 .764 1.1 ± 0.5 .176 .853 
 
TFA = total abdominal fat area, SFA = subcutaneous fat area, VFA = visceral fat area, AUC = area under the curve. *Variables were log-transformed prior to 
use in inferential statistics.
 166 
 
Standard measures of cardiovascular function and elastance when grouped by 
insulin resistance and PCOS status 
Women with insulin resistance (but without PCOS) had higher heart rate, brachial 
and central systolic blood pressure, scaled arterial and ventricular elastance than 
controls (Table 5-5). The differences that were evident in LV wall thickness, mass 
and diastolic function when groups were stratified by BMI (Chapter 3) were no 
longer significant when stratification was based on insulin resistance. 
Women with PCOS who were insulin resistant had higher heart rate than controls 
but similar blood pressure. In addition, those with PCOS had a shorter isovolumic 
relaxation time than both other groups.   
The effects of insulin resistance and PCOS on wave intensity measures 
Table 5-6 shows separated WI measures according to PCOS and insulin resistance 
status. Measures of artery stiffness were comparable across the groups. 
Compared with metabolically healthy controls, women with insulin resistance 
had greater energy forward compression and expansion waves from the LV, as well 
as greater energy backward wave reflections from the circulation. The reflection 
coefficient and timing of the backward compression wave were not different 
between groups. 
Women with PCOS had WI signals that were similar to metabolically healthy 
controls, despite having higher levels of obesity and insulin resistance. In addition, 
those with PCOS had significantly lower energy forward expansion waves and 
backward compression waves than those with insulin resistance, despite similar 
levels of obesity and insulin resistance. These data are also illustrated in Figure 5-6 
for clarity.  
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Table 5-5. Standard measures of cardiovascular function and elastance in the study population 
when grouped by PCOS status and insulin resistance. 
 Control 
(PCOS-IR-) 
(n=50) 
 
Insulin 
Resistance 
(PCOS-IR+) 
(n=29) 
IR vs. 
Control 
 
PCOS 
(PCOS+IR+) 
(n=43) 
PCOS 
vs. 
Control 
 
PCOS 
vs.  
IR 
 
Heart rate (bpm) 67 ± 9 75 ± 12 .004 75 ± 10 .002 .995 
bSBP (mmHg) 109 ± 10 117 ± 9 .004 113 ± 8 .170 .343 
bDBP (mmHg) 68 ± 9 66 ± 7 .331 66 ± 9 .338 .996 
cSBP (mmHg) 93 ± 11 99 ± 9 .048 96 ± 9 .558 .458 
cDBP (mmHg) 63 ± 10 67 ± 8 .265 67 ± 9 .160 1.0 
SVR (dynes/s/cm
5
) 1512 ± 343 1419 ± 296 .581 1356 ± 280 .074 .817 
SAC (ml/mmHg) 1.39 ± 0.31 1.29 ± 0.26 .488 1.40 ± 0.28 .999 .418 
ccIMT (mm)* 0.51 ± 0.06 0.51 ± 0.06 .966 0.50 ± 0.07 .914 .725 
AIx -75 (%) 2.7 ± 15.4 7.1 ± 14.1 .475 3.2 ± 11.0 .997 .587 
PWV (m/s)* 6.15 ± 0.89 6.59 ± 0.88 .109 6.34 ± 0.92 .704 .571 
RWT* 0.36 ± 0.06 0.39 ± 0.07 .286 0.36 ± 0.05 1.0 .301 
LV mass I (g/m
2.7
)* 32 ± 8 36 ± 8 .127 34 ± 7 .490 .786 
FS (%) 34 ± 5 34 ± 6 .997 35 ± 5 .460 .709 
s′ (cm/s)* 9.7 ± 1.6 10.2 ± 2.1 .779 9.8 ± 1.6 .999 .868 
MAPSE (mm) 1.33 ± 0.13 1.34 ± 0.15 .961 1.36 ± 0.14 .620 .941 
e′/a′* 1.9 ± 0.6 1.8 ± 0.6 .629 1.8 ± 0.1 .686 .998 
IVRT (ms) 85 ± 9 82 ± 10 .539 78 ± 11 .012 .553 
FPV (cm/s) 56 ± 10 59 ± 11 .700 58 ± 11 .913 .967 
EaI 
(mmHg/ml/m
2.4
)* 
3.1 ± 0.5 3.8 ± 0.8 <.0001 3.6 ± 0.9 .017 .494 
EesI 
(mmHg/ml/m
2.1
)* 
2.6 ± 0.6 3.1 ± 0.8 .031 3.1 ± 0.8 .008 1.0 
VAC 1.1 ± 0.2 1.1 ± 0.2 .997 1.1 ± 0.2 .273 .533 
B: brachial, c: central, SBP: systolic blood pressure, DBP: diastolic blood pressure, SVR: systemic vascular 
resistance, SAC: systemic arterial compliance, ccIMT: common carotid intima-media thickness, AIx-75bpm: 
augmentation index for a heart rate of 75bpm, PWV: aortic pulse wave velocity, RWT: LV relative wall thickness, FS: 
fractional shortening, MAPSE: mitral annular plane systolic excursion, IVRT: isovolumic relaxation time, FPV: flow 
propagation velocity, EaI: scaled arterial elastance, EesI: scaled ventricular elastance, VAC: ventricular-arterial 
coupling ratio.* Variables were transformed using natural log before use in ANOVA.
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Table 5-6. Selected separated wave measures (mean ± s.d.) of the study population group by PCOS status and/or HOMA-IR > 2.5. 
 
 Control  
(PCOS-IR-) 
 
Insulin 
Resistance 
(PCOS-IR+) 
IR vs.  
Control  
p-value 
PCOS 
(PCOS+IR+) 
PCOS vs.  
Control  
p-value 
PCOS vs. 
IR 
p-value 
Wave speed (m/s)* 3.8 ± 3.7 2.9 ±  0.8 .418 3.4 ± 1.5 1.0 .480 
Beta index* 5.5 ± 1.3 5.6 ± 1.3 .996 5.3 ± 1.4 .742 .688 
Epsilon (kPa)* 63 ± 16 68 ± 19 .569 61 ± 18 .961 .337 
AIx (%) 2.8 ± 9.8 2.3 ± 9.5 .996 4.9 ± 7.8 .657 .615 
FCWi (J/m
2
)* 526 ± 209 628 ± 170 .027 532 ± 144 .929 .122 
BCWi (J/m
2
)* 219 ± 79 289 ± 123 .020 216 ± 87 .996 .014 
R wave to BCW (ms)* 139 ± 22 133 ± 20 .614 135 ± 13 .746 .989 
BCWi/FCWi (%) 42 ± 10 46 ± 17 .582 40 ± 9 .647 .116 
FEWi (J/m
2
)* 74 ± 39 98 ± 32 .001 75 ± 25 .845 .015 
AIx: local augmentation index, FCW: forward compression wave, BCW: backward compression wave, FEW: forward expansion wave, i: 
integral. *Variables were transformed using natural log before use in ANOVA.
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Figure 5-6. Median forward compression, backward compression and 
forward expansion wave by study group. Error bars give 95% CI. 
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Associations of separated wave intensity signals with tonometry and echo 
measures 
To improve my understanding of the additional information carried by WI signals, I 
explored the associations of selected separated signals with other conventional 
measures of artery structure, regional artery stiffness, ventricular structure, systolic 
function, and diastolic function, as well as the measures of arterial and ventricular 
elastance and the coupling ratio calculated in Chapter 4.  These data are shown in 
Tables 5-7 and 5-8. 
Waves generated by the left ventricle: The forward compression wave occurs in 
the carotid artery at the start of ventricular ejection and is an indication of the energy 
transmitted from the LV into the conduit arteries. It causes an increase in aortic flow 
velocity as well as an increase in pressure. The timing of the wave means that it has 
yet to be affected by wave reflections. As such, I expected it to be associated with 
measures of systolic ventricular function, heart rate, and static vascular resistance. 
The data confirmed that the most important associations of the separated forward 
compression wave integral were heart rate, brachial pulse pressure, arterial elastance 
and longitudinal systolic function (direct associations). The wave was inversely 
associated with systemic vascular resistance and local wave speed. There was no 
significant association with fractional shortening or with ventricular elastance. 
The forward expansion wave occurs in the carotid artery towards the end of 
ejection. It is caused by the drop in left ventricular pressure in the protodiastolic 
period and causes a deceleration of aortic blood flow (as well as a drop in aortic 
pressure). Since this wave occurs late in systole, I anticipated that it might be 
associated with measures of pulsatile as well as static loading. I also expected it to be 
related to early diastolic function. The data confirmed that the separated forward 
expansion wave integral was directly associated with peripheral and central pulse 
pressure and mean arterial pressure, arterial end-systolic elastance, regional stiffness 
(aortic pulse wave velocity), heart rate and epsilon (a measure of local stiffness 
affected by blood pressure).  The wave was inversely associated with local wave 
speed. I found a direct association of the forward expansion wave integral with left 
ventricular mass but no significant associations with diastolic function.
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Table 5-7. Associations of selected separated wave intensity signals [Spearman’s Rho (p-
value)] with other measures of artery stiffness and function.  
 FCWi FEWi BCWi BCWi/FCWi R-BCW 
Heart rate .23  (.009) .20  (.020) .13 (.140) −.09  (.317) −.23 (.009) 
bPP .36  (<.0001) .30  (<.0001) .30  (<.0001) .03  (.776) .02  (.827) 
cPP .14  (.118) .16  (.060) .07  (.435) −.04  (.659) −.09  (.291) 
SVR −.25  (.005) −.11  (.207) −.24  (.006) −.07  (.410) −.19  (.031) 
EaI .18  (.034) .27  (.002) .13  (.130) <.01  (.970) −.05  (.563) 
bMAP .16  (.064) .28  (.001) .09  (.286) .02  (.858) −.06  (.475) 
cMAP .08  (.343) .22  (.013) .01  (.876) −.04  (.680) −.11  (.208) 
SAC −.15  (.085) −.17  (.052) −.07  (.393) .11  (.195) −.08  (.339) 
AIx-75 −.21  (.018) −.02  (.843) −.31 (<.0001) −.24  (.005) −.27  (.001) 
ccIMT .09  (.307) .05  (.589) .10  (.246) .09  (.313) −.15  (.077) 
PWV .05  (.551) .23  (.007) −.06 (.517) −.15  (.092) −.21  (.019) 
WS −.25  (.003) −.24  (.005) −.45 (<.0001) −.54  (<.0001) .04  (.619) 
β −.04  (.611) .07  (.431) −.14  (.116) −.17  (.046) .01  (.905) 
ε .05  (.605) .17  (.049) −.04 (.688) −.10  (.261) −.04  (.626) 
b:brachial, c: central, PP: pulse pressure, SVR:  systemic vascular resistance, EaI: scaled arterial 
elastance, MAP: mean arterial pressure, SAC: systemic arterial compliance, AIx-75: augmentation 
index corrected for a heart rate of 75bpm, ccIMT: common carotid intima-media thickness, PWV: 
pulse wave velocity, WS: wave speed, β: beta stiffness index, ε: epsilon, FCW: forward compression 
wave, BCW: backward compression wave, FEW: forward expansion wave, and i: integral. 
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Table 5-8. Univariate correlations of selected separated wave intensity signals [Spearman’s 
Rho (p-value)] with echocardiographic variables, ventricular elastance and coupling ratio. 
 FCWi FEWi BCWi BCWi/FCWi R-BCW 
LVIDd .13  (.147) .17  (.053) .23  (.009) .21  (.018) .20  (.023) 
RWT <.01 (.994) .05 (.545) .02 (.822) .13 (.137) −.05 (.580) 
LV mass .10  (.244) .24  (.007) .23  (.008) .33 (<.0001) .17  (.051) 
FS .07  (.430) −.05  (.611) −.01  (.948) −.13  (.136) −.45  (<.0001) 
sʹ .27  (.003) .07  (.446) .16  (.087) −.10  (.288) −.37  (<.0001) 
MAPSE .18 (.040) .07 (.429) .17 (.059) .05 (.590) −.20 (.022) 
EesI .13  (.160) .11  (.214) .04  (.694) −.09  (.299) −.38  (<.0001) 
VAC <.01  (.989) .13  (.133) .08  (.386) .14  (.122) .48  (<.0001) 
eʹ .16  (.094) .07  (.478) .12  (.196) −.05 (.595) .06  (.532) 
aʹ .13  (.176) .17  (.075) .02  (.858) −.12  (.200) −.38  (<.0001) 
eʹ/aʹ .03  (.755) −.05  (.578) .07  (.458) .04  (.695) .29  (.002) 
IVRT −.12  (.192) .03  (.731) .01  (.923) .19  (.028) .20  (.026) 
FPV .13 (.202) −.07 (.454) .08 (.401) −.05 (.599) −.04 (.718) 
LVIDd: left ventricle internal dimension in diastole, RWT: relative wall thickness, FS: fractional 
shortening, sʹ: longitudinal systolic tissue velocity, EesI: scaled ventricular elastance, VAC: 
ventricular arterial coupling ratio (Ea/Ees), eʹ:  early diastolic tissue velocity, aʹ: late diastolic tissue 
velocity,  IVRT:  isovolumic relaxation time, FCW:  forward compression wave, BCW: backward 
compression wave, FEW: forward expansion wave, and i: integral. 
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Wave reflections from the arterial circulation: The backward compression wave 
occurs in the carotid artery in mid-systole and is an indication of the energy reflected 
backward to the heart from the circulation. It causes an increase in artery pressure 
but, due to its backward nature, a decrease in flow velocity. Therefore, it adds to the 
resistance or loading that the LV has to overcome to continue ejecting blood. Since 
this wave is a reflection of the preceding forward compression wave I expected it to 
be associated with systemic vascular resistance and measures of systolic function. In 
addition, I expected direct relationships with measures of artery stiffness and 
surrogate measures of pulsatile loading such as mean arterial pressure and 
augmentation index as well as with left ventricular size and mass. 
The data confirmed that the backward compression wave integral was inversely 
associated with the local wave speed, central augmentation index, and systemic 
vascular resistance. There was no significant relationship with mean arterial pressure 
or arterial compliance. The direction of these associations was the same as for the 
forward compression wave and is likely dominated by that shared factor.   I found 
evidence of a direct association between the backward compression wave integral 
and left ventricular mass.  
When I normalised the backward compression wave with the integral of the 
forward compression wave, the dominant inverse association with local wave speed 
remained, as did the direct associations with left ventricular size and mass. A new 
direct association emerged between this reflection coefficient and the isovolumic 
relaxation time indicating that higher pulsatile loading was associated with 
lengthening of this relaxation period. I was surprised that the reflection coefficient 
was inversely associated with the augmentation index since this has been proposed as 
a measure of the effect of wave reflections by others.  
Timing of wave reflections: The timing of reflections back towards the heart was 
assessed by measuring the time from the R wave of the ECG to the peak of the 
backward compression wave. The strongest correlates of the reflected compression 
wave timing were the ventricular-arterial coupling ratio (direct) and fractional 
shortening (inverse). There were also inverse associations with other measures of 
systolic function, ventricular elastance, the late diastolic tissue velocity, heart rate, 
augmentation index and pulse wave velocity. 
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Independent contributions of wave intensity measures to left ventricular mass 
In Chapter 3, the variation in LV mass was predicted by a model that included 
weight, systolic blood pressure and common carotid intima-media thickness (r
2
 = 
.503, p<.0001). I tested whether adding measures of elastance and WI improved the 
model and independently explained some of the variation in LV mass. These 
variables were added to the second block of a hierarchical model using a stepwise 
approach.  
The compression wave reflection coefficient, timing of the backward 
compression wave, intrinsic local artery stiffness and the scaled arterial elastance to 
the model explained a further 15% of the variation in left ventricular mass (r
2
 = .651, 
p<.0001). The final model is shown in Table 5-9. Weight explained most of the 
variation in LV mass but similar independent contributions were made by the other 
variables. Arterial elastance had an unexpected inverse association with LV mass in 
the final model after adjustment for other factors. 
No independent contribution of wave intensity measures to diastolic function 
In Chapter 3, the variation in diastolic function (eʹ/aʹ) was explained reasonably well 
by a basic model comprising age, visceral fat area, insulin area under the curve and 
systolic blood pressure (r
2
 = .585, p<.0001).  I tested whether adding measures of 
arterial elastance, ventricular arterial coupling or the timing of the backward 
compression wave improved the model and independently explained some of the 
variation in diastolic function (eʹ/aʹ). These variables were added to the second block 
of a hierarchical model using a stepwise approach. This approach did not result in an 
improved model. When visceral fat and insulin resistance were removed from the 
model, the measures of elastance and ventricular arterial coupling were independent 
predictors but the model explained less of the variation in diastolic function (r
2
= 
.445, p<.0001).  
Therefore, the components of the model remain as shown in Chapter 3 although 
the relevant contributions are slightly altered because this iteration only included 
those in whom WI measures were feasible (Table 5-10). Age explained most of the 
variation in diastolic function, followed by insulin area under the curve, visceral fat 
and central systolic blood pressure.  
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Table 5-9. Final multivariate regression model for left ventricular mass. 
Dependent variable: LV mass* 
Standardised 
β 
P-value 
Part 
correlations 
Weight* .671 <.0001 .488 
EaI* -.255 .001 -.184 
BCWi/FCWi* .237 <.0001 .226 
ccIMT* .186 .004 .159 
Local β stiffness index* .203 .003 .164 
R-BCW* .224 <.0001 .214 
Central systolic BP .186 .009 .144 
Model r
2
 = .650, p<.0001 
EaI: scaled arterial elastance, BCWi: backward compression wave integral, FCWi: forward 
compression wave integral, ccIMT: common carotid intima-media thickness, R-BCW: time from R 
wave of ECG to peak of backward compression wave. *Variables were transformed by taking the 
natural log prior to use in multivariate regression. 
 
Table 5-10. Final multivariate regression model for eʹ/aʹ. 
Dependent variable: eʹ/aʹ 
Standardised 
β 
P-value 
Part 
correlation 
Age* -.492 <.0001 -.420 
Insulin AUC* -.262 .001 -.241 
Visceral fat area* -.193 .020 -.165 
Central systolic BP -.161 .049 -.139 
Model r
2
 = .555, p<.0001 
AUC: area under curve. *Variables were transformed by taking the natural log prior to use in 
multivariate regression
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Discussion 
Feasibility and reproducibility 
Carotid ultrasound images were obtained by an operator who was experienced in 
performing cardiac ultrasound but a novice to vascular ultrasound. Despite this, WI 
measures were feasible in the majority of subjects regardless of the presence of 
obesity. None of the published studies explicitly document the feasibility of the 
technique but the implication in each paper is that feasibility was 100%. However, 
the majority of studies elected to use data from either the left or right common 
carotid artery. The feasibility in my study may by lower (90%) because I elected to 
take an average of the two sides in an effort to understand the general effects of 
obesity and PCOS on ventricular-arterial coupling in conduit arteries. In addition, I 
believed that averaging the measures would reduce error associated with noisy data. 
The repeatability and reproducibility of WI measures in our lab is comparable 
with figures in the published literature.
141, 144, 146, 148, 151
 There is consistently less 
variation in the larger amplitude forward compression wave compared with the 
smaller forward expansion wave and wave reflections. Others have reported that the 
variation is likely related to physiological variability of pressure and flow velocity 
signals rather than systematic bias.
146
 This variability in data may affect the 
sensitivity of WI measures to detect subtle but significant between-group differences 
in the sub-clinical phases of disease. Nevertheless, I was able to detect between-
group differences using this technique.  
Net wave intensity indices 
There is evidence that the forward compression wave which dominates the first net 
WI signal, W1, is directly associated with local augmentation index 
156
 and that 
central augmentation index is associated with height.
221
 Therefore, I anticipated that 
net WI measures would be associated with height or body surface area in lean 
control subjects. This was not the case so I used unscaled measures in between-group 
analyses. My findings are in agreement with Hughes et al. who used different 
methods to derive a wave reflection coefficient but also reported no association with 
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height in a small study of healthy, normotensive individuals (n=65).
144
 This should 
be confirmed in a larger study of the healthy, community-dwelling population.   
The mean values of net WI in the lean control group were higher than the normal 
values reported by others who used similar methods  but subject characteristics are 
not reported in their paper and there is no information about how the ‘healthy status’ 
of volunteers was assured.
146
 As a result, it was difficult to suggest reasons for the 
discrepancy. It is unlikely that the differences are due to the all-female population in 
my study since women tend to have lower WI values than men. The subjects in my 
study were comprehensively characterised in terms of metabolic, anthropometric and 
cardiovascular health so I consider that the data accurately reflect normal values in a 
young and healthy female population.  
PCOS and general obesity did not affect net wave intensity measures 
Neither PCOS nor general obesity was associated with altered net WI signals.  This 
may suggest that net WI signals, which sum forward and backward components at 
any given point in the cardiac cycle, are not sufficiently precise or sensitive to detect 
sub-clinical differences attributable to increased body size. I considered whether the 
lack of between-group difference may be attributable to the study design; the initial 
power calculation suggested a sample size sufficient to detect differences in standard 
tonometric and echocardiographic variables. Wave intensity signals were not among 
the primary outcome measures and there is typically greater physiological variation 
in the signals. It may be that a greater sample size is needed to reach sufficient power 
for these measures.  
Insulin resistance due to obesity did not affect local artery stiffness 
In Chapter 3 I found that regional arterial stiffness (aortic pulse wave velocity) was 
increased in obese subjects without PCOS compared with controls. However, aortic 
pulse wave velocity is not a true measure of the intrinsic stiffness of the artery since 
it is affected by blood pressure (which tends to be increased in obesity), ejection time 
and the early systolic rise in left ventricular pressure (dP/dT).
222
  
A key finding of this study is that women with insulin resistance due to obesity 
had similar intrinsic carotid artery stiffness (β stiffness index) to controls. 
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In the pooled data, there were no associations of the beta stiffness index with 
measures of obesity or insulin resistance. In contrast, epsilon was associated with 
central obesity but not insulin resistance. I found a trend towards higher epsilon 
measures in those with insulin resistance compared with controls but this was not 
significant.  
These findings differ from Malshi et al. who report an increase in carotid artery 
stiffness measures in overweight (n=23) and obese (n=57) subjects compared with 
controls (n=25).
158
 However, details of the mean stiffness measures and the 
statistical significance of these are not reported in the brief conference proceedings. 
In addition, the subjects were drawn from a wider age range (18-68 years) than in my 
study and it is unclear whether their groups were matched for age. The same group 
also found that in a small, predominantly female population (n=33, 9 males), obesity 
tended to cause a non-significant increase in beta and epsilon.
159
 It seems intuitive 
that obese subjects are likely to have elevated epsilon and local augmentation index 
since these are affected by blood pressure 
148
 which tends to be higher in obesity.  
In my study the standard deviation of local augmentation index, another measure 
of local artery stiffness, was wide in comparison with the mean (e.g. in controls it 
was 2.75 ± 9.80 %). This is likely to affect the ability to detect small between-group 
differences.  
Insulin resistance due to obesity was associated with increased wave intensity 
signals 
A key finding of this study is that obese women with insulin resistance had increased 
amplitude separated wave intensity signals compared with age-matched controls. 
These changes suggest increased energy transmitted from the LV into the circulation, 
and increased reflections from the circulation which augment pulsatile loading of the 
LV.  
The forward compression wave is initiated by ventricular ejection and arrives in 
the common carotid artery shortly after the aortic valve opens. It correlates strongly 
with the rise in left ventricular pressure during early systole (dP/dT) 
147
 which 
creates the momentum to move blood (stroke volume) into the aorta. This rise in 
ventricular pressure generates a wave that propagates into the circulation at a rate 
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faster than the blood travels. Therefore, the forward compression wave can be 
thought of as a wave that ‘pushes’ blood forward into the circulation – it is 
associated with an increase in both pressure and flow at the measurement site. The 
increase in arterial pressure must be overcome by the LV as it continues to eject so 
the forward compression wave contributes to early systolic loading of the LV.   
Wave intensity is the flux of energy per unit area carried by such waves and is 
defined by the product of instantaneous changes of pressure and flow velocity 
(dP.dU). This gives information about the amplitude of the wave in units of W/m
2
 
but others have suggested that the duration of the wave may be as important as the 
amplitude, therefore I chose to focus my analysis on the integral of the forward 
compression wave (the area under the wave) which has units of J/m
2
.
135
   
In my study obese women with insulin resistance had higher forward 
compression wave integral than metabolically healthy controls. The mechanisms 
underlying this increase are likely to include sympathetic nervous system 
overactivity because of hyperinsulinaemia, as well as decreased systemic vascular 
resistance which is a feature of general obesity in the absence of hypertension.
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Indeed, I confirmed significant associations with heart rate (direct), systolic 
longitudinal tissue velocity (direct), and systemic vascular resistance (inverse). A 
similar effect of increased adrenergic activity and vasodilation on the forward 
compression wave has been described in a canine experimental study using 
dobutamine and nitroglycerin,
139
 and in a clinical study where caffeine was found to 
have a positive inotropic effect.
153
 
My data add to those of Tian et al. who describe a significant increase in W1 of 
patients with type 2 diabetes compared with controls and higher values still in those 
with diabetes and hypertension.
224
 In addition, Avgeropoulou et al. describe an 
increase in W1 in subjects with type 2 diabetes and hypertension (n=65 with type 2 
diabetes compared with 57 controls),  some of whom were taking cardiovascular 
medication.
148
 While I found that net WI signals were insensitive to sub-clinical 
cardiovascular changes, I demonstrated an increased separated forward compression 
wave integral in obese women with pre-clinical levels of dysglycaemia who were 
normotensive.  
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I was rather surprised that the forward compression wave was not associated with 
other echocardiographic measures of systolic function (beyond s’), or ventricular 
end-systolic elastance and cannot explain this. To the best of my knowledge I am the 
first to explore relationships between echocardiographic measures of ventricular 
function and separated WI signals so there are no other studies from which to draw 
comparisons.   
The forward compression wave is reflected back toward the heart from sites of 
impedance mismatch in the arterial system. Impedance mismatches tend to occur at 
bifurcations where there is a change in vessel diameter or at the resistance vessels 
(arterioles).
135
 The reflected wave is of the backward compression type which has 
the effect of pushing back towards the heart in mid-systole, causing an increase in 
pressure and opposing ejection. Therefore, this wave increases the pulsatile loading 
on the LV and is affected by the amplitude of the forward compression wave, as well 
as by artery stiffness.
156
 
In my study obese women with insulin resistance had higher backward 
compression wave integral than metabolically healthy controls. This appeared to be 
largely explained by the increase in the preceding forward compression wave since 
the two were highly correlated (r = .853, p<.0001), and there were no between-group 
differences in the reflection coefficient which normalizes the backward compression 
wave by the integral of the forward compression wave. Furthermore, measures of 
obesity and insulin resistance were not related to the reflection coefficient in my 
study population. While this suggests that obesity and insulin resistance do not affect 
the degree of impedance mismatch at reflection sites, the very fact that the 
percentage reflection does not increase, suggests that a greater energy may be 
transmitted to the distal circulation. It is tempting to speculate that this might have 
implications for the microvasculature and this is worthy of further study. In addition, 
a larger forward compression wave with an unchanged reflection coefficient will 
result in an increase in the absolute energy of the backward compression wave so 
that pulsatile loading is increased.  
Roberts et al. describe an increased separated backward compression wave in 18 
older patients (mean age 67 years) with newly diagnosed type 2 diabetes who were 
naïve to treatment compared with age comparable controls.
225
 My data add to these 
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findings because I found an increased backward compression wave integral in young 
obese women with pre-clinical levels of abnormal glucose handling.  
My data showed that that the reflection coefficient was inversely associated with 
the central augmentation index. This appears counterintuitive since the augmentation 
index has been proposed as a surrogate marker of wave reflections, with increased 
augmentation reflecting increased wave reflections. Others have also shown a weak 
but negative association of augmentation index with the ratio of forward to backward 
pressure (r=-.200, p=0.1) in a group of healthy volunteers (n=65, age 21-78 years, 43 
male, r=).
144
 The authors suggest that the poor relationship between the two may be 
affected by the shape of the aortic pressure waveform and the presence of re-
reflected waves in mid systole which were evident in some subjects. Together, these 
data suggest that the augmentation index cannot be used as a measure of wave 
reflection in all subjects.   
The aortic pressure waveform is affected by the timing of reflected compression 
waves as well as their amplitude,
138
 which suggests that both contribute to 
ventricular pulsatile loading. The earlier a reflected wave arrives back at the heart, 
the greater the maximum systolic pressure in the artery. In pooled data I found 
significant inverse associations between the timing of the backward compression 
wave and age, visceral fat and fasting glucose. In between-group analyses those with 
insulin resistance tended to have earlier compression wave reflections than controls 
but the differences were not significant. This may be because subjects were young 
and free from impaired fasting glucose.  
The forward expansion wave occurs toward the end of systole in the 
protodiastolic period. At this time, the ventricular pressure begins to decrease and 
this decelerates the blood that is moving forward (stroke volume), eventually leading 
to closure of the aortic valve. This generates a wave that propagates forward into the 
circulation but has the effect of pulling back towards the heart, decreasing arterial 
pressure and flow velocity. Therefore, the forward expansion wave plays a key role 
in the rapid unloading of the LV at the end of ejection.  
In an experimental canine study, Wang et al. 
226
 showed that the expansion wave 
generated by the ventricle continued through the isovolumic relaxation period until 
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the mitral valve opened, suggesting that the time-course of the wave was similar to 
that of the untwisting of the LV. In addition, the energy of the forward expansion 
wave was related to LV end-systolic volume as well as the rate at which the ventricle 
relaxed. Finally, the authors found that while early diastolic filling of the LV was 
largely dependent on passive decompression of the left atrium, it was also affected 
by the early diastolic suction of the LV.  
In my study, young women with insulin resistance and obesity had increased 
forward expansion wave integral compared with metabolically healthy controls. This 
increase is intuitive given increase in the forward compression wave. The rate of 
decline in left ventricular pressure (and therefore the deceleration in flow) is likely 
affected to some degree by the preceding rate of increase in left ventricular pressure. 
Therefore, an increase in forward compression wave should be followed by an 
increased forward expansion wave and it might be expected that both are affected by 
adrenergic state. Indeed, I found direct associations of both forward waves with heart 
rate and arterial elastance which is affected by vasomotor tone. Furthermore, the 
associations of forward waves with visceral fat and insulin resistance were no longer 
significant when heart rate was controlled in the analysis (data not presented).  
In Chapter 3 I found that obese women had worse diastolic function than 
controls. Therefore, I was surprised that the forward expansion wave integral was not 
associated with measures of diastolic function in the pooled data but my results are 
comparable with other limited reports in the published literature.
227
 I found that 
when the forward expansion wave integral was divided by the forward compression 
wave integral, an inverse association was revealed with the flow propagation 
velocity, a measure of early diastolic function which reflects LV suction (r= -.238, 
p=.014). This may suggest that a relative increase in the forward expansion wave is 
associated with poorer early diastolic function of the LV.  
One study has shown that the net W2 signal (which is dominated by the forward 
expansion wave) tended to be increased in patients with type 2 diabetes but the 
differences were not statistically significant.
148
 These subjects also had an increase in 
W1. However, over half of the patients with diabetes had abnormal diastolic function 
according to age-corrected cut off velocities and it may be that the forward 
expansion wave is increased early in the course of disease then declines with the 
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advent of clinically relevant diastolic dysfunction. If this was true then including 
subjects with subclinical and more advanced disease would unwittingly negate 
significant differences in the WI signal.  
Arterial elastance and wave intensity signals independently explain some of the 
variation in left ventricular mass 
A key finding of this study is that arterial elastance, the normalised backward 
compression wave and the timing of the backward compression wave independently 
explained some of the variation in left ventricular mass in a model that included 
weight and systolic blood pressure. 
There is a general consensus that obese subjects are more likely to develop LV 
hypertrophy than lean counterparts. A systematic review of echo studies used to 
identify left ventricular hypertrophy in obese subjects confirmed an odds ratio of 4.2 
in obese compared with non-obese counterparts.
45
 In addition, body size (BMI) was 
directly associated with LV hypertrophy and the eccentric pattern of hypertrophy 
was more prevalent than a concentric pattern (66 vs. 34%, p<.01). However, of the 
15 studies and ~5,000 obese subjects included in the review, 70% were hypertensive, 
50% were taking cardiovascular medication and 10% had type 2 diabetes. These 
confounding factors are likely to influence the development of hypertrophy so it is 
unclear whether the results are applicable to those who are at an earlier stage in the 
disease process.  
There is recent evidence from the Multi-Ethnic Study of Atherosclerosis (MESA) 
that both pulsatile and static loading independently contribute to LV mass, with the 
former explaining a greater proportion of the variation.
161
 The methods included 
cardiac magnetic resonance imaging to determine LV mass and arterial tonometry to 
derive forward and backward pressure waves. The backward pressure wave, which 
occurred in mid-late systole, was the main correlate of LV mass, emphasizing the 
importance of the time-course of loading in the development of hypertrophy. By 
design, subjects in the study were older (mean age 61.3±10.1 years) and included 
those with hypertension (42%) and diabetes (12%). 
My data add to the findings of these studies by confirming that body weight was 
the main contributor to the variation in LV mass in a young female population 
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without hypertension or diabetes, and who were not taking cardiovascular 
medication. I also found that the eccentric pattern of hypertrophy was more 
prevalent. In addition, I demonstrated that WI measures of local artery stiffness and 
mid-late systolic pulsatile loading independently explained some of the variation in 
mass when weight and systolic blood pressure were included in the model. These 
aspects of pulsatile loading were related to central obesity and insulin resistance and 
it is tempting to speculate that these are more likely to result in the development of a 
concentric pattern of hypertrophy.  
Central obesity independently contributes to the variation in diastolic function but 
wave intensity signals do not improve the model 
In Chapter 3 I found that a significant proportion of the variation in diastolic function 
(eʹ/aʹ) could be explained by age, regional artery stiffness (aortic pulse wave 
velocity) and visceral fat.  
A key finding of this study is that when subjects are grouped by BMI, those who 
are obese have poorer diastolic function than controls, but when subjects are grouped 
by insulin resistance the differences did not reach significance. In addition, measures 
of arterial elastance and wave intensity did not independently explain any of the 
variation in diastolic function when added to the model.  
These findings may seem incongruent with those of Chapter 3, but an 
explanation may lie in the possibility that diastolic function was impaired because of 
increased epicardial fat rather than alterations in ventricular afterload. Epicardial fat 
is the visceral fat around the heart and there is evidence from magnetic resonance 
imaging that epicardial and abdominal visceral fat are strongly associated (r=.864, 
p=.01).
66
 
There is some evidence in the literature that epicardial fat can be reliably 
measured from echocardiographic images.
66
 I reviewed the stored images from my 
study but could not perform this measurement because images had not been 
optimised to provide maximum resolution in the near-field.  
The mechanisms linking epicardial fat and diastolic function are yet to be 
elucidated. It is possible that epicardial fat may affect the left ventricular transmural 
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pressure in early diastole, impeding passive ventricular filling with the consequence 
of increased left atrial pressure. This, in turn, would generate a larger contribution to 
diastolic ventricular filling during the subsequent atrial contraction (as noted in my 
data).  In addition, epicardial fat is anatomically contiguous with the myocardium 
(there is no dividing muscle fascia) and functions as an endocrine and paracrine 
organ, secreting bioactive molecules such as inflammatory cytokines. Therefore, 
epicardial fat may also affect left ventricular function through biochemical 
pathways.
64
 
Women with PCOS have normal wave intensity signals despite obesity and insulin 
resistance 
I expected to find similar energy WI signals in women with PCOS as in the insulin 
resistance group. Both groups had comparable levels of central obesity and women 
with PCOS had worse insulin resistance; features which were directly associated 
with WI signals in the pooled data.  
A key finding of this study is that women with PCOS had wave intensity signals 
that were lower than counterparts in the insulin resistance group who were free from 
PCOS. In fact, wave intensity signals in the PCOS group were similar to 
metabolically healthy controls, despite the presence of obesity and insulin resistance.  
I believe this adds further evidence to my hypothesis that women with PCOS are 
somehow protected from the deleterious effects of obesity on cardiovascular 
haemodynamics. In particular, it appears that pulsatile loading is mitigated by some 
feature of PCOS since arterial and ventricular elastance were elevated in this group.  
An alternative explanation would be that the intensities were reduced because of 
poorer ventricular systolic function but I performed comprehensive echocardiograms 
and could find no evidence of this. Others have similarly shown that left ventricular 
function is similar in obese women with PCOS and insulin resistance compared with 
obese controls with insulin resistance.
98
 
Given the lower prevalence of left ventricular hypertrophy in women with PCOS 
in my study, it is tempting to speculate that the lower pulsatile loading of the 
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ventricle in PCOS is, at least in part, delaying the development of left ventricular 
hypertrophy. 
Since measures of pulsatile loading were not independent contributors to 
diastolic function, the effects of central obesity on diastolic function should be 
comparable in those with PCOS and in controls. This was evident in my data and it 
is worth noting that increased ventricular mass was not an independent predictor of 
diastolic function in the subclinical phase of disease of these young women.  
Limitations 
Carotid ultrasound images and WI analysis were performed by a novice to vascular 
ultrasound (although experienced in echoes) after a short training period. This may 
have reduced feasibility and led to greater variability in data. In addition, WI 
measures were not among the primary outcome measures. Nevertheless, I was able 
to detect between-group differences in WI associated with subclinical levels of 
disease.  
The large physiological variability in WI signals means that this technique may 
not be suitable for the clinical environment but I am not proposing that it should be 
used in this way. My aim was to use the technique to better understand the effects of 
obesity and PCOS on cardiovascular haemodynamics and in that respect I believe the 
technique has led to new insights, particularly in relation to women with PCOS.  
I would have liked to explore whether separated WI measures could explain the 
variation in hypertrophy patterns but this was not possible because of the small 
numbers of women with hypertrophy in the study. This could easily be addressed in 
a larger study of those who are further along the disease pathway although the 
confounding influence of hypertension may impact the results.  
The case-control nature of this study means that I cannot infer causality between 
central obesity, pulsatile loading and left ventricular hypertrophy. However, my data 
suggest that this could be explored in a longitudinal study with an intervention that 
results in improved insulin sensitivity, lower central obesity or reduced sympathetic 
activity.  
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Conclusions 
My data suggest that young women with uncomplicated obesity have evidence of 
altered pulsatile loading of the LV.  
In the rapid ejection phase the forward compression wave was increased, and this 
is likely to be attributable to sympathetic overactivity. This increase in early systolic 
loading was not independently associated with ventricular mass. The backward 
compression wave in mid-ejection was increased, despite an absence of between-
group differences in intrinsic artery stiffness, and represents increased mid-systolic 
loading of the LV. The timing and amplitude of the backward compression wave 
were independent contributors to the variation in left ventricular mass confirming 
that mid-late systolic loading is important in the development of hypertrophy.  
The reflection coefficient and timing of the backward compression wave were 
not significantly different in obese women in my study. This supports the finding 
that ventricular-arterial coupling is not altered in obesity when there are no 
confounding influences of hypertension or impaired fasting glucose.   
My hypothesis that women with obesity would have a decreased forward 
expansion wave associated with diastolic function was not supported by the data. I 
found that the forward expansion wave was increased in obesity and that it was not 
associated with diastolic function. However, when the wave was normalised for the 
forward compression wave there was an inverse association with the flow 
propagation velocity through the valve (a measure which represents diastolic suction 
of the LV). It may be that the normalised forward expansion wave provides 
information about early diastolic suction of the LV and this is worthy of further 
study.  
An important finding of this study is that women with PCOS had lower WI 
signals than age and BMI-matched controls with similar levels of obesity and insulin 
resistance. Furthermore, the WI signals were similar to those of metabolically 
healthy control. These data suggest that women with PCOS who have yet to develop 
diabetes are protected from the increased pulsatile loading by an as yet unappreciated 
factor.  
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Analysis of separated WI signals has provided new insights to the mechanisms 
underpinning increased left ventricular mass in obese women. While the most 
important contributor to ventricular mass was weight (body size), a significant 
proportion of the variation was explained by WI measures of pulsatile loading, even 
in the absence of hypertension or increased intrinsic artery stiffness.
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6. General discussion 
This thesis was designed to investigate the effects of obesity and pre-diabetic states 
on ventricular-arterial coupling in young women. The motivation for the study came 
from a lack of evidence about the natural history of cardiovascular dysfunction in 
obese women despite epidemiological evidence of an increased risk of diabetes,
2
 
HFpEF 
228
 and cardiovascular mortality 
229
 in those who are older. The relative risk 
of cardiovascular disease is higher in those with diabetes 
8
 and it appears that women 
with diabetes have a higher relative risk of cardiovascular mortality than men.
10
 
Finally, there is evidence that early diagnosis and intervention are necessary because 
once diabetes has developed it may be too late to prevent adverse cardiovascular 
outcomes.
12
  
LV hypertrophy 
45
 and diastolic dysfunction 
48
 are well-established consequences 
of obesity and potent markers of cardiovascular risk,
49
 but the precise mechanisms 
linking uncomplicated obesity and pre-diabetic states with these features are not well 
defined. Early diagnosis of sub-clinical dysfunction and its precise nature may be 
useful in identifying those at highest risk of altered cardiovascular outcomes and 
may inform interventional studies. Since the relative contributions of central obesity 
and metabolic disturbances on ventricular loading were particularly unclear it 
seemed appropriate to develop a study to address this question.  
The hypothesis was that quantitative measures of ventricular-arterial coupling 
would complement standard measures of cardiovascular function and lead to an 
improved understanding of sub-clinical pathophysiology.  
Two non-invasive methods of quantifying the ventricular-arterial interaction 
were used in this work (i) arterial and ventricular end-systolic elastance and their 
ratio (ii) measures of carotid artery WI. These methods were chosen because they 
have been validated against gold-standard measurements in experimental and clinical 
studies and because they could be obtained from ultrasound techniques which are 
ideal to study cardiovascular function in a relatively healthy population. 
There were three specific aims of the work. The first was to examine whether the 
non-invasive methods of quantifying the ventricular-arterial interaction were 
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sufficiently sensitive to detect sub-clinical changes in cardiovascular function 
associated with uncomplicated obesity and insulin resistance. The second was to 
determine whether measures of ventricular-arterial coupling were more strongly 
associated with central obesity and insulin resistance than with general obesity. The 
third was to determine whether measures of ventricular-arterial coupling 
independently contributed to left ventricular mass and diastolic function.  
In the planning stages of this project an opportunity arose to collaborate with an 
endocrinologist who was interested in studying the effects of body composition on 
cardiovascular function in women with PCOS, a common condition which is 
associated with a high prevalence of obesity 
82
 and which is considered a non-
modifiable risk factor for diabetes. As a result it seemed sensible to combine our 
planned studies to maximize the data yield from subject participation and, as a result, 
we obtained a very rich data-set which comprehensively characterised lean and 
obese women with and without PCOS.  
Novel findings of this thesis 
The novel findings of this thesis are summarised below. 
1. Both elastance and wave intensity measures of ventricular-arterial 
coupling were sufficiently sensitive to detect sub-clinical differences in 
physiology associated with obesity and pre-diabetic states in women 
(Table 4-2, page 135 and Table 5-5, page 183 respectively).  
2. These methods of quantifying ventricular-arterial coupling helped to 
explain the haemodynamic effects of general obesity, central obesity and 
insulin resistance on the cardiovasculature. Both general and central 
obesity were important contributors to the finding of increased arterial 
and ventricular elastance (Table 4-3, page 137). In contrast, visceral fat 
and insulin resistance were more important contributors to the finding of 
altered wave reflections which served to increase mid- to late-systolic 
pulsatile loading of the left ventricle (Table 5-3, page 179).  
3. Measures of ventricular-arterial coupling helped to explain the finding of 
increased LV mass in obese young women. General obesity (weight) was 
the most important independent contributor to LV mass but arterial 
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elastance, local artery stiffness and the amplitude and timing of wave 
reflections also made independent contributions even after adjustment for 
systolic blood pressure (Table 5-9, page 192).  
4. In contrast, measures of ventricular-arterial coupling did not help to 
explain the finding of worse diastolic function in this population. Neither 
was this explained by the finding of increased LV mass. The most 
important independent contributors to diastolic function after adjustment 
for pulse pressure and regional aortic stiffness were age, insulin levels 
and visceral fat (Table 5-10, page 192).  
5. Obese women with PCOS had a lower odds ratio of having LV 
hypertrophy than obese controls despite similar body composition and 
worse insulin resistance (Table 3-4, page 99). This may be explained by 
lower amplitude wave reflections (Figure 5-6, page 185) perhaps as a 
result of better arterial compliance and lower intrinsic carotid artery 
stiffness which tended to be closer to normal values. 
Themes arising from the findings  
No single test fully described cardiovascular function: No single test within the 
protocol fully described the sub-clinical cardiovascular dysfunction associated with 
obesity in young women. Between-group differences in LV mass and diastolic 
function were evident from echocardiography but even sensitive measures of systolic 
function such as myocardial velocity and strain were unchanged. Non-invasive 
measures of systolic elastance allowed a neat and intuitive visualization of the 
ventricular-arterial interaction in the pressure-volume plane. The diagrams derived 
from these results are familiar to those working in cardiology and helped to describe 
the effects of obesity on blood pressure sensitivity to volume changes and stroke 
work. However, these diagrams are an oversimplification of the intact circulation 
and arterial elastance did not fully capture the effects of pulsatile loading.  
Wave intensity signals added information about the amplitude and timing of 
pulsatile loading but these measures had considerable physiological variation and 
were more challenging to interpret since they reflect complex interactions and are 
subject to phenomena such as re-reflections and wave-trapping. While composite 
measures of arterial and ventricular function such as PWV and EF have established 
 192 
 
prognostic significance and are clinically useful measures, they do not provide 
sufficiently detailed information to inform research studies whose aim is to define 
subclinical pathophysiology. 
There was increased loading of the left ventricle in the absence of altered 
ventricular-arterial coupling per se: The ratio of elastances and the reflection 
coefficient were unaltered in obesity and, as such, the ventricular-arterial system 
remained ‘closely-coupled’ but this did not mean that ventricular loading was 
unaffected. The separate components of ventricular arterial coupling (arterial and 
ventricular systolic elastance, forward and backward compression wave) provided 
greater insight to the components of static and pulsatile load on the LV. 
When the system is closely coupled, ejection fraction and stroke volume remain 
normal but at the expense of higher systolic blood pressure. In addition, a higher 
forward compression wave with an unchanged reflection coefficient (%) necessarily 
means that there is a larger backward compression wave which will augment blood 
pressure and oppose late systolic ejection of the LV. Furthermore, there will be a 
larger amplitude residual wave transmitted to the distal circulation. It is unclear 
whether this can be interpreted as increased pulsatile flow transmitted to the more 
distal circulation which could have relevance to the finding of microvascular 
dysfunction which is evident in more advanced diabetic states.  
The late-systolic pulsatile loading appeared to be driven by increased 
sympathetic nervous system activation because of hyperinsulinaemia and not 
body size: Wave intensity measures of pulsatile loading appeared to be specifically 
elevated in those who were obese and had insulin resistance. The main determinant 
of the reflected compression wave was the preceding forward compression wave 
driven by the LV.  The forward compression wave was determined by heart rate, 
systemic vascular resistance and LV contractile function, but only heart rate was 
different between IR and control groups.  This suggests that heart rate and perhaps 
the rate of ejection are important determinants of pulsatile loading in the sub-clinical 
phase of disease associated with obesity. It may be worth confirming this in a larger 
number of subjects since pulsatile loading contributes to LV hypertrophy and there is 
a drug (Ivabradine) which can selectively reduce heart rate without having a negative 
impact on ventricular contractile function.  
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It is tempting to speculate that the mixed pattern of eccentric and concentric 
hypertrophy in obese subjects is related to whether there is significant insulin 
resistance and increased heart rate. This could be determined by classifying subjects 
by obesity and metabolic health which I did not attempt because the sample sizes 
would have been too small to be meaningful.  
In uncomplicated obesity, diastolic dysfunction may be predominantly related 
to the mechanical and paracrine effects of epicardial fat or the endocrine effects 
of visceral fat: In this study the impaired diastolic function in obese subjects was not 
determined by pulsatile loading or LV mass and was more strongly associated with 
visceral fat than with BMI. This suggests that in the earliest stages, diastolic 
dysfunction may be more closely related to the mechanical and paracrine effects of 
epicardial fat or the endocrine effects of visceral fat, rather than to the 
haemodynamic effects of obesity which lead to left ventricular hypertrophy. My 
findings add to those of Kozakova et al. who also reported that diastolic function 
was most strongly associated with abdominal obesity and fasting insulin in obese 
children,
61
 but they did not characterise body composition and pulsatile loading as I 
have.  
PCOS is not a good model for obesity and insulin resistance in the general 
population: I had envisaged that PCOS may be a good model to study the effects of 
obesity and pre-diabetic conditions on cardiovascular function in women. However, 
my data suggest that the results from women with PCOS should not be generalised 
to a non-PCOS population. There appeared to be some element of PCOS which 
mitigates the effects of central obesity and insulin resistance on pulsatile loading and 
the subsequent increased LV mass. This finding may have relevance for the lack of 
conclusive evidence of altered cardiovascular mortality in women with PCOS.
86
  
There may be a PCOS phenotype that is associated with 
hyperadiponectinaemia: I found that lean women with PCOS tended to have higher 
levels of HMW-adiponectin than lean controls despite similar body composition and 
worse insulin resistance. However, this group was small (n=20) and there was 
considerable between subject variation. The difference was not statistically 
significant when the parametric test ANOVA was used with post-hoc corrections for 
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multiple group comparisons, but the equivalent non-parametric test was significant 
(Kruskal-Wallis p=.006 for lean PCOS vs. lean controls).   
It is unclear whether there is a specific reproductive phenotype of PCOS that is 
associated with hyperadiponectinaemia. Since HMW-adiponectin has insulin-
sensitising, anti-inflammatory and anti-atherogenic effects,
21
 it may be that those 
with higher values are less likely to develop significant insulin resistance and are 
therefore protected against the deleterious effects on cardiovascular function. In 
support of this I found that adiponectin was inversely associated with ccIMT, aortic 
PWV, LV mass, as well as scaled elastances and their ratio. In addition, it was 
among the independent predictors of ccIMT after adjustment for age. However, it is 
possible that a situation of adiponectin resistance exists (in the same way as cells can 
develop insulin resistance) so that higher than normal circulating levels actually 
indicate an already altered state. This may be an as yet unappreciated feature of 
milder forms of PCOS. Furthermore, others have described a paradoxical finding of 
increased cardiovascular mortality in those with higher adiponectin levels after 
adjustment for other risk factors,
34
 This suggests that there may be circumstances 
where the higher adiponectin has a toxic effect or is a marker of an as yet 
unappreciated risk factor for disease. 
 This debate may be addressed by including a measure of HMW-adiponectin in a 
large longitudinal study of women with PCOS who are classified by reproductive 
phenotype. Such a study should also include comprehensive assessment of the 
ventricular-arterial interaction and body composition as well as having HFpEF 
among the key outcome measures.  
Limitations 
There are several limitations of this work. I chose to study women with 
uncomplicated obesity i.e. they were free from hypertension and diabetes. The 
majority of women in the study were Caucasian and all were younger than 45 years. 
As a result the findings may not be applicable to other populations. Women with 
PCOS were largely drawn from a hospital database and may not be representative of 
those with PCOS in the general population. The initial power calculation for the 
study was based on detecting clinically relevant differences in established measures 
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of cardiovascular function (aortic pulse wave velocity and diastolic function). 
Quantitative measures of ventricular-arterial coupling were not considered and there 
was insufficient published information in uncomplicated obesity and in PCOS to 
perform the calculation. Despite this, I found significant differences in obese versus 
lean subjects across several key measures.   
It was not possible to establish whether increased arterial elastance and wave 
reflections were among the causes of increased LV mass in this case-control study 
and it would be useful to establish this in an interventional study. 
Wave reflections in the section of aorta adjacent to the heart are likely to be most 
relevant to ventricular loading but I am not aware of a non-invasive method for 
measuring these. I analysed reflections in the common carotid artery but this has 
different geometry, branching morphology and wall structure from the proximal 
aorta. In addition, backward wave reflections in the carotid artery are from the 
cerebrovascular system which may have different vasomotor tone from the systemic 
circulation. These differences are likely to affect both the conduit function of the 
artery (and static resistance) as well as the cushioning or Windkessel effect of the 
artery (and pulsatile resistance). However, I found that the amplitude and timing of 
wave reflections in the carotid artery were independently associated with LV mass so 
they are likely to have pathological significance regardless of the mechanisms 
driving reflections. 
I recruited a separate sample of six individuals to test reproducibility of the 
elastance and WI measures at two separate visits prior to much of the analysis for 
this thesis. These individuals were drawn from a wide range of age and BMI but they 
were not necessarily representative of final sample of young, female women with 
obesity and/or PCOS.  In addition, the Aloka equipment used to measure WI 
developed a technical fault in the period between data collection and thesis writing. 
This meant that it was not possible to access the repeated WI measures of this small 
sample group so I have included the measures previously reported by our lab (using 
the same environment, equipment and software). Nevertheless, the standard 
deviation of measurements within the study population was sufficiently narrow to 
detect subtle between-group differences associated with sub-clinical disease. 
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I did not study the interaction effects of testosterone and adiponectin (or other 
metabolic factors) on cardiovascular function and this may be important in some 
women with PCOS. 
Conclusion 
This is the first study to comprehensively study the effects of uncomplicated obesity, 
insulin resistance and PCOS on ventricular-arterial coupling. Quantification of the 
ventricular-arterial interaction using ultrasound is feasible in an obese, female 
population and sufficiently sensitive to detect changes in the sub-clinical phase of 
disease. In addition, the measures independently contribute to the finding of 
increased LV mass in the study population who are at risk of developing HFpEF and 
of having a higher cardiovascular mortality later in life. Thus, the data provide new 
information about the early natural history of cardiovascular dysfunction which may 
be useful in counseling patients about life-style modifications and may inform 
intervention studies which seek to reverse altered static and pulsatile loading before 
irreversible changes in cardiovascular structure and function occur. 
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